Practical Pulmonary Pathology 3rd ed. Kevin O. Leslie, MD

Chapter 20. Benign and Borderline Tumors of the Lungs and Pleura

Mark R. Wick, MD, and Stacey E. Mills, MD

Malignant neoplasms are more common, by far, than benign tumors in the lower respiratory tract. In the United States, lung carcinoma is the leading cause of cancer-related death in both sexes, and it accounts for more than 0.7% of new malignancies each year in men.¹ In Europe, the situation is even worse; for example, more than 3.0% of newly diagnosed malignant neoplasms in Germany are lung cancers.² These data reflect the continuing use of cigarettes worldwide and the relative potency of tobacco smoke as a carcinogenic agent.

Because of the prognostic gravity and the frequency of lung cancers, less attention has been given to benign pulmonary neoplasms and those that have borderline malignant potential. Nonetheless, they comprise an interesting array of lesions with diverse lineages, the causes of which are known only in a minority of cases. This chapter provides an overview of such tumors, with an emphasis on the differential diagnosis.

Benign Pleuropulmonary Neoplasms

Clinical Features

The clinical characteristics of benign tumors in the lower respiratory tract can be considered in an overview because they are generally not specific to any particular diagnosis. Most benign intrapulmonary lesions are associated with no symptoms or signs whatsoever and are found incidentally with screening radiographic studies. As discussed elsewhere in this book, hamartomas are often separable from other benign but truly neoplastic masses of the lung on imaging studies because of their common content of distinctive calcifications, fat densities, or both (Fig. 20.1).³ Otherwise, the radiologist is not typically able to distinguish between specific histologic entities in this context. Endotracheal and endobronchial tumors are more often related to clinical symptoms such as wheezing, hemoptysis, obstructive pneumonia, and postobstructive pulmonary hyperinflation, depending on their anatomic location.

Figure 20.1 This computed tomogram of the lung shows a well-demarcated peripheral nodule with internal calcification, typical of pulmonary hamartoma.

In the past, radiologists were comfortable simply observing a pulmonary mass over time, if it had reassuring morphologic characteristics. In fact, statistical paradigms have been constructed to aid in this process.⁴ However, because of the unfortunate pressure of litigation involving putative delays in diagnosis of malignant neoplasms at various sites⁵— together with the modern availability of techniques such as video-assisted thoracoscopic surgery⁶—many more benign lesions of the lungs are excised today than in previous years.

Bronchoscopic examination and endobronchial biopsy are productive diagnostically if the tumor in question protrudes significantly into the lumen of the airway. However, brushing cytology is only variably effective in sampling such growths, depending on whether the mucosa over them is intact and the level of intercellular cohesion in the tumor itself. Transthoracic or transbronchial aspirates or needle biopsies are usually necessary for adequate sampling of deeply seated masses in the parenchyma. In this setting, these procedures are most effective in the diagnosis of malignant neoplasms; if the pathologist sees only histologically banal tissue elements in the latter specimens, it is often impossible to discern whether they truly represent the lesion or are simply part of the adjacent lung. Moreover, in small biopsy specimens, the morphologic attributes of some cytologically low-grade malignancies may be virtually identical to those of benign tumors belonging to the same general cellular lineage.

Benign Tumors That Are Principally Tracheal and Endobronchial

Solitary Tracheobronchial Papilloma

A solitary papilloma of the tracheobronchial tree (SPTT) most often arises in adults—typically middle-aged—with a slight male predomi- nance.^7-22 Occasionally, even though only one papillomatous lesion of the lower respiratory tract may be present, it may coexist with papillary squamous proliferations of the larynx or oropharynx.

Grossly, SPTTs form a pedunculated tan-white polypoid excrescence in the mucosa of the airway, with variable luminal compromise. The surface may be smooth or slightly verrucoid.

Microscopically, SPTTs are similar to viral papillomas elsewhere in the body, particularly in the genitoperineal region. ’Hiey are constituted by arborizing fronds with fibrovascular cores, mantled by relatively bland squamous epithelial cells (Fig. 20.2). These often exhibit nuclear hyperchromasia and crenation, but the nuclear chromatin may be homogenized and glassy. The cytoplasm is commonly unremarkable; alternatively, it may show perinuclear clearing, eosinophilic globular inclusions, or hypergranulation with clumping of keratohyaline granules (Figs. 20.3 and 20.4). Nuclear atypia has been observed in squamous SPTT, and squamous carcinoma may develop in this setting.^23,24

Figure 20.2 Solitary papilloma of the bronchus represented by a papillary proliferation of bland squamous epithelium supported by well-formed fibrovascular stroma.

Figure 20.3 Koilocytotic change in the squamous cells of a solitary bronchial papilloma represented by nuclear hyperchromasia and crenation and perinuclear clearing of the cytoplasm.

Another even rarer variant of SPTT is the columnar papilloma, composed of columnar epithelial cells rather than squamous elements.¹⁴ Putatively, it has no potential for malignant change.

Interestingly, the biologic associations between squamous SPTT and human papillomavirus (HPV) types are comparable to those in the genital tract. Specifically, HPV types 7 and 11 are most commonly seen in uncomplicated SPTT; in contrast, HPV types 16 and 18 are associated with dysplastic nuclear features and a higher risk of carcinomatous transformation.^23,24 the presence of these viral agents can be evaluated using in situ hybridization (Fig. 20.5), the hybrid capture method, or polymerase chain reaction.^23-27

In light of the usual behavior of SPTT, conservative therapeutic approaches, such as endoscopic removal, cryotherapy, or fulguration, are typically applied. Lesions in which malignancy develops must be treated in a manner appropriate for ordinary lung cancers (Fig. 20.6).^28-31

Figure 20.4 Clumped keratohyaline and eosinophilic cytoplasmic inclusions are seen in the lesional cells of this solitary squamous papilloma of the bronchus with a viral causation.

Figure 20.5 the presence of integrated nucleic acid from human papillomavirus type 11 is apparent in this in situ hybridization preparation, as evidenced by nuclei that show a blue chromogenic signal.

Multifocal Respiratory Tract Papillomatosis

Respiratory tract papillomatosis (RTP) is the multifocal form of viral papillomagenesis, as described earlier. Its onset is early in life because the mode of transmission is natal inhalation of virally infected genital tract secretions during vaginal delivery.^32-41 Children with RTP typically have oropharyngeal or laryngeal disease initially; it may remain localized or spread to involve the lower airways as well, as seen in 5% of cases.⁴⁰ In the latter instance, growth into the lung parenchyma may supervene, with the eventual appearance of cavitary lesions that can simulate carcinomas radiographically.^32,41 Obstruction of the tracheal or bronchial lumina is associated with recurrent pneumonia, hemoptysis, and asthmalike symptoms. Even though RTP is often said to be recurring, the entire respiratory tract is at risk for infection by HPV in this disorder. Thus it is more apropos to consider separate lesions as metachronously or synchronously independent of one another pathogenetically.

Figure 20.6 Rarely, multifocal respiratory papillomatosis may give rise to squamous cell carcinoma manifested as a mass in the posterior left lung, seen on this computed tomogram (A) and microscopically (B and C). (Courtesy Dr. Benjamin Kozower, Charlottesville, Virginia.)

The gross and histologic features of RTP are largely the same as those of solitary respiratory tract papilloma (SRTP) (Figs. 20.7 and 20.8). Exceptions include the multiplicity of lesions and the greater tendency for “inverting” or tissue-destructive growth of the papillomatous lesions in RTP (Fig. 20.9). The HPV profiles of RTP and SSTP are comparable, with the notable proviso that HPV-11 is overwhelmingly the most common viral type seen in RTP. Mutations of the p53 gene have been linked to malignant transformation of individual lesions in both conditions.^{23,24,27,41-46}

It does not appear as though treatment with HPV-targeted antiviral medications (specifically, cidofovir) produced morphologic changes in persistent papillomatous lesions of the airway.⁴⁷

Figure 20.7 Bronchoscopic appearance of multifocal respiratory papillomatosis showing a multiplicity of smooth-domed and confluent lesions in the bronchial mucosa.

Figure 20.8 the histologic appearance of individual lesions in multifocal respiratory papillomatosis is similar to that of a solitary papilloma of the tracheobronchial tree.

Figure 20.9 Inverting growth into the bronchial submucosa by an individual lesion of multifocal respiratory papillomatosis.

The incidence of previous HPV integration was assessed by Clavel et al.,²⁵ using the hybrid capture method in a series of bronchopulmonary carcinomas. They found evidence of oncogenic HPV integration in only 2.7% of those tumors. On the other hand, Yousem et al.⁴⁸ demonstrated similar positivity by in situ hybridization in 30% of squamous carcinomas and 17% of large cell undifferentiated carcinomas of the lung; Syrjanen²⁸ likewise observed histologic viral changes in adjacent metaplastic bronchial mucosa in 26 of 104 squamous carcinomas (25%). Based on these data, it must be acknowledged that HPV may play a greater role in the etiology of lung carcinomas (particularly of the squamous type) than previously thought.

Bronchial Mucous Gland Adenoma

The term bronchial adenoma has been plagued by many misconceptions and misapplications since its introduction by Liebow in 1952.⁴⁹ However, two benign neoplastic entities could still properly be called bronchial adenomas—mucous gland adenoma (MGA) and mixed tumor (MT; pleomorphic adenoma; discussed later).

MGA is an extraordinarily rare lesion. England and Hochholzer⁵⁰ noted that one series of more than 3000 pulmonary tumors included no examples of MGA,⁵¹ and only 1 MGA was represented in another report of 130 benign neoplasms of the lung seen at a large referral center.⁵² In the vast experience of the US Armed Forces Institute of Pathology, only 10 examples of MGA were found. Men and women were equally affected, and the patients ranged in age from 25 to 67 years.⁵⁰’⁵³ There is no particular predilection for anatomic location; MGAs may arise in any of the major lobar or segmental bronchi. Radiographs either show changes of postobstructive pneumonia or hyperinflation, or demonstrate a discrete nodule or coin lesion that is centered on a bronchus (Fig. 20.10).^54-66 Kwon et al.⁶⁷ have noted that MGA may produce the “air meniscus sign” on computed tomogram (CT) of the airways.

MGAs measure between 0.5 and 1 cm in maximal dimension. They often demonstrate encapsulation, with mucoid cut surfaces; internal fibrous septations may yield a loculated appearance as well. Occasional lesions may completely occlude the bronchial lumen (Fig. 20.11).

As succinctly stated by England and Hochholzer,⁵⁰ “cystic change [is] the cardinal feature of MGA of the bronchus.” Microcystic arrays of cuboidal or columnar tumor cells may permeate the bronchial wall to the level of the cartilaginous plates; however, growth beyond that point is absent. Cystic contents are either overtly mucinous or more serous. Secondary formation of cholesterol clefts and dystrophic calcifications may also be seen, and squamous metaplasia in the most luminal aspect of the lesion may occur. Nuclei are generally bland, with small nucleoli, and cytoplasm may be amphophilic, oxyphilic, clear, or foamy. Mitotic figures are scarce.

The internal substructure of MGA has been divided into two morphologic patterns: glandular-tubulocystic (Fig. 20.12) and papil- locystic (Fig. 20.13). Within each of these categories, there may be a spectrum of appearances, ranging from a monotonous tubular pattern (Fig. 20.14) to a complex arborizing aggregation of papillary structures.⁵⁰ Stromal sclerosis may be present.

Immunohistologic features of MGA are comparable to those of nonneoplastic bronchial glands. The constituent cells are consistently labeled for cytokeratin, epithelial membrane antigen (EMA), and blood group isoantigens, with less uniform reactivity for carcinoembryonic antigen. Stromal cells show myoepithelial features, with concurrent staining for keratin, actin, and S-100 protein.⁵⁰ Squamous-type (“high- molecular-weight”) keratins may be expressed in MGAs.⁶⁸ This could be a diagnostic trap vis-à-vis the alternative interpretation of mucoepidermoid carcinoma (discussed later).

The differential diagnosis includes predominantly cystic mucoepidermoid carcinoma, MT, sclerosing hemangioma (pneumocytoma), and primary or metastatic mucinous (“colloid”) adenocarcinoma. Of these possibilities, the first two are the most problematic, necessitating adequate biopsies for visualization of the tumor architecture. Cytologi- cally, MGA shows bland nests and sheets of monotonous epithelioid cells (Fig. 20.15).⁶⁹ Diagnostic separation from mucoepidermoid carcinoma or MT usually is not possible using fine-needle aspiration (FNA) biopsy or bronchial brushing specimens.

Figure 20.10 Posteroanterior (A) and lateral (B) chest radiographs showing a nodular lesion that is centered on a bronchus (arrow) that proved to be a mucous gland adenoma. (Reproduced with permission from England DM, Hochholzer L. Truly benign “bronchial adenoma”: report of 10 cases of mucous gland adenoma with immunohistochemical and ultrastructural findings. Am J Surg Pathol. 1995;19:887-899 and courtesy Dr. Douglas England, Madison, Wisconsin.)

Figure 20.11 Gross (A) and scanning microscopic view (B) of a mucous gland adenoma of the bronchus demonstrating an epithelial lesion that fills the bronchial lumen and shows internal gland formation. (B, Courtesy Dr. Douglas England, Madison, Wisconsin.)

An admixture of squamous elements throughout the mass, infiltrative growth through the bronchial wall, or both would tend to argue for a diagnosis of mucoepidermoid carcinoma. Although MGA does not manifest chondromyxoid stroma or immunoreactivity for glial fibrillary acidic protein, as seen in some MTs,⁷⁰ the possibility that MGA is related nosologically to monomorphic adenoma—a variant of MT—cannot be dismissed. In any event, it represents a distinctive clinicopathologic entity that is believed to deserve its own diagnostic designation.

Treatment of MGA can be conservative, with sleeve resection of the bronchus and reconstruction when clinically feasible.^50,57

Figure 20.12 (A and B) A glandular-tubulocystic growth pattern is present in this mucous gland adenoma of the bronchus.

(Courtesy Dr. Douglas England, Madison, Wisconsin.)

Figure 20.13 This mucous gland bronchial adenoma shows a papillocystic configuration. (Courtesy Dr. Douglas England, Madison, Wisconsin.)

Figure 20.14 (A and B) Lesional tubules are composed of bland mucinous epithelium in this glandular-tubulocystic mucous gland bronchial adenoma.

Figure 20.15 Fine-needle aspiration biopsy of mucous gland adenoma showing composition by monomorphic, cohesive polygonal cells with bland nuclear features.

Figure 20.16 This computed tomogram of the chest shows a mass attached to the right bronchus intermedius, representing a mixed tumor.

Salivary Gland Analog Tumors

Mixed Tumor (Pleomorphic Adenoma)

Pleomorphic adenoma, or MT, occurs predominantly in adults, with a slight preference for women.^70,71-74 the age range is 8 to 75 years.⁷⁵ the lesion may present as either a central or a peripheral mass (Fig. 20.16).^76-78

Grossly, central main stem bronchial lesions are commonly polypoid, whereas those in the periphery present as well-circumscribed tumors usually attached to bronchi (Fig. 20.17). The size of the neoplasms varies from 1 to 16 cm in greatest diameter. The cut surfaces of MTs may be chondroid and firm, or may have a soft consistency, with only focal induration.

By definition, pleomorphic adenomas show at least a biphasic microscopic image; they are characteristically composed of epithelial tubules and nests that are embedded in a chondromyxoid stroma (Figs. 20.18 and 20.19). Interestingly, intrapulmonary MTs rarely show the amount of mature cartilaginous stroma present in MTs of the salivary glands. In some lesions, the predominant growth pattern may be solid myoepithelial proliferation that approximates that of cellular MTs in the head and neck. Those neoplasms comprise compact epithelioid cells with round or oval nuclei, which generally lack nuclear atypia, necrosis, hemorrhage, and mitotic activity (Fig. 20.20). Notably, there have been no well-documented cases of carcinoma arising from preexisting MTs of the lung, as may rarely occur in salivary glandular sites. Other variants of MT include a myoepitheliomatous subtype that may manifest either a spindle cell composition (Fig. 20.21)⁷⁹ or a plasmacytoid constituency; a form with extensive squamous metaplasia (Fig. 20.22); a subtype in which sizable zones of the lesion demonstrate an adenoid cystic carcinoma-like cribriform architecture; and a chondroid-rich form that simulates pulmonary chondroma or chondromatous hamartoma.

Figure 20.17 Gross photograph of a bronchial mixed tumor showing that the mass is partially intramural with respect to the wall of the airway. The lesion is internally solid, mottled, and white-tan.

The differential diagnosis depends on whether one is dealing with a biopsy specimen or a complete resection of the tumor. In the former instance, MTs can be confused with other salivary glandlike tumors, such as adenoid cystic carcinoma, as well as with hamartoma/chondroma, squamous cell carcinoma (when squamous metaplasia is dominant), and biphasic malignancies, such as sarcomatoid carcinoma. In resection specimens, the diagnosis is typically straightforward. However, if MTs demonstrate an overwhelmingly prominent solid pattern with spindle cell (myoepitheliomatous) differentiation, sarcomas may also be considered. In this setting, concurrent immunoreactivity for keratin, vimentin, S-100 protein, actin or caldesmon, p63 protein, and glial fibrillary acidic protein^80,81 provides the necessary evidence for a conclusive diagnosis of MT.

MTs of the lung behave in an indolent fashion. There are only anecdotal reports of metastasizing lesions of this type,⁸² in analogy to rare examples in the salivary glands. No particular pathologic features of such neoplasms can be used to predict this unusual adverse behavior. Complete but conservative excision is the treatment of choice.^76,77

Figure 20.18 (A-C) Bronchial mixed tumors comprise a variable mixture of solid epithelial, tubular, and chondroid matrical elements. (D) This mixed tumor is almost completely composed of chondroid stroma, simulating a chondroma.

Figure 20.19 Fine-needle aspiration of a mixed tumor showing classic fibrillary stromal material admixed with bland-appearing basaloid epithelial cells. (Courtesy Dr. Matthew A. Zarka, Mayo Clinic, Scottsdale, Arizona.)

Figure 20.20 This photomicrograph depicts a cellular (epithelial-predominant) mixed tumor, bearing a resemblance to basaloid adenoma of salivary glands.

Figure 20.21 Myoepitheliomatous variants of mixed tumor showing spindle cell (A) and plasmacytoid cell (B) compositions. These lesions are immunoreactive for both keratin (C) and muscle-specific actin (D).

Figure 20.22 Prominent squamous metaplasia is apparent in the epithelial element of this bronchial mixed tumor.

Figure 20.23 Bronchial oncocytoma has a relatively uniform, fleshy, brown cut surface.

Figure 20.24 Either solid or tubular profiles of oxyphilic polygonal cells can be seen in oncocytoma.

Oncocytoma

There are only a few reported cases of pulmonary oncocytoma.^83-92 These tumors exhibit morphologic similarities to comparable tumors in the salivary glands, showing a brownish gross appearance (Fig. 20.23). They are composed of nests of uniformly large polygonal cells with prominently eosinophilic granular cytoplasm and bland nuclei (Figs. 20.24 and 20.25). In view of the existence of other, more common pulmonary tumors that can show oncocytic changes, it is important to properly exclude those other possibilities by adjunctive studies. Neuroendocrine tumors showing oncocytic features (oncocytic carcinoids; grade I neuroendocrine carcinomas) are far more common than oncocytomas and are recognizable by their immunoreactivity for chromogranin-A, synaptophysin, and CD56.⁹³’⁹⁴ Metastatic tumors from the salivary glands and kidneys also must be considered, particularly in rare cases where pulmonary oncocytomas appear to be synchronously multifocal.⁸⁷ Clinical information is important in this context because the electron microscopic and immunophenotypic properties of primary and metastatic oncocytic neoplasms may be very similar (see Chapter 17).

In general, oncocytomas in the lung and other anatomic sites are epithelial, demonstrating immunoreactivity for keratins and EMA; vimentin is inconsistently present, but markers of muscular, neural, or neuroendocrine lineages are absent.^87,95 Immunolabeling with antibodies to mitochondrial proteins is common,⁹⁶ corresponding to the ultrastructural hallmark of these neoplasms.

FNA biopsy of oncocytic neoplasms yields a monomorphic population of large epithelioid cells with round to oval nuclei, dispersed chromatin, small nucleoli, and amphophilic to acidophilic cytoplasm. They are variably cohesive and typically show little nuclear pleomorphism.⁸⁷

Because of problems with the previous definition of pulmonary oncocytoma, as noted earlier, meaningful comments on its behavior are difficult. However, we have seen cases that obviously invaded the lung parenchyma and had atypical morphologic features, such as nuclear pleomorphism and atypical mitoses (Fig. 20.26). Accordingly, such lesions are defensibly labeled as “malignant” oncocytomas.⁸⁴

Peripheral Nerve Sheath Tumors

Primary neoplasms of the lung that demonstrate schwannian or perineu- rial differentiation are more often located in the walls of the major bronchi than in the peripheral lung.^97-112 Chest radiographs show nodular or irregular masses associated with bronchi; secondary atelectasis is sometimes noted as well (Fig. 20.27).⁹⁷ Some patients with primary neurogenic pulmonary tumors have neurofibromatosis type 1 (NF1; von Recklinghausen disease), and that is true for both neurofibroma and neurilemmoma.¹¹³ Neurogenic sarcomas also arise in the lungs,¹¹⁴¹¹⁶ but it is unclear how many have occurred in the context of NF1 in association with preexisting pulmonary neurofibromas.

Figure 20.25 Tumor cells in oncocytoma have oval nuclei with dispersed chromatin, distinct chromocenters, and abundant granular eosinophilic cytoplasm.

Figure 20.26 A rare example of bronchial oncocytoma shows infiltrative growth and focal necrosis (arrow), justifying an interpretation of malignancy.

Figure 20.27 A computed tomographic image of a bronchial neurilemmoma showing a mass in the lumen of the right mainstem bronchus.

Grossly, peripheral nerve sheath tumors (PNSTs) of the bronchus are well-demarcated yellow-white masses centered on the bronchial wall and often protruding into the bronchial lumen (Figs. 20.28 and 20.29). Gross foci of hemorrhage, necrosis, or cystification are absent in benign lesions of this type.

Figure 20.28 This bronchoscopic image of a bronchial neurilemmoma shows a rounded polypoid lesion that is covered by intact mucosa.

Figure 20.29 the resected lung in a case of bronchial neurilemmoma demonstrates occlusion of the bronchial lumen by a uniform, yellow, solid tumor.

The histologic images associated with benign PNSTs are varied. Prototypical neurofibromas are plexiform in NF1, putatively reflecting a neoplastic attempt to recapitulate a neural plexus. Constituent cells are serpiginous, with attenuated fusiform nuclei and delicately fibrillary cytoplasm (Fig. 20.30). The supporting matrix is myxoedematous or collagenized, and it may contain scattered foam cells, mast cells, and lymphocytes. Mitotic activity is typically absent. Neurilemmomas—also termed schwannomas—are biphasic in their classic form, with compactly cellular (“Antoni A”) areas alternating with zones of loose cellularity and myxoid change (“Antoni B” foci; Figs. 20.31 and 20.32). Nuclei may be aligned in register in Antoni A areas, representing Verocay bodies (Fig. 20.33). Intralesional blood vessels have thick walls in many neurilemmomas, and a well-defined peripheral tumor capsule may be identified in some instances. Variants of neurilemmoma include cellular schwannoma, which manifests intersecting bundles of densely apposed, focally mitotic spindle cells in the context of an encapsulated mass (Fig. 20.34)¹¹⁰; glandular schwannoma; ancient schwannoma, showing scattered pleomorphic hyperchromatic nuclei in degenerative cells (Fig. 20.35); plexiform schwannoma, in which broad plexiform fascicles of tumor cells show the substructure of neurilemmoma; and melanotic psammomatous schwannoma, exhibiting microcalcifications and melanin pigmentation (Fig. 20.36).¹¹⁷ the last of these subtypes may be associated with myxomas of the skin, heart, and breast; the presence of cutaneous ephelides; and overactivity of the endocrine glands.

The immunophenotype of PNSTs features reactivity for vimentin and variable labeling for S-100 protein (Fig. 20.37), CD56, CD57, glial fibrillary acidic protein, and EMA. The last of these markers is believed to represent perineurial differentiation in this context. Keratin positivity is absent, except in the glands of glandular schwannoma, and myogenous markers should be negative.

Figure 20.30 the tumor cells in neurofibroma show serpiginous nuclear profiles and eosinophilic cytoplasm. They are bland, with no nuclear atypia or mitotic activity.

Figure 20.31 Antoni A areas of growth are shown in a bronchial neurilemmoma, represented by compact cellular apposition and intralesional vascular sclerosis.

Figure 20.32 An Antoni B focus in a bronchial neurilemmoma (lower left) with a myxoid intercellular matrix.

Figure 20.33 Verocay bodies are zones in Antoni A areas of neurilemmoma, in which nuclei form linear “stacks” that are aligned in register.

Figure 20.34 Cellular schwannoma (neurilemmoma) demonstrating densely agglomerated spindle cells with focal mitotic activity.

Figure 20.35 “Ancient” neurilemmoma showing degenerative atypia of tumor cell nuclei with mild pleomorphism and hyperchromasia.

Figure 20.36 (A) Melanotic psammomatous schwannoma (neurilemmoma) exhibiting internal microcalcifications and cytoplasmic pigment. (B) Positivity with a Fontana-Masson stain confirms the identity of the intralesional pigment as melanin.

As is true of all spindle cell lesions of the lung, it is necessary to exclude sarcomatoid carcinoma before making a final diagnosis of PNST; immunohistologic evaluation is the most expeditious means of doing so. In addition, other mesenchymal lesions of the lung—especially leiomyoma and leiomyomatous hamartoma—must be considered as alternatives to an interpretation of neurofibroma or neurilemmoma. The immunoprofiles of those lesions are dissimilar as well.

If the identification of PNST can be established in evaluations of bronchial biopsy specimens and radiographic findings support a benign diagnosis, the surgeon can undertake a conservative approach to the removal of such lesions.^101,104 However, small samples of neurogenic neoplasms are notoriously unreliable in predicting the biologic potential of PNSTs, and they should not be used in isolation to govern decisions on therapy.

Figure 20.37 Intense immunoreactivity for S-100 protein is seen in this bronchial neurilemmoma.

Granular Cell Tumors

Granular cell tumor (GCT; also known as Abrikossoff tumor^11%) may be seen in many anatomic locations.¹¹⁹ Fewer than 200 have been reported in the trachea and lungs.¹²⁰¹³⁸ Patients of any age may have such lesions, and multiple tumors in the same individual have been reported.¹³¹,¹³⁴,¹³⁷,¹³⁹,¹⁴⁰

Endoscopic examination often reveals a sessile polypoid endoluminal component, with intact overlying mucosa (Fig. 20.38).¹³⁰ Radiographic studies confirm that characteristic, but also demonstrate an infiltrative aspect to many GCTs that may lead to a mistaken preoperative diagnosis of malignancy.¹²⁹¹³⁵ GCTs in the peripheral lung parenchyma are unusual,¹³⁷ but these likewise may assume a spiculated appearance that closely simulates that of adenocarcinoma. This situation is further complicated by occasional case reports of GCTs that coexisted with malignant neoplasms.^141,142

Grossly, GCT is a white-tan, ill-defined mass with a gritty cut surface, again simulating the features of an infiltrating carcinoma. However, necrosis and hemorrhage are distinctly unusual. Maximum tumor size approximates 5 cm.

Figure 20.38 (A and B) the homogeneous white-gray cut surface of an endobronchial granular cell tumor (arrow) is seen in these gross photographs.

Figure 20.40 (A and B) Eosinophilic cytoplasmic granularity, with focal formation of targetoid bodies, is typical of granular cell tumors. Nuclei are oval with distinct chromocenters.

Figure 20.41 A fine-needle aspiration biopsy specimen of a bronchial granular cell tumor recapitulates and amplifies the cytologic features seen in tissue sections.

Figure 20.43 Nuclear and cytoplasmic immunoreactivity for S-100 protein in a bronchial granular cell tumor. This marker is present in approximately 80% of such lesions.

Figure 20.42 This electron photomicrograph of a granular cell tumor demonstrates innumerable secondary and tertiary cytoplasmic lysosomes.

Microscopically, these tumors comprise a uniform population of polygonal or fusiform cells that contain small ovoid hyperchromatic nuclei with indistinct nucleoli (Fig. 20.39). The cytoplasm is abundant, eosinophilic, or amphophilic, and coarsely granulated, often with the additional presence of rounded inclusions that superficially resemble Michaelis-Gutman bodies (Fig. 20.40). Like Michaelis-Gutman bodies, these may also have a targetoid configuration. Mitotic figures are typically scarce and physiologic; necrosis and vascular invasion are absent. The advancing border of GCTs may be “pushing” or irregular and permeative. A proportion of these lesions infiltrate deeply into the bronchial wall or even through it into the adjacent parenchyma. In nonpulmonary sites, such a growth pattern has been linked to a greater risk of recurrence,¹⁴³ but that correlation does not seem to apply to GCTs in the airways or lungs. The existence of primary malignant GCT of the respiratory tract has never been convincingly documented, and recurrent neoplasms are typically those that have never been completely excised.

FNA biopsy of GCT yields a monotonous population of large epithelioid cells that are variably cohesive. They contain ovoid nuclei, distinct chromocenters, and abundant granular cytoplasm that are best seen in Romanowsky-stained slides (Fig. 20.41). A plasmacytoid appearance is common.¹⁴⁴

Electron microscopy of GCTs shows a distinctive multiplicity of secondary and tertiary lysosomes in the cytoplasm of the tumor cells, virtually to the exclusion of other organelles (Fig. 20.42).^145,146 Immu- nohistologic evaluation most often reveals evidence of schwannian differentiation, with reactivity for S-100 protein, CD56, CD57, myelin basic protein, and combinations There of, in 80% to 85% of cases (Fig. 20.43).^{146 149} the abundance of lysosomes is reflected by their CD68 reactivity. Recently, the presence of calretinin and alpha-inhibin has also been reported in GCT.¹⁵⁰

An important caveat regarding the immunophenotype of this tumor type is that nonschwannian lesions containing granular cells are a heterogeneous group.¹⁵¹ Carcinomas (both neuroendocrine and non- endocrine),^152,153 smooth muscle tumors, endothelial proliferations, and neoplasms of uncommitted lineage have all been described with a granular cell phenotype. There fore it is important to include immunohistologic evaluations to address these possibilities in differential diagnosis, with or without ultrastructural studies. Oncocytoid granular cell grade 1 neuroendocrine carcinoma (carcinoid) of the lung is the most common simulator of GCT,^93,154 making chromogranin-A and synaptophysin important markers in this context.

As discussed earlier, aggressive behavior by bronchopulmonary GCT has not been observed. There fore conservative therapy for this neoplasm is warranted.

Benign Lesions Affecting Either the Airways or the Lung Parenchyma

Alveolar Adenoma

Alveolar adenoma (AA)¹⁵⁵ is typically a solitary peripheral parenchymal nodule found incidentally in asymptomatic adult patients, with no sex predilection.¹⁵⁶ On imaging studies, AA presents a rounded configuration and measures 1 to 6 cm in greatest dimension (Fig. 20.44).¹⁵⁷ the surgeon is likely to report that it “shells out” from the surrounding lung tissue.¹⁵⁸

Grossly, AA is circumscribed, with a spongy gray-white multilocular cut surface. Microscopically, it comprises many cystic spaces of variable sizes, which are mantled by low-cuboidal epithelial cells (Fig. 20.45).^155,156 Eosinophilic granular material is commonly present in the cyst lumina. The tissue between the cysts is represented by cytologically bland and closely apposed bluntly fusiform cells in a loose fibromyxoid matrix. Mitotic activity, nuclear pleomorphism, and necrosis are absent.¹⁵⁹ the immunohistochemical features of AA closely parallel those of sclerosing hemangioma (pneumocytoma; discussed later), and it is our belief— shared by other authors as well¹⁶⁰—that the two tumors are likely part of a neoplastic family rather than entirely distinct entities. One sees epithelial markers—including thyroid transcription factor 1—in the cuboidal cells lining tumoral microcysts, but not in the stromal elements.^156,159-162 On the other hand, the latter components are reactive for vimentin, and often for CD34.¹⁵⁶

Figure 20.44 This computed tomogram of the chest shows a 5- to 6-mm "coin” lesion beneath the pleura in the left posterior lung field (arrow), representing an alveolar adenoma.

Figure 20.45 (A-D) Alveolar adenoma of the lung demonstrates a sharply circumscribed low-power image and internal microcyst formation. Bland low cuboidal epithelium lines the cyst cavities, and bland, bluntly fusiform stromal cells are set in a fibromyxoid stroma between the microcysts.

The differential diagnosis of AA is limited. Aside from sclerosing hemangioma, which is usually larger than AA and does not have its prominently cystic substructure,¹⁶⁰ the principal considerations are pulmonary hemangioma-lymphangioma and atypical adenomatous hyperplasia (see Chapter 16). The vascular lesions can be identified by appropriate immunohistochemical stains.^163,164 Atypical adenomatous hyperplasia lacks microcysts and does not contain a mesenchymal stromal cell component.¹⁶⁵

Even though fewer than 50 cases of AA have been reported, the behavior of this tumor has been uniformly favorable. Hence conservative wedge excision appears to represent adequate treatment.^{156,158,166,167}

Papillary Adenoma

Another uncommon neoplasm that is likely related to sclerosing hemangioma has been reported separately as papillary adenoma of the lung (PAL). It may be seen in children and adults alike as a nondescript and asymptomatic parenchymal nodule in imaging studies.^8,168-177 Multifocality occurs, and in one case, such multiplicity was seen in a patient with neurofibromatosis.¹⁷⁴ Grossly, this tumor usually shows sharp circumscription from the surrounding lung tissue in most cases, with a solid tan-white cut surface (Fig. 20.46). Nonetheless, a few cases have had infiltrative characteristics.^170,178,179

Histologically, PAL shows papillary profiles of cuboidal to low columnar, nonciliated, focally vacuolated epithelial cells that mantle well-formed fibrovascular cores (Fig. 20.47). The stroma in the latter structures may contain mixed inflammatory infiltrates, potentially including lymphocytes, mast cells, plasma cells, and eosinophils. The surrounding lung typically demonstrates a fibroblastic response to the lesion, sometimes with formation of a circumferential pseudocapsule. Mitotic activity is limited, and necrosis is absent.

Immunohistochemical studies of PAL show consistent reactivity for keratin, surfactant-related apoproteins, thyroid transcription factor 1, and napsin-A in the neoplastic cells.^170,179 In addition, labeling for Clara cell antigen and carcinoembryonic antigen may be present. Ultrastructural analysis shows microvillous differentiation of the plasmalemmae and the presence of lamellar bodies in the tumor cell cytoplasm (Fig. 20.48).^168-171,179

Figure 20.46 Gross photograph of pulmonary papillary adenoma, which the surgeon reported as having "shelled-out” from the surrounding lung parenchyma.

Because of the sometimes-infiltrative nature of PAL, some authors have suggested that it be considered borderline malignant.^170,178,179 Nevertheless, there have been no reports of recurrence or metastasis of this lesion, and conservative surgical removal appears sufficient.

Leiomyoma

Solitary leiomyoma of the respiratory tract has been reported as an independent entity, distinct from hamartomas. These tumors are most often located in the wall of the trachea or bronchi (Fig. 20.49), with pulmonary parenchymal or pleural origins rare.^180-192 Bronchoscopic and gross evaluation of central lesions shows a dome-shaped endoluminal mass, usually with a smooth mucosal surface (Figs. 20.50 and 20.51).

Histologically, bronchial leiomyoma is identical to benign smooth muscle tumors elsewhere in the body, comprising intertwining fascicles of spindle cells with fusiform nuclear contours, perinuclear cytoplasmic vacuolization, and finely fibrillary eosinophilic cytoplasm (Fig. 20.52). Mitotic activity is limited, there is no infiltration of adjacent tissues, and necrosis is absent.

The fine structural features of smooth muscle proliferations in the lung include pericellular basal lamina, plasmalemmal hemidesmosomes and micropinocytotic vesicles, skeins of cytoplasmic thin filaments, and intrafilamentous dense bodies.^193-195 Immunohistologically, one typically sees reactivity for muscle-specific actin, alpha-isoform (“smooth muscle”) actin, desmin, calponin, and caldesmon, with an absence of S-100 protein, CD56, CD57, and keratin.¹⁸⁵

The differential diagnosis of primary smooth muscle tumors of the respiratory tract includes hamartomas as well as PNSTs and sarcomatoid carcinomas. Although conventional histologic analysis is usually sufficient to distinguish between those possibilities, the special studies just cited may be necessary.

Solitary smooth muscle tumors are treated with simple but complete excision, if thorough clinical evaluation has excluded an extrapulmonary primary lesion of the same type. The latter proviso relates to the fact that some leiomyosarcomas (particularly in the retroperitoneum) are extremely low-grade proliferations that may produce pseudoleiomyo- matous metastases.¹⁹⁶

Glomus Tumor and Glomangioma

Glomus tumor and glomangioma (GTG)^197-202 are most often seen in the skin and superficial soft tissue,²⁰³ but also occur with relative frequency in the alimentary tract²⁰⁴ and rarely the respiratory system.²⁰¹ Pulmonary GTG affects adults, with an age range of 20 to 68 years (Fig. 20.53).²⁰¹

The gross features of GTG include a nodular configuration, with uniform gray-white or yellow cut surfaces and a maximum dimension of 6.5 cm, sometimes mimicking a carcinoid tumor.²⁰²

Microscopically, the lesions include compact polygonal or round cells that are closely apposed (Fig. 20.54). Nuclei are round or oval, with dispersed chromatin, scarce mitotic activity, and little if any pleomorphism. Cytoplasm is modest in amount and amphophilic or eosinophilic (Fig. 20.55). Supporting stroma consists of delicate fibro- vascular septations. In lesions that lie toward the glomangioma pole of the spectrum, dilated vascular spaces also punctuate the lesions (Fig. 20.56), and some of these may assume a “moose antler” shape, as in the vessels seen in hemangiopericytomas. Although most are well circumscribed, a proportion of pulmonary GTGs are infiltrative.

Figure 20.47 (A and B) Papillary fronds of variable size and shape are mantled by bland polygonal epithelial cells in papillary adenoma of the lung.

Figure 20.48 (A and B) These electron photomicrographs of papillary adenoma show plasmalemmal microvilli and cytoplasmic tigroid inclusions. The latter are organelles that contain surfactant apolipoprotein, typical of type II pneumocytes.

Figure 20.49 An endoluminal mass evident in the right bronchus intermedius proved to be a leiomyoma.

Figure 20.50 A leiomyoma of the bronchus, which was endoscopically removed, shows internal fasciculation and a white-gray cut surface.

Figure 20.51 Low-power micrograph demonstrates the relationship of an endoluminal bronchial leiomyoma to the wall of the airway.

Figure 20.52 A leiomyoma of the bronchus is composed of fascicles of cytologically bland spindle cells with bluntly fusiform nuclei, perinuclear lucency, and finely fibrillar eosinophilic cytoplasm.

Figure 20.53 (A) This chest radiograph shows a circumscribed nodular lesion in the right upper lung field. (B) A computed tomogram from another patient demonstrates an internally heterogeneous spherical nodule in the right midlung. Both lesions were glomus tumors.

Figure 20.54 A low-power micrograph of a pulmonary glomus tumor showing a monotonous sheetlike proliferation of cells.

Figure 20.55 (A and B) A higher-power micrograph of a pulmonary glomus tumor demonstrating cellular monomorphism with round to oval nuclei, dispersed chromatin, and amphophilic cytoplasm. A differential diagnosis with a low-grade neuroendocrine tumor would be difficult morphologically.

Figure 20.56 (A) This example of glomangioma demonstrates dilated vascular structures that punctuate a proliferation of bland cuboidal cells. (B) the myogenous-perivascular nature of the tumoral elements is supported by immunoreactivity for muscle-specific actin.

One exception to this description was represented by a tumor in the series of Gaertner and associates.²⁰¹ This tumor demonstrated infiltrative growth, obvious nuclear atypia with prominent nucleoli, necrosis, and brisk mitotic activity. It metastasized to several visceral sites and soft tissue, causing death in 1.3 years. Thus it was classified as a glomangiosarcoma.

Electron microscopic examination of GTGs shows evidence of specialized smooth muscle differentiation (discussed earlier), as expected in pericytic perivascular cells.^200,201 the immunophenotype of GTG includes reactivity for vimentin, actin, laminin, and collagen type IV, with an absence of keratin, neuroendocrine markers, CD31, and CD34.²⁰¹

The differential diagnosis of GTG centers on the alternatives of grade 1 neuroendocrine carcinoma (carcinoid), primitive neuroectodermal tumor of the lung, intrapulmonary paraganglioma, and hemangiopericytoma-solitary fibrous tumor (SFT). The first three of these lesions reproducibly demonstrate neuroendocrine or neuroectodermal markers, such as chromogranin-A, synaptophysin, CD56, and CD99—all of which are absent in GTG—and hemangiopericytoma- SFTs consistently lack the actin positivity that is expected in glomus tumors.

Glomus tumors and glomangiomas are treated variably with lobectomy, sleeve resection of the bronchus, or wedge resection of the subpleural lung parenchyma. Findings on follow-up are benign.

Chondroma, Myxoma, and Fibromyxoma

Several authors have posited that true chondromas and fibromyxomas of the lung^205,206 exist apart from pulmonary hamartomas (see Chapter 18).^207-210 In particular, Carney²¹¹ and Wick et al.²¹² have documented a constellation of masses in young women wherein multifocal cartilaginous neoplasms—apparently true chondromas—are part of a syndromic triad that includes extraadrenal paragangliomas and gastric epithelioid stromal tumors. These are histologically different from “usual” chondroid hamartomas of the lung.²¹³ They are frequently multiple, although they may occur singly (Fig. 20.57) in young women, more often than in elderly men (as is true for hamartomas). Chondromas lack the epithelial entrapment and “uncommitted” fibroblastic mesenchymal component that is observed in chondroid hamartomas. Instead, the interface between chondromas and the surrounding lung parenchyma is sharply demarcated (Fig. 20.58). Constituent chondrocytes are hyaline, and metaplastic osteoid is common in such lesions, more than in pulmonary chondroid hamartomas.

Pulmonary chondromas do not have malignant potential but are frequently confused with metastases from gastrointestinal stromal tumors because of the clinical setting in which they occur.

Figure 20.57 A peripherally calcified spheroid mass is seen in the anterior right lung field in this computed tomogram. Excision of the mass revealed a globular lesion with obviously chondroid features on gross examination.

Solitary Pulmonary Hemangioma and Hemangiomatosis

True hemangiomas of the tracheobronchial tree and lung are vanishingly rare. They are usually detected in childhood.²¹⁴ Discrete, variably dense and sometimes-cystic masses are present on chest radiographs (especially high-resolution CT; Fig. 20.59)²¹⁵; they may be multiple. The maximum size of individual lesions can be several centimeters. In at least one case, an intrapulmonary hemangioma was interpreted radiographically as an intrapulmonary bronchogenic cyst.²¹⁴ Simple excision has been curative.

Microscopically, true hemangiomas of the airways and lungs completely replace a portion of the native tissue, with a proliferation of tubular vascular spaces lined by bland endothelial cells. A capillary hemangioma pattern appears to be most common, in which the caliber of the neoplastic vessels approximates that of normal small venules or capillaries (Fig. 20.60). It is implicit in this diagnosis that no other tumoral elements be identified; this is an important caveat because several other neoplasms in the lung—including some carcinomas—may contain blood lakes or pseudovascular foci that resemble the image of vascular proliferations.²¹⁶

Figure 20.59 This thoracic computed tomogram shows an enhancing nodular lesion (arrow) in the anterior left lung field, representing an intrapulmonary hemangioma.

Another salient differential diagnostic consideration is pulmonary hemangiomatosis (see Chapter 11). That is a condition in which capillarysized blood vessels proliferate throughout the preexisting pulmonary parenchyma and stroma, including the alveolar septa, interlobular and interlobar septa, bronchial and bronchiolar walls, intrapulmonary vasa vasorum, and pleural surfaces.²¹⁷’²¹⁸ In reality, it is probably not a neoplastic process at all, but rather a malformative or reactive proliferation. For example, some cases of pulmonary hemangiomatosis have been associated with longstanding passive congestion of the lungs, as seen in left-sided heart failure.²¹⁸

Lipoma and Lipoblastoma

Separating examples of lipoma of the trachea and major bronchi and lung parenchyma (LTMB)^219-232 from adipocytic predominant hamartomas may be difficult, and pathologic criteria for doing so are arbitrary.²²⁵ Patients with LTMB are adults, usually in the fifth or sixth decade of life.²²²’²²⁶ Endoscopic examination shows a variably polypoid submucosal nodule in one of the first three subdivisions of the tracheobronchial tree; radiographs demonstrate secondary atelectasis, obstructive pneumonia, or a mass in 80% of cases, but the remainder have no radiologic abnormalities on plain films.²²⁰ CTs are more sensitive in revealing the presence of lesions in airway lumina (Figs. 20.61 and 20.62).²²⁴ Current treatment recommendations are for conservative endoscopic resection after a transbronchial biopsy has established the adipocytic nature of the lesion.

Intrapulmonary lipomas are often subpleural (Fig. 20.63) and may even protrude into the pleural space. They are typically detected incidentally on chest radiographs. CT shows that lipomas of the lung have a density approximating that of pleural adipose tissue.²²⁴ Occasional lesions of this type have been found coincidentally in patients with pulmonary carcinomas.²²¹ If the lipomas are multiple, small, and subpleural, they may also imitate metastatic lesions.²³¹’²³²

Figure 20.60 (A and B) Numerous closely set small tubular vascular lumina are apparent in this capillary hemangioma, apposing the lumen of an airway.

Figure 20.61 This computed tomogram demonstrates an endoluminal tracheal mass that proved to be a lipoma.

Lipoblastoma, a neoplasm of young children,²³³ may affect the pleura and chest wall, but only anecdotal reports exist of intrapulmonary lipoblastomas.^234,235 They may be extremely large, filling almost an entire hemithorax.²³⁴ Excision is curative in the few cases with meaningful follow-up.

Liposarcoma is the rarest of primary pulmonary adipocytic neoplasms, and it has usually presented as a large single peripheral mass.^236,237 Liposarcoma-like components can be seen as part of sarcomatoid carcinomas,²³⁸ and the latter lesions are far more common than primary liposarcomas of the lung.

The principal gross feature of intrapulmonary adipocytic tumors is a yellow, globular, relatively soft mass in the parenchyma (Fig. 20.63). Internal fibrous septation may be apparent, as may a circumferential capsule or small foci of intralesional sclerosis. There is no necrosis or hemorrhage.

Figure 20.62 This resection specimen of the lesion shown in Fig. 20.61 shows uniform yellow tissue with internal lobulation.

Figure 20.63 A peripheral intrapulmonary lipoma, represented by a large globular tan-yellow lesion beneath the pleural surface.

Microscopically, one sees sheets of fully mature adipocytes in ordinary lipomas (Fig. 20.64), supported by delicate fibrovascular stroma. Atypical intrapulmonary lipomas, showing scattered multinucleated “floret” cells, have been rarely reported²²⁸; however, this does not seem to have any bearing on prognosis. Lipoblastomas have a more lobulated substructure, with an admixture of uncommitted fibromyxoid tissue among mature fat cells (Fig. 20.65).^233,239 True lipoblasts may be apparent as well, rare mitotic figures may be evident, and the supporting stromal tissue contains a delicately arborizing capillary network (Fig. 20.66). There fore the overall image of lipoblastoma may be quite similar to that of myxoid liposarcoma, and the mutually exclusive occurrence of those tumors in different age groups—with liposarcomas being seen in adults—is important to their proper identification.

Liposarcoma in the lung may assume any of the recognized morphotypes of that tumor (e.g., lipoma-like, sclerosing, myxoid, round cell, pleomorphic, and dedifferentiated).^236,237 Those variants are recapitulated in metastatic intrapulmonary liposarcomas from primary soft tissue sites.²⁴⁰

Figure 20.64 Mature adipocytes with compact eccentric nuclei and abundant lipid-filled cytoplasm are evident in this pulmonary lipoma.

Figure 20.65 (A) A fatty mass with areas of more fibrous growth was removed from the left thorax in a young patient. (B) An admixture of mature lipocytes, bland stellate cells, and myxoid stroma is apparent in the lesion, which is a lipoblastoma.

Karyotypic analysis using fluorescent in situ hybridization may be useful in the differential diagnosis. Abnormalities in chromosome 8q are most common in lipoblastomas,²³⁹ whereas myxoid liposarcoma demonstrates a reproducible t(12;16) chromosomal translocation.²⁴¹ Parenthetically, cytogenetic profiles are somewhat less helpful in the distinction between lipomas of the lung and lipomatous hamartomas, both of which may show abnormalities in chromosome 12.^229,242 However, exchanges of material between chromosomes 6 and 14 are also potentially observed in hamartomas, but not lipomas.²⁴³

Immunohistology of fatty tumors of the lungs shows consistent reactivity for S-100 protein in the adipocytic elements, as well as high- mobility-group proteins.²⁴² Lipoblastoma may also show positivity for factor XIIIa in its stellate and fusiform cells.²³⁹

Angiomyolipoma

In recent years, it has become apparent that a family of neoplasms—which may arise in the kidney, pancreas, alimentary system, liver, soft tissue, or respiratory tract—demonstrates differentiation toward a unique cell type that has both myogenous and melanocytic features.^244-247 These tumors have been variously called angiomyolipomas, perivascular epithelioid cell neoplasms (PEComas), and myomelanocytomas (MMCs).^244-248 If a typical morphologic appearance, including smooth muscle, fat, and vascular proliferation, is observed, the first of these terms is still preferred; a few lesions with such characteristics have been reported in the lung.^249-254 Another member of this nosologic group— The pulmonary clear cell or “sugar tumor”—is discussed later. All of these proliferations potentially share immunoreactivity with the melanocyte-related antibody human melanin black (HMB)-45, as well as antiactins.²⁴⁵ Other immunohistochemical markers of melanocytic and smooth muscle differentiation— such as antibodies to S-100 protein, tyrosinase, HMB-50, melanoma antigen recognized by T cells 1 (MART-1), caldesmon, calponin, and desmin—may also label them.²⁴⁶

Figure 20.66 An internal vascular stroma is evident in this lipoblastoma, superficially simulating the appearance of myxoid liposarcoma.

A proportion of patients with angiomyolipomas, regardless of anatomic location, will have phakomatosis tuberous sclerosis (Bourneville syndrome). It classically includes nodular periventricular glial proliferations and subependymal giant cell astrocytomas in the brain; cutaneous connective tissue nevi; often-multifocal renal angiomyolipomas; and pulmonary lymphangioleiomyomatosis, with or without multifocal micronodular pneumocytic hyperplasia (see Chapter 7).^250,255-257

Angiomyolipoma of the lungs is typically small, usually less than 2 cm in maximal dimension. They show sharp interfaces with the surrounding lung tissue and uniform yellow-tan cut surfaces.

Microscopically, pulmonary angiomyolipoma is identical to its better-known renal counterpart. Prototypically, it manifests a concatenation of mature fat, variably sized, and haphazardly arranged blood vessels with muscular walls, and nests or skeins of fusiform or epithelioid smooth muscle elements (Fig. 20.67). Either the fat or the smooth muscle may dominate the histologic picture and cause diagnostic confusion with either pure adipocytic neoplasms or sarcomas, respectively. Nuclear atypia has been seen in the smooth muscle elements of angiomyolipomas in extrapulmonary sites, and rare cases outside the lung have even shown overtly malignant transformation with necrosis and atypical mitotic activity.²⁵⁸ Those attributes have not been seen in pulmonary lesions of this type.

Electron microscopic analysis of angiomyolipoma demonstrates findings that recall the characteristics of smooth muscle cells, including pericellular basal lamina and plasmalemma-associated pinocytotic vesicles.²⁴⁹ Cytoplasmic bundles of thin filaments have not been found. Approximately 50% of such neoplasms show cytoplasmic premelanosomes.²⁴⁶

The principal immunohistologic findings in angiomyolipomas have been described earlier. Adachi and coworkers²⁵⁹ have reported immu- noreactivity for CD1a in PEComas, including angiomyolipoma, but we have been unable to reproduce this finding.

In its “classic” form, angiomyolipoma has no realistic differential diagnostic alternatives. Nevertheless, its morphologic variants may be difficult to distinguish from metastatic melanomas, carcinomas, or sarcomas in the lung. Before an unqualified diagnosis of a pure pulmonary smooth muscle tumor or melanoma is made, additional immunocyto- chemical evaluation with HMB-45 (Fig. 20.68) and antiactins is probably a prudent step.

Myelolipoma

Myelolipoma is a peculiar lesion that is typically located in the adrenal glands or the retroperitoneum.^260,261 As its name suggests, it comprises a tumefactive admixture of mature adipose tissue and hematopoietic precursor cells, including megakaryocytes (Figs. 20.69 and 20.70). It is still unclear whether myelolipoma represents a true neoplasm or a peculiar form of extramedullary hematopoiesis; the difference between those entities may sometimes be only semantic. Alternatively, myelolipoma could be regarded as a lipoma that has been secondarily populated by bone marrow elements.

In any event, anecdotal reports have been made of primary pulmonary myelolipoma, all of which occurred in adult patients.^262-266 They may occur multiply and mimic metastases.²⁶²

The pathologic features of myelolipoma are so distinctive that it has no viable differential diagnosis. Nevertheless, it is probably worthwhile to evaluate the peripheral blood picture to exclude the possibility of functional extramedullary hematopoiesis.

Benign Tumors of the Pleura

Adenomatoid Tumor

It is an unfortunate truism that completely benign neoplasms of the pleura are a distinct rarity. Indeed, the only representative of that diagnostic category is the adenomatoid tumor. That neoplasm is a lesion with mesothelial differentiation that is most often encountered in the adnexal soft tissue surrounding the uterus and testes.^267,268

Figure 20.67 Angiomyolipomas show a tripartite constituency of mature adipocytes, large blood vessels, and epithelioid and fusiform myogenous cells, with variable prominence of each component.

Figure 20.68 HMB-45 immunoreactivity in angiomyolipoma.

Figure 20.69 (A) A relatively circumscribed homogeneous nodule is present in the mid-left lung field in this computed tomogram. (B) This gross photograph of the excised lesion shows a lobulated circumscribed yellow and red lesion, resembling a hemorrhagic lipoma. In reality, the tumor was a myelolipoma. The patient had no evidence of a hematologic disorder.

Only five cases have been described in the pleura.^269-272 These lesions occurred in a middle-aged man, two middle-aged women, an elderly woman, and an elderly man. They were all incidental findings during surgical procedures that were done for unrelated lesions (pulmonary squamous cell carcinoma, mesothelioma, pulmonary adenosquamous carcinoma, esophageal adenocarcinoma, and pulmonary histoplas- moma), and they showed no subsequent evidence of aggressive behavior.

Pleural adenomatoid tumors are unencapsulated and measure 0.5-2.5 cm in greatest dimension. Microscopically, the lesions are composed of epithelioid cells organized into compact glandlike profiles (Fig. 20.71). They have vesicular nuclear chromatin, inconspicuous nucleoli, and relatively abundant eosinophilic or vacuolated cytoplasm. No areas of nuclear pleomorphism should be present, mitotic figures are rare, and they do not invade the subjacent lung parenchyma.

Electron microscopy²⁶⁹ shows branching plasmalemmal microvilli and prominent intercellular attachment complexes, typical of mesothelial lesions. Immunohistologically, the tumor cells label for keratin and calretinin, but are negative for carcinoembryonic antigen, CD15, CD34, Ber-EP4 antigen, and tumor-associated glycoprotein 72.

The principal components of the differential diagnosis for pleural adenomatoid tumor are metastatic adenocarcinoma and malignant mesothelioma. Both of those possibilities are rendered unlikely by the bland histologic images of pleural adenomatoid tumor, with no evidence of infiltrative growth (see Chapter 20). Ki-67 (MIB-1) staining may also be helpful in this setting²⁷² because the labeling index in adenomatoid tumor is only 1%-2%. In contrast, microcystic (adenomatoid tumor-like) mesothelioma of the pleura shows a high Ki-67 index (>50%).²⁷¹

Calcifying Fibrous Pseudotumor

An unusual entity known as calcifying fibrous pseudotumor (CFPT) has been described in the pleura.^273-276 This lesion is histologically similar, if not identical, to CFPTs of the soft tissue.²⁷⁷

The documented cases of pleural CFPT have occurred in adults (age range, 23-46 years), most of whom were women. Pleural-based masses^278,279 are present on chest radiographs, and CT scans demonstrate well-demarcated, partially calcified nodular lesions, measuring up to 12 cm in diameter (Fig. 20.72). An intrapulmonary CFPT has been reported.²⁸⁰

Histologically, the masses are circumscribed nonencapsulated fibrous lesions composed of dense, hyalinized, collagenous tissue, with interspersed bland spindle cells (Fig. 20.73). They are generally hypocellular, particularly at the periphery, without nuclear atypia. A scant chronic inflammatory infiltrate may be seen, without lymphoid aggregates, giant cells, or necrosis. All lesions also feature calcifications of the psammomatous (Fig. 20.74), as well as dystrophic types. These histologic features are identical to those of CFPTs of soft tissue.^281-283

Figure 20.72 A computed tomogram (A) and a gross photograph (B) of a calcifying fibrous pseudotumor of the pleura show a well-demarcated nodular lesion.

Figure 20.73 A calcifying pseudotumor of the pleura, represented by a hypocellular proliferation of bland spindle cells that are set in a dense and hyalinized collagenous stroma.

The differential diagnosis includes inflammatory myofibroblastic tumor (IMT; discussed later), as well as hyaline pleural plaques, tumefac- tive pleural fibrosis, calcified or hyalinizing granulomas, and amyloidosis. The clinical presentation, gross features, and microscopic features of CFPT argue against any of those considerations, as does its regular content of psammomatous calcifications. Follow-up has shown no examples of untoward behavior.

Leiomyoma

Leiomyoma of the pleura has been reported only anecdotally.^284,285 One might question whether a distinction between that lesion and desmoid tumor (DT) was pursued conclusively in such cases.

Biologically Borderline Tumors of the Lung and Pleura

The biologic difference between benign and borderline (very low-grade malignant) tumors is a subtle one because few of the latter neoplasms cause significant mortality. For this discussion, we have defined borderline lesions of the lung and pleura as those that have shown a potential for local recurrence after apparently adequate excision, rare embolic metastasis, or both. It is readily acknowledged that other observers may regard the same tumors as either benign or overtly malignant.

Inflammatory Myofibroblastic Tumor (Inflammatory Pseudotumor)

In 1939, Brunn²⁸⁶ described two pulmonary lesions that were composed of spindle cells admixed with inflammatory elements in patients with fever and weight loss. The systemic symptoms disappeared after surgical removal of the lung tumors. Although they were believed to be true neoplasms of probable smooth muscle lineage, subsequent authors espoused the theory that masses with the same attributes were inflammatory and reparative lesions.^287,288 Hence the term inflammatory pseudotumor gained favor. However, Spencer²⁸⁹ noted that a proportion of such proliferations behaved in a biologically malignant fashion, and other reports also documented the presence of vascular invasion and recurrences.^290-292 Molecular analyses done in the 1990s revealed a clonal character of some inflammatory pseudotumors in the lungs and other anatomic sites,^293-295 and together with aggregated clinicopathologic information, these data resulted in amendment of their name to inflammatory myofibroblastic tumors.²⁹⁶ It is now accepted that they are separate from inflammatory pseudotumors and that IMTs form a conceptual continuum with inflammatory fibrosarcoma or myofibrosarcoma.^297-300 Because they may recur and occasionally metastasize, IMTs are best considered biologically “borderline” neoplasms.

The lung is most frequently affected by IMT, among all potential topographic locations.²⁹² Although the majority of IMTs are seen in children and young adults, they may be encountered in patients of all ages, with no sex predilection.²⁹² Some IMTs are situated in the large airways, with no parenchymal involvement, but they are exceptional; most arise in the peripheral lung fields. Systemic symptoms of a paraneoplastic nature have been reported in up to 50% of cases, including such findings as anemia, fever, weight loss, hyperglobulinemia, leukothrombocytosis, and elevations in the erythrocyte sedimentation rate.^298,300 As discussed earlier, those abnormalities typically remit when the IMT is removed. The remaining cases present with cough, vague chest discomfort, or hemoptysis, or are asymptomatic, with the lesions found incidentally on chest radiographs.²⁹⁶ On imaging studies, IMT is typically a lobulated or globoid mass (Fig. 20.75), usually measuring less than 5 cm in maximum dimension. Occasionally, it may attain a size of greater than 10 cm; internal calcifications are commonly seen. Infiltration of great vessels, mediastinal soft tissue, or the chest wall is apparent radiographically in a minority of cases.

Figure 20.74 Spherical (A) and irregular (B) calcifications are apparent in these photomicrographs of a calcifying fibrous pseudotumor of the pleura.

Figure 20.75 Inflammatory myofibroblastic tumors of the lung manifest as a small peripheral nodule (A) and a large, variably dense hemithoracic mass (B) on computed tomograms.

Gross examination of IMTs shows a deceptively circumscribed appearance, with a gray-tan or yellow cut surface. Grittiness may be encountered during sectioning because of microcalcification. Foci of gross necrosis and hemorrhage are exceptional. When the tumor is in proximity to large airways or blood vessels, growth into those structures can be seen, with compromise of their lumina by tumor tissue.

The histologic profile of IMT features a proliferation of relatively bland spindle cells arranged haphazardly or in vague fascicles (Figs. 20.76 and 20.77).^296,298,301 In contrast to the gross appearance, this lesion has an irregular peripheral zone of growth microscopically, with tongues of tumors that comingle with adjacent normal tissues. Not surprisingly, infiltration of blood vessels, bronchi, and pleura may be evident. Nuclei in the neoplastic fusiform elements usually contain dispersed or vesicular chromatin with compact nucleoli (Fig. 20.78). Mitotic activity is typically easily found, but without pathologic division figures. Cytoplasm is amphophilic or lightly eosinophilic, and may show a faintly fibrillar character. Admixed inflammatory cells are greatly variable in density and type, and some cases of IMT show virtually none. Lymphocytes, plasma cells, macrophages, eosinophils, and neutrophils are also potentially represented (Fig. 20.79), and intralesional aggregates of xanthomatized foam cells are sometimes apparent. Some cases demonstrate rather striking zones of sclerosis, and these may even be hyalin- ized. On the other hand, 20% to 30% of these lesions show dense cellularity with focal or global nuclear atypia, relatively high nuclear- to-cytoplasmic ratios, nuclear hyperchromasia, mild nuclear pleomor- phism, and zones of necrosis.²⁹²

Figure 20.76 Inflammatory myofibroblastic tumor of the lung showing a fascicular spindle cell proliferation with admixed lymphoid elements.

Figure 20.77 the spindle cells in this pulmonary inflammatory myofibroblastic tumor are arranged in interweaving bundles.

Figure 20.78 This area in an inflammatory myofibroblastic tumor demonstrates moderate pleomorphism of the constituent tumor cells.

Figure 20.79 Intralesional lymphocytes and plasma cells are numerous in this pulmonary inflammatory myofibroblastic tumor.

Figure 20.80 Diffuse immunoreactivity is present for ALK-1 protein in this inflammatory myofibroblastic tumor of the lung.

Electron microscopic evaluation of IMTs shows that the tumor cells possess some features associated with smooth muscle, such as plasmalemmal dense patches, pinocytotic vesicles, and cytoplasmic bundles of thin (actin-type) filaments. Pericellular basal lamina is variably present, but There are no intercellular attachment complexes.²⁹⁶

By immunohistochemical assessment, the spindle cells react with antibodies to vimentin, alpha-isoform, and muscle-specific actins, and calponin, but usually not with desmin, caldesmon, CD34, or keratin.²⁹⁸ Mutant p53 protein is detectable immunohistologically in fewer than 10% of cases.²⁹⁵ On the other hand, two proteins that relate to reproducible cytogenetic abnormalities in chromosome 2p23 in IMTs are detectable in approximately 40% of these lesions. These are known as anaplastic lymphoma kinase 1 (ALK-1; Fig. 20.80) and p80 and were originally studied in anaplastic large-cell (Ki-1) lymphomas.³⁰² Coffin et al.³⁰³ found that ALK-1 reactivity predominated in IMTs of patients 20 years of age and older; those lesions also were more likely to demonstrate cytomor- phologic atypia.

Figure 20.81 Inflammatory sarcomatoid carcinoma (ISC) represents an important differential diagnostic alternative to inflammatory myofibroblastic tumor (IMT). (A) the gross appearance of such a carcinoma is shown and is similar to that of many IMTs. (B) Similarly, admixed chronic inflammatory cells are seen in both IMT and ISC. These may obscure the tumor cells, which are best seen in immunostains for keratin and epithelial membrane antigen. Vascular invasion is particularly predominant in ISC, as shown.

The differential diagnosis of pulmonary IMT includes tumefactive organizing pneumonia³⁰¹; true inflammatory pseudotumor or plasma cell granuloma (see Chapter 18); immunoglobulin G4 (IgG4)-predominant lymphoplasmacytic lesions³⁰⁴; smooth muscle proliferations in the lung; inflammatory sarcomatoid carcinoma (Fig. 20.81)²⁹²; and inflammatory malignant fibrous histiocytoma. ALK-1/p80 reactivity is diagnostic of IMT in this setting, but as mentioned earlier, is seen in only a minority of cases. The spindle cells of inflammatory sarcomatoid carcinoma can be labeled for keratin and EMA, in contrast to those of IMT.^292,305 Inflammatory malignant fibrous histiocytoma is typically nonreactive for actins or calponin, as seen in IMT. Spindle cells in organizing pneumonia typically form smaller whorls of spindle cells than IMT.²⁹⁹ IgG4-predominant lymphoplasmacytic lesions are, by definition, recognized by a preponderance of IgG4-immunoreactive cells in the inflammatory components.³⁰⁴

There are few, if any, pathologic variables that can be used successfully in any given case of IMT to predict its biologic behavior with certainty.³⁰⁶ Some examples of pulmonary IMT have been observed for extended periods with minimal growth. Spontaneous complete resolution has also been recorded, and a few lesions have diminished in size after nonsurgical therapy.²⁹⁸ Operative removal is usually necessary to establish a firm diagnosis of IMT, and if the lesion has been completely excised, no further intervention is required. On the other hand, it is logical to expect that incomplete removal—particularly if invasion of adjacent extrapulmonary tissues is present—might, in some instances, be followed by continued growth.³⁰⁷ In particular, involvement of the pleura, pulmonary hilum, diaphragm, or mediastinum is associated with morbidity from IMTs of the lung. In exceptional cases, they may even prove fatal if they are massive and infiltrate the mediastinum extensively, or if distant spread occurs. Overall, recurrence of IMT is seen in approximately 55% of cases, and roughly 10% metastasize.³⁰³

Sclerosing Hemangioma (Pneumocytoma)

More than 50 years ago, Liebow and Hubbell³⁰⁸ described a peculiar tumor of the peripheral lung parenchyma with a sclerosing, angiomatoid, and papillary architecture. They gave it the name sclerosing hemangioma, but this designation was chosen in unfortunate mimicry of a convention then extant in dermatopathology. In the 1950s, the lesion now known as dermatofibroma or cutaneous fibrous histiocytoma was likewise commonly called sclerosing hemangioma,³⁰⁹ because it sometimes showed internal blood lakes and hemosiderosis. In their seminal description of sclerosing hemangioma of the lung, Liebow and Hubbell disavowed an endothelial derivation for the tumor and appended the alternative appellations of histiocytoma and xanthoma, perhaps in deference to the true identity of its alleged dermal analog. This enigmatic series of nosologic and terminologic choices set the stage for confusion in the succeeding decades. Various studies of the cellular nature of pulmonary sclerosing hemangioma have suggested vascular, fibrohistiocytic, mesothelial, and epithelial lineages,^310-314 and controversies over such proposals persist to some extent.

Based on the aggregated data,^315,316 this tumor is properly considered as a neoplasm showing differentiation that is most like that of embryonic (uncommitted) respiratory epithelium. There fore the entity in question is best designated as pneumocytoma, as suggested by Shimosato³¹⁷; however, the World Health Organization has persisted in using the historic name sclerosing hemangioma.

Sclerosing hemangioma can affect patients of almost any age, from early childhood³¹⁸ through the end of life. Females predominate by a factor of 5 : 1.^319-329 Only approximately 20% of patients have any respiratory symptoms at the time their tumors are found. It may arise in any of the pulmonary lobes; localization in the large airways, pleura, and mediastinum has been rarely reported.^319,330

Radiographically, patients with sclerosing hemangioma usually have solitary peripheral masses with well-defined homogeneous round or oval profiles on chest roentgenograms (Fig. 20.82). CT shows homogeneity and high density of the lesions in the great majority of cases (Fig. 20.83); low-density areas may be apparent in some tumors because of cystic change. In addition, the “air meniscus sign” (also known as the “air trapping” or “air crescent” sign)^324,325,331—a rim of air that partially or circumferentially surrounds a mass—is evident in the lung parenchyma adjacent to some lesions of this type.

Grossly, most sclerosing hemangiomas are less than 3 cm in maximum dimension (Fig. 20.84), but sometimes they attain a size of up to 10 cm. Multifocality, sometimes featuring a satellitotic configuration of small nodules around a dominant central nodule,³¹⁹ is apparent in approximately 4% of cases.³³² Roughly the same proportion are pleural-based and may be polypoid, potentially simulating the appearance of SFTs.³¹⁹ Sharp circumscription from the surrounding lung parenchyma is the rule, so much so that these tumors are sometimes “shelled out” by the surgeon with little if any attached alveolated tissue. ’tteir cut surfaces are tan-gray, yellow, or mottled. Cystic areas are evident in roughly 3% of cases; 20% show areas of intralesional hemorrhage, which may be extensive.

Figure 20.82 This plain-film chest radiograph demonstrates a relatively well-delineated nodular lesion in the mid-right lung field, representing a sclerosing hemangioma.

The histologic images of sclerosing hemangioma include varying admixtures of four basic growth patterns—sclerotic (Fig. 20.85), papillary (Fig. 20.86), solid (Fig. 20.87), and hemorrhagic/angiomatoid (Fig. 20.88). Approximately 15% of cases are monomorphic, and approximately 20% contain areas representing all of the patterns in the same lesion. Two basic cell types comprise the neoplastic elements in sclerosing hemangioma—surface cells, which mantle papillary projections, and round cells, seen in the cores of papillary structures and in solid sheets within the lesions. Surface cells often show intranuclear invaginations of cytoplasm, yielding pseudoinclusions such as those seen in type II pneumocytes and Clara cells. They also may be multinucleated. Round cells are actually polygonal, with oval nuclei, dispersed chromatin, indiscernible nucleoli, and extremely rare mitotic figures. They may focally exhibit cytoplasmic vacuolation and even assume the morphologic features of a signet ring cell. Rarely, nuclear hyperchromasia and moderate pleomorphism are seen in the round cell element.^319,333

Figure 20.83 A sclerosing hemangioma. This computed tomogram of the lesion shown in Fig. 20.82 shows a circumscribed spherical tumor with a uniform internal density.

Figure 20.84 (A and B) Gross photographs of a sclerosing hemangioma, showing circumscribed white-yellow nodules in the peripheral lung parenchyma.

Figure 20.85 Stromal sclerosis is prominent in this sclerosing hemangioma.

Figure 20.86 Papillary epithelial groups are numerous in this sclerosing hemangioma.

Figure 20.87 Solid growth of polygonal cells is apparent in this sclerosing hemangioma.

Figure 20.88 An angiomatoid focus is evident in this sclerosing hemangioma

Figure 20.89 Fine-needle aspiration biopsy specimen of a sclerosing hemangioma, showing a three-dimensional group of epithelioid cells with increased nuclear-cytoplasmic ratios and distinct nucleoli. There is a strong resemblance to the cytopathologic appearance of adenocarcinoma.

Secondary features of sclerosing hemangioma include blood lakes in angiomatoid foci; limited areas of necrosis; stromal hemosiderosis, calcification, cholesterolosis, or combinations There of; internal cystification, with mucinous contents; granulomatous inflammation; and a potential association with foci of neuroendocrine hyperplasia (“tumor- lets”) in the surrounding lung parenchyma.^{319,320,333,334}

We have previously stated our opinion that pneumocytoma/sclerosing hemangioma, AA, and papillary adenoma comprise a biologically interrelated family of pulmonary lesions. Nevertheless, these entities differ morphologically, in that sclerosing hemangioma lacks the “Swiss cheese” microcystic structure of AA and papillary adenoma does not contain the round cell elements of sclerosing hemangioma.¹⁵⁶

Several publications have addressed FNA biopsy findings in sclerosing hemangioma, and most have noted substantial morphologic overlap between those lesions and well-differentiated adenocarcinomas (particularly of the bronchioloalveolar type).^{323,326,327,335-337} A shared potential for nuclear atypia, intranuclear pseudoinclusions, and micropapillary growth in both tumor entities makes the definitive cytologic recognition of sclerosing hemangioma very difficult (Fig. 20.89). Despite assertions that it can be accomplished,³³⁸ we believe that an unqualified interpretation of sclerosing hemangioma by FNA biopsy is unwise. In appropriate cases, that possibility can be included in the diagnostic report, prompting an intraoperative frozen-section examination to further guide the surgeon’s choice of procedure. This proviso relates to the very close cytologic similarity we have noted between pneumocytoma and selected adenocarcinomas.

Figure 20.90 A sclerosing hemangioma with immunoreactivity for keratin showing staining of the surface cells (A), and for thyroid transcription factor 1 (B), supporting its identity as a respiratory epithelial neoplasm.

Electron microscopy of sclerosing hemangiomas has shown that both the surface cell and round cell components demonstrate type II pneumocytic features, containing cytoplasmic lamellar bodies with variable levels of maturation.^312,319 Other organelles are nonspecific. These findings support the interrelatedness of sclerosing hemangioma and papillary adenoma.

Immunohistologically, variable reactivity has been seen for keratin, EMA, surfactant-related proteins, Clara cell antigen, and thyroid transcription factor 1 in both cellular components of sclerosing hemangioma (Fig. 20.90).^{319,328,329,335,339-346} Receptors for estrogen and progesterone are also demonstrable in a minority of cases.³¹⁹ On the other hand, mesothelial markers, such as calretinin, HBME-1, cytokeratin 5/6, and WT-1 protein are absent in these lesions, as are neuroendocrine, neural, and myogenous determinants.

Justification for inclusion of sclerosing hemangioma as a borderline”lesion stems from reports of its recurrence^338,347 and the finding of lymph nodal metastases in 10 patients to date.^{319,321,348-350} In the US Armed Forces Institute of Pathology series, this behavior was observed in 1% of cases.³¹⁹ Despite that observation, no patient with metastatic tumors has died of the tumor, and lymph node involvement³²¹ does not appear to affect survival.

As mentioned earlier, the principal differential diagnostic alternative to sclerosing hemangioma is low-grade adenocarcinoma of bronchioloalveolar or conventional types.^327,336,337 An adequate tissue sample— allowing for evaluation of the architecture of the entire mass—is essential to making that distinction. Another diagnostic possibility is the papillary variant of low-grade mucoepidermoid carcinoma,³⁵¹ but its particular histologic pattern, with an intimate admixture of mucinous and squamous epithelium, should allow for a distinction from sclerosing hemangioma.

Pulmonary Mucinous Cystadenoma and Borderline Mucinous Tumor

Mucinous cystadenomas and cystic mucinous tumors of low malignant potential—borderline mucinous neoplasms (BMTs)—are well known to gynecologic and gastrointestinal pathologists because they rather commonly arise in the ovaries, gut, and pancreas.^352,353 A primary origin in the lung for such lesions is unusual, but possible, and approximately 50 cases have been reported.^354-366 These neoplasms occur in adults as solitary lesions in the peripheral parenchyma. An association with von Hippel-Lindau disease has been reported.³⁶³ Both plain films and CTs of the thorax clearly show the cystic nature of these tumors (Fig. 20.91), which generally measure several centimeters in diameter.

Figure 20.91 This chest radiograph shows a large ovoid mass in the right lower lung field, representing a cystic mucinous tumor.

Grossly, mucinous cystadenomas and BMTs are sharply demarcated from the surrounding lung parenchyma (Fig. 20.92) and may even “shell out” for the surgeon. Their walls are relatively thick and fibrous, enclosing locules that contain thick viscous mucoid material. Foci of granular tissue are present on the internal aspects of the cysts, representing epithelial projections.

Histologically, the latter structures comprise cytologically bland mucin-containing tumor cells that are cuboidal or low columnar (Fig. 20.93). Nuclei are generally basally located and relatively banal, with no pleomorphism or mitotic activity (Fig. 20.94). Cystadenomas do not demonstrate invasive growth into the fibrous walls of the lesions, but BMTs may do so, and may manifest a “piling up” of lesional epithelium that yields complex micropapillary structures (Fig. 20.95). Cases in which frank adenocarcinoma evolved from preexisting pulmonary mucinous cystadenoma have been reported (Fig. 20.96).^355,361,365

Figure 20.92 Gross photograph of a cystic mucinous tumor of the lung showing circumscription from the lung parenchyma and mucoid lesional contents.

Figure 20.93 Mucinous cystadenoma of the lung showing a fibrous cyst wall mantled by bland mucinous epithelial cells. The cavity of the lesion contains abundant and inspissated mucinous material.

Figure 20.94 the neoplastic epithelial cells of pulmonary mucinous cystadenoma are banal, with no significant nuclear atypia. Cytoplasmic mucin is apparent.

Figure 20.95 Micropapillary growth is evident in some cystic mucinous tumors of the lung, justifying use of the term "borderline."

Figure 20.96 Some pulmonary cystic mucinous tumors undergo overtly malignant evolution, as shown by this example containing invasive adenocarcinoma (bottom).

The differential diagnosis for these lesions is largely academic. The clinical and histologic features of such tumors are quite different from those of other respiratory tract lesions that may contain mucin. The latter include mucoepidermoid carcinoma, MGA, and bronchioloalveolar carcinoma.

The classification of pulmonary BMT as a neoplasm with low malignant potential is supported by the observations of Gao and Urbanski.³⁶⁵ Those authors documented a mortality rate (due to metastatic tumor) of 30% in their series, with up to 10 years of postoperative surveillance, raising the possibility that these should be considered frank carcinomas rather than borderline lesions. They further described a spectrum of histologic appearances in the epithelium of BMT, ranging from completely bland to overtly malignant. Pathologic findings that were proposed as adverse prognosticators included solid epithelial growth at the periphery of the lesion, adhesion of the tumor to the pleura, crossing of the intrapulmonary septa by the tumor, obvious nuclear atypicality, and invasive growth into the surrounding lung tissue.³⁶⁵

Solitary Fibrous Tumor

SFT (formerly called fibromafi^6v№ of the lung and pleura is still confused by some clinicians with mesothelial neoplasms. This is because of a nosologic scheme advanced by Klemperer and Rabin in 1931369 that was used for many years There after and gave SFT the designation of localized fibrous mesothelioma. Particularly in the last two decades, much work has been done that unequivocally shows that SFT lacks mesothelial differentiation³⁷⁰; instead, this tumor is composed of facultative fibroblastic elements, such as those seen in the submesothelial zone of the normal lung. Even though it may occasionally recur and sometimes demonstrates locally aggressive growth—justifying its classification as a borderline mesenchymal tumor—SFT generally has a favorable prognosis that differs markedly from that of mesothelioma.^370-380 Likewise, pleural fibrous tumors have no etiologic relationship whatsoever with occupational-level asbestos exposure, in contrast to a proportion of mesotheliomas.³⁷⁸

Approximately two mesotheliomas are encountered for every SFT in general thoracic surgical practice.³⁷⁰ Outside of infancy, patients of any age may have an SFT, but they are most often seen in patients older than 40 years old, with no sex predilection. The great majority of cases present with an asymptomatic pleuropulmonary mass that is seen on screening radiographs. Rarely, one of two paraneoplastic complexes accompanies SFT; those are represented by hypertrophic osteoarthropathy and tumor-associated hypoglycemia (Doege-Potter syndrome).³⁷⁸ the cause of the first condition is unknown; the second is related to an insulin-like growth factor that is produced by the neoplastic cells.

Radiographically, SFT may be as small as 1 cm in maximal dimension or as large as 36 cm. Occasional lesions of this type have occupied virtually an entire hemithorax and weighed in excess of 5 kg.³⁷⁷ They are usually globoid neoplasms with a relatively homogeneous internal density, but cystic change, calcification, or foci of necrosis may be sometimes apparent (Fig. 20.97). A minority of cases demonstrate a pedicle that attaches an SFT in the pleural space to the pleura itself. Conversely, other lesions “invert” into the lung parenchyma or may arise from interlobar pleural reflections, producing the appearance of a peripheral intrapulmonary mass^{367,368,381-385}; large tumors also may displace the trachea or intramediastinal structures.³⁷⁰ Rarely, overt invasion of the chest wall, vertebral bodies, or adjacent lung tissue is apparent on imaging studies.^381,386 A small number of SFTs show regional satellitotic growth in the pleura.³⁸⁵

Figure 20.98 the gross cut surfaces of solitary fibrous pleural tumors may be either homogeneous (A) or septated, and tan-white to yellow, with foci of degeneration or necrosis (B).

Figure 20.99 A "patternless pattern” is apparent in this solitary fibrous pleural tumor, wherein spindle cells are randomly arranged.

Gross examination shows a lobulated mass that is invested by pleural tissue (Fig. 20.98). Cut surfaces can be homogeneous, tan-gray, and vaguely “whorled,” or may show distinct internal septa and foci of degeneration, mucoid change, hemorrhage, calcification, or necrosis.^380,381 Intralesional cystic change can also be present.

The microscopic spectrum of pleuropulmonary SFT is broad.³⁸⁰ A solid spindle cell growth and a diffuse sclerosing pattern are most frequent. In the first of these configurations, fusiform cells are arranged in random arrays (a “patternless pattern”; Fig. 20.99), with fascicular groupings, storiform or herringbone patterns, or regimented arrays with nuclear palisading. SFT may also have epithelioid cells (Fig. 20.100) and branched intralesional blood vessels resembling “moose antlers,” as seen in hemangiopericytoma (which has been merged nosologically with SFT) or synovial sarcoma.

Zones of fibrosis may be interspersed with cellular zones and dominate in lesions classified as diffuse sclerosing SFT (Fig. 20.101). Focal collagenous degeneration is occasionally apparent, simulating true necrosis. Less frequent features include multinucleated tumor giant cells, ami- anthoid arrays of collagen fibers, myxoid stromal change, limited areas of spontaneous necrosis, hemorrhage, and metaplastic ossification. Mitotic activity in most SFTs is present but not prominent, and division figures are normal.

Figure 20.100 Epithelioid cytologic composition is seen in this solitary fibrous tumor of the pleura, potentially simulating the appearance of synovial sarcoma or hemangiopericytoma.

England and associates³⁸¹ attempted a codification of criteria for malignancy in SFT. These included dense cellularity with overlapping nuclei; nuclear hyperchromasia and pleomorphism (Fig. 20.102); mitotic activity greater than four division figures per 10 high-power (x400) microscopic fields; and necrosis and hemorrhage. However, only 55% of the lesions with such features actually had an aggressive course, with recurrence, metastasis, or both. Harrison-Phipps et al.³⁸⁷ found that approximately 13% of SFTs showed the malignant attributes described earlier, and they also noted that the likelihood of morphologic atypia correlated directly with tumor size. In that series, malignant SFTs averaged 12 cm in maximal dimension, compared with 4.5 cm for tumors that lacked histologic atypia. Vallat-Decouvelaere and coworkers³⁷² also emphasized that histologic findings in SFTs may not be accurate predictors of their behavior. In line with this admonition, a small proportion of histologically banal SFTs manifest untoward behavior, typically with invasion of the bony structures and soft tissues of the thorax, or recurrence.^370,378 Because of these attributes, it is best to consider SFT a borderline neoplasm. As Vallat-Decouvelaere et al.³⁷² sagely stated, “it is probably unwise to regard any such lesion as definitely benign.”

Figure 20.101 (A and B) Hyalinizing collagenous stroma is prominent in this solitary fibrous pleural tumor.

Figure 20.102 Atypical features seen in a solitary fibrous pleural tumor that raise the possibility of malignancy include uniformly dense cellularity (A) and nuclear overlapping with vesicular change in chromatin (B).

In FNA biopsy specimens,^386,388,389 smears show variably cohesive and pleomorphic spindle cells in a bloody background, representing an image that corresponds to a sizable differential diagnosis. Preparation of cell block sections and procurement of adjunctive pathologic studies is essential to a specific diagnosis.

Electron microscopic analysis of SFT has shown that the tumor cells are fibroblast-like. They lack basal lamina, intercellular junctions, and plasmalemmal microvilli, as expected in epithelial or mesothelial cells, and instead contain only basic intracellular organelles.³⁷⁸ Occasionally, intrareticular collagen fibrils are apparent within profiles of endoplasmic reticulum.

Immunophenotypically, SFT demonstrates reactivity for vimentin, CD34, CD99, and bcl-2 protein in more than 85% of cases (Fig. 20.103).^{372,379,381,386,389-393} There is typically no labeling for keratin, EMA, desmin, actins, S-100 protein, collagen type IV, CD31, or CD57. Anecdotally, lesions with malignant histologic features may exhibit mutant p53 protein immunoreactivity,³⁹⁴ but this relationship has not been subjected to rigorous evaluation.

Cytogenetic assessment of SFT is still developmental. However, the most frequent defects reported in this tumor type have involved chromosomes 4q, 8, 13q, 15q, and 21q.^395,396 One case has shown a balanced t(4;15)(q13;q26) translocation.³⁹⁶

The differential diagnosis of pleuropulmonary SFT includes primary and secondary sarcomatoid carcinoma, sarcomatoid or desmoplastic mesothelioma, fibrosarcoma, storiform malignant fibrous histiocytoma, synovial sarcoma, hemangiopericytoma, and metastatic endometrial stromal sarcoma.³⁸⁰ Among these possibilities, carcinomas, mesotheliomas, and synovial sarcomas may be excluded because of their immu- noreactivity for keratin, EMA, or both. In addition, synovial sarcoma reproducibly shows a t(X;18) chromosomal translocation³⁹⁷ and nuclear immunoreactivity for transducin-like enhancer of split 1 (TLE1),³⁹⁸ both of which are absent in SFT. Consistent CD10 reactivity in metastatic endometrial stromal sarcoma differs from the properties of SFT.³⁹⁹ Fibrosarcoma and malignant fibrous histiocytoma lack CD34, CD99, and bcl-2 protein, all of which are typically manifest in SFT.

Figure 20.103 Representative morphologic images of another solitary fibrous tumor are seen in panels A-C. Panel D shows characteristic nuclear immunoreactivity for STAT6.

The biologic attributes of SFT have been largely discussed previously. However, some of its characteristics merit reiteration. Approximately 10% of “ordinary” intrathoracic SFTs (lacking histologic indicators of possible malignancy) recur, sometimes massively.^370,400 This behavior has most often been linked to incomplete lesional excision at initial surgery, and salvage of the patient is still a distinct possibility if total removal of the tumor (e.g., by extrapleural pneumonectomy)⁴⁰¹ can be accomplished.^292,294 Metastastic disease is very unusual,⁴⁰² and it tends to be refractory to oncologic intervention.

Desmoid Tumor

DT is best known as a borderline neoplasm of the deep soft tissues and as a member of the family of fibromatoses.^403,404 It can be seen sporadically in patients of virtually any age, but also has a biologic linkage to familial adenomatous polyposis syndrome, in which it is overrepresented.⁴⁰⁵ Wherever it arises in the body, DT pursues a slowly progressive, infiltrative course of growth, eventually impinging on nerves, blood vessels, and other anatomic structures. That property accounts for associated symptoms and signs, which reflect secondary compressive effects of the mass.⁴⁰³

Several examples of DT have been reported as apparently primary pleural neoplasms.^406-410 Demographic, radiologic, and clinical findings in such cases are superimposable on those associated with SFT.^406,410 Pleural desmoids are deceptively circumscribed in imaging studies, and they typically have a homogeneous radiodensity (Fig. 20.104).

Grossly, DTs of the pleura show a fleshy, uniform, tan-gray cut surface with subtly incorporated bands of internal fibrous tissue (Fig. 20.105). They often appear to have a distinct interface with surrounding tissues, but this attribute is misleading because microscopic study often shows tumor growth beyond the gross boundaries of the lesion.

Histologically the usual appearance of pleural DT is reproducible. It is a hypocellular neoplasm that composes bland fusiform and stellate cells, set in a fibromyxoid stroma (Fig. 20.106). Mitoses are absent or rare; nuclear atypia and necrosis are lacking.^403,404 A helpful diagnostic feature is the presence of regularly spaced small blood vessels throughout the lesion; these have open round or oval lumina and relatively thick pericytic cuffs. As mentioned earlier, permeative infiltration of surrounding tissues by the tumor is common.

A potential diagnostic trap is represented by selected examples of DT that have a markedly myxoedematous stroma, with or without extravasated erythrocytes (Fig. 20.107). The resulting microscopic image can strongly resemble that of nodular fasciitis, a completely innocuous pseudoneoplastic condition.⁴¹¹ Nodular fasciitis has not been reported in the pleura, however.

Figure 20.104 Desmoid tumor of the pleura represented by a localized peripheral thoracic mass that resembles solitary fibrous tumors on computed tomography.

Figure 20.105 Desmoid tumors form homogeneous tan-pink masses. In this case, there is invasion into the chest wall, as cut surfaces of the ribs are evident.

Figure 20.106 (A and B) Desmoid tumors comprise vague fascicles of bland spindle cells that are set in a variably fibrous or myxoedematous stroma. Supporting blood vessels are small but have relatively thick walls and open lumina.

FNA biopsy of DT may show either hypocellular or hypercellular foci, often in juxtaposition.⁴¹² the stromal staining characteristics are those of mature collagen. Individual tumor cells are dyshesive and morphologically bland, with tapered ends, fusiform nuclei, dispersed chromatin, and a lack of pleomorphism.

As a derivative of the association between desmoids and familial adenomatous polyposis syndrome, beta-catenin protein is usually dysregulated in DT. Instead of exclusively cytoplasmic immunolocalization of that moiety, it is instead seen as an intranuclear reactant (Fig. 20.108).⁴⁰⁶’^412-414 Unfortunately, an important (if not the principal) differential diagnostic consideration—SFT—also commonly demonstrates nuclear labeling for beta-catenin.⁴¹⁴’⁴¹⁵ Hence one must rely on other immunohistochemical discriminants to separate those two neoplasms. DT is reactive for alpha-isoform and muscle-specific actins, and sometimes for desmin, whereas SFT is not.⁴⁰⁶ Conversely, reactivity for CD34 and CD99 is common in SFT but absent in DT. Diagnostic distinctions among DT, other myofibroblastic proliferations, leiomyomas, and low-grade leiomyosarcomas are not possible at an immunohistochemical level of analysis^406,412 and must be made by other means.

Figure 20.107 This desmoid tumor manifests an unusually myxoedematous stroma in which scattered erythrocytes are present. The general appearance of the lesion simulates that of nodular fasciitis; however, the latter process does not affect the pleura.

Figure 20.108 Nuclear (and cytoplasmic) immunoreactivity for beta-catenin is seen in desmoid tumors. Solitary fibrous tumors may share this feature.

The biologic behavior of DT approximates that of low-grade sarcomas; local recurrences can be tenacious and even life-threatening, but distant metastasis does not occur.403,404,410 Curative surgical excision requires complete removal of the mass.416,417

Clear Cell Tumor

The general premises underlying the nosologic family of MMCs have been described previously in reference to angiomyolipomas. Another member of that conceptual group—clear cell “sugar” tumor of the lung (CCT)—is a purely epithelioid MMC,²⁴⁷ which, for reasons to be discussed, is probably best regarded as a biologically borderline neoplasm.

Pulmonary sugar tumor was first described noncommittally as “clear cell tumor of the lung” due to the presence of intracytoplasmic glycogen.⁴¹⁸ It typically occurs in patients older than 40 years of age^419-436 as a peripheral lung nodule. However, occasional examples have been reported in the trachea or large bronchi.^422,433 Like angiomyolipoma, CCT has been found concurrently with lymphangioleiomyomatosis and multifocal micronodular pneumocytic hyperplasia in some patients with tuberous sclerosis.⁴³⁰ Tumors in such patients demonstrate a loss of heterozygosity in the TSC2 region of chromosome 16p13.^437,438

The radiographic attributes of CCT are nondescript.^421,426 It is a homogeneously dense, round to ovoid, peripheral lung mass that may be seen in any region of the lung (Fig. 20.109). CT has typically shown sharp circumscription.

The same features are reflected in gross examination. Theіг cut surfaces are pink to brown and uniform, although necrotic foci may sometimes be present. Maximum diameter is generally less than 5 cm.

Histologic examination shows one of two general growth patterns in CCTs. The first is organoid, with broad cords and rounded nests of cells separated by a variably prominent fibrovascular stroma, mimicking renal cell carcinoma. The second configuration is a medullary image, showing sheets of epithelioid cells with little internal clustering (Fig. 20.110). Preexisting small bronchi and bronchioles are often entrapped by the neoplastic cells. Nuclei are round to ovoid with small nucleoli; intranuclear invaginations of cytoplasm also may be apparent, but mitotic figures are usually difficult to find. Cytoplasm is clear or lightly eosinophilic, and may be finely granular. Histochemical evaluation with the periodic acid/Schiff method usually shows intense cytoplasmic labeling for glycogen in the tumor cells (Fig. 20.111). Intralesional blood vessels can be markedly sclerotic in some cases, spontaneous necrosis is occasionally seen, and sparse intratumoral chronic inflammatory cells may be identified.

Ultrastructural studies of CCT have shown attributes suggesting a hybrid cell type that incorporates elements of modified perivascular smooth muscle and melanocytes. These include interdigitating cellular processes, pericellular basal lamina, primitive intercellular attachment complexes, plasmalemmal pinocytosis, membrane-bound and free cytoplasmic glycogen granules, and variant form premelanosomes 420,423,425,427,429,432

Immunohistologically, one sees a uniform lack of reactivity for epithelial markers in CCT, but consistent reactivity for vimentin, CD117, collagen type IV, HMB-45, MART-1, and microphthalmia transcription factor 1 (with the last three determinants all related to melanocytes; Fig. 20.112).^{243,424,425,429,431} Inconsistent but generally positive results are obtained for muscle-specific actin, S-100 protein, and neuron-specific enolase. Panizo-Santos et al.⁴³⁹ have described aberrant but virtually exclusive cytoplasmic immunoreactivity for Myo-D1 in members of the MMC family of tumors. This marker is a nuclear transcription factor related to striated muscle development, and bona fide labeling for it would not be expected in the cytoplasm. Hence it appears that the cited pattern of staining probably represents a reproducible artifact, but if corroborated, it could prove to be useful diagnostically.

The differential diagnosis for CCT is a lengthy one, including primary carcinomas of the lung with clear cell features; metastatic clear cell carcinomas from the kidney, urogenital tract, breast, and other locations; metastatic clear cell sarcoma; and metastatic “balloon cell” melanoma.^{440 the} generic possibility of carcinoma can be excluded by the lack of keratin and EMA in CCT, but clear cell sarcoma and melanoma are not as easily dismissed, because they potentially share the entire complement of immunohistologic melanocyte markers with MMCs. Reactivity for actin or cytoplasmic Myo-D1 would strongly argue in favor of CCT in this setting because those determinants have not been reported in metastatic melanomas with epithelioid features.

Biologically, CCT has traditionally been considered a benign pulmonary tumor. Nonetheless, at least two examples^432,434 have metastasized to other visceral sites, and one proved fatal. This behavior parallels the biologic potential of MMCs in other organs, notably the kidney. Діш it would seem appropriate to regard CCT as another borderline neoplasm of the lung. With that having been said, however, simple surgical removal of the lesion—with wedge excision of the peripheral lung parenchyma, if possible—is believed to represent adequate therapy.

Primary Pleuropulmonary Thymoma

Even though thymomas typically arise in the anterosuperior mediastinum, the literature contains ample evidence of their ability to develop in ectopic sites. These tumors have been described in the soft tissue of the lower neck, as well as the thyroid, pericardium, lungs, and pleura.^441-446 Because of their ability to show a relatively wide morphologic spectrum, heterotopic thymic tumors may be quite difficult to recognize diagnostically.

Intrapulmonary thymoma is seen in adults between the ages of 20 and 80 years. In the minority of cases where the lesion is linked to one of several distinctive thymoma-related paraneoplastic syndromes— principally myasthenia gravis, pure red cell aplasia, and acquired hypogammaglobulinemia—its identity may be suspected clinically.⁴⁴⁷ However, the majority of these tumors present as asymptomatic masses that are found radiographically. They can be situated centrally, close to the hilum, and even endobronchially in rare instances, as well as in the midlung fields or beneath the pleural surfaces (Fig. 20.113).^448-458 Occasionally, two or more intrapulmonary masses are seen concurrently. In analogy to mediastinal thymomas, those arising in the lungs may be either circumscribed or infiltrative, and some demonstrate prominent intralesional cystification.

Figure 20.109 (A) This highlighted plain-film chest radiograph of a clear cell pulmonary "sugar tumor” demonstrates a nondescript well-defined nodule in the right lung field. (B) This computed tomogram of a clear cell tumor demonstrates a globular, internally homogeneous mass that abuts the mediastinum in the right lung. (C) Gross photograph of a pulmonary clear cell tumor showing a uniform white-gray cut surface and demarcation from the surrounding parenchyma.

Pleural thymomas may simulate the appearance of any other solitary serosal neoplasm. In rare examples, they have diffusely effaced the pleural space in one or both hemithoraces, reproducing the radiographic and gross pathologic image of diffuse pleural mesothelioma or metastatic serosal carcinoma.^456-458

All of the scenarios discussed earlier include an absence of abnormalities in the anterior mediastinum. With that in mind, it is easy to understand why a definitive radiographic interpretation of ectopic thymoma is virtually impossible.

These tumors have fleshy pink-tan cut surfaces that closely resemble those of lymphoreticular neoplasms, but areas of necrosis, hemorrhage, or cyst formation are much more common than they are in lymphomas. They may also contain internal fibrous septations, subdividing the masses into angulated tissue compartments (Fig. 20.114). Dystrophic calcification may be present.

Microscopically, circumferential fibrous encapsulation of pulmonary or pleural thymomas is unusual, in contrast to their intrathymic counterparts. As a result, ectopic lesions in the hemithoraces must commonly be classified as “invasive,” almost by definition (Fig. 20.115). As stated previously, intralesional fibrous septa intersect one another at acute angles (Fig. 20.116), differing from the obtuse connections that are seen in nodular sclerosing Hodgkin lymphoma or sclerosing non- Hodgkin lymphomas in the chest. At the University of Virginia, the classic Bernatz system of histologic classification for thymic epithelial tumors is used, which has five subdivisions:

• Lymphocyte-predominant thymoma (>66% lymphocytes)

• Mixed thymoma (34% to 65% lymphocytes)

• Epithelial-predominant thymoma (<33% lymphocytes)

• Spindle cell thymoma (a variant of epithelial-predominant thymoma in which the majority of the neoplastic cells are fusiform; Fig. 20.117)

• Thymic carcinoma, containing obviously anaplastic and cytologically malignant tumor cells⁴⁵⁹

Figure 20.110 (A) A rounded interface with the adjacent lung is evident in this low-power microscopic image of a pulmonary clear cell tumor. (B) the growth pattern of a pulmonary sugar tumor is frequently medullary, comprising sheets of clear neoplastic cells with indistinct internal fibrovascular septations. (C) the tumor cells are polygonal, with amphophilic, granular, or clear cytoplasm. (D) Nucleoli may be prominent.

Figure 20.111 Diffuse strong reactivity is seen with the periodic acid/Schiff stain in a clear cell tumor of the lung, revealing abundant intracellular glycogen.

Figure 20.112 Immunoreactivity with HMB-45 is typical of a pulmonary clear cell tumor.

Other alternative nosologic constructions for thymic tumors have entered common use as well, including the Marino-Muller-Hermelink scheme,⁴⁶⁰ the World Health Organization system,⁴⁶¹ and the Suster-Moran codification.⁴⁶² the last one can easily be linked with the Bernatz system to specifically address tumors that demonstrate a notable degree of nuclear atypia, yet whose features are insufficient for an outright diagnosis of carcinoma. Such neoplasms are termed atypical thymomas.

Figure 20.113 This computed tomogram of the thorax shows a lobulated mass in the anterior right lung field (arrowheads), representing a primary intrapulmonary thymoma.

Figure 20.114 (A) This gross photograph of an intrapulmonary thymoma shows a uniform tan-gray cut surface and internal subdivision by fibrous septa. (B) Another tumor demonstrating pleuroparenchymal thymomatosis, where deposits of thymoma are present on the visceral pleura (left) and within the lung. This appearance may simulate that of mesothelioma.

The epithelial cells of thymomas—not the lymphoid cells—are the neoplastic elements. They are characterized by a range of cytologic images. Some have vague cellular borders, oval nuclear contours, dispersed chromatin, and indistinct nucleoli. At the other end of the spectrum, one sees rather clear-cut plasmalemmal interfaces, moderate nuclear irregularity and hyperchromasia, and distinct nucleoli (Fig. 20.118). As mentioned earlier, spindle cell change is another potential image in thymomas, and the nuclei in such lesions tend to have bland and uniform morphologic characteristics. Mitotic activity in thymic tumors is greatly variable as well, and it achieves importance as a possible marker of thymic carcinoma only in neoplasms that also show nuclear abnormalities.

Figure 20.115 Infiltration of the lung parenchyma is seen in this case of intrapulmonary thymoma.

Figure 20.116 Internal fibrous septas in thymomas intersect one another at acute angles, yielding a distinctive image in this Masson trichrome stain.

Figure 20.117 Predominantly spindle cell (medullary, World Health Organization type A) intrapulmonary thymoma.

Secondary architectural changes in thymomas include the formation of perivascular “lakes” of serum, in which lymphoid cells are suspended; pseudoglandular arrays or pseudorosettes of epithelial cells; microcysts or areas of gross cystic change, with or without necrosis; stromal blood lakes and vascular dilatation; and medullary differentiation, in which loose and vaguely nodular aggregates of stromal lymphocytes are present.⁴⁵⁹ Hassall corpuscles are seen in only a small minority of cases. Some spindle cell thymomas contain a vascular network comprising numerous vessels with a “moose antler” configuration, yielding a pattern that virtually perfectly imitates that of hemangiopericytoma-SFT.

Epithelial-predominant thymomas with nuclear atypia, an organoid growth pattern, and distinct cellular borders have been called well- differentiated thymic carcinomas.⁴⁶³ However, their generic clinicopatho- logic characteristics are clearly dissimilar to those of outright thymic carcinomas, and some observers believe that they are more properly termed atypical thymomas.⁴⁶²

Figure 20.118 An atypical epithelial-predominant (World Health Organization type B3) thymoma shows increased nuclear-cytoplasmic ratios, nucleoli, nuclear hyperchromasia, and distinct intercellular membranes. However, these changes fall short of the cytomor- phologic threshold for thymic carcinoma.

The cytopathologic attributes of thymic epithelial tumors seen in FNA biopsy specimens are well described^464-466 and reflect their histologic heterogeneity. Mature lymphocytes are admixed with thymic epithelial cells, which show a tendency toward cohesion. However, scattered single epithelial cells may also be evident. Epithelial cell nuclei are generally monomorphic, with dispersed chromatin and small chromocenters. Cytoplasm is amphophilic, with indistinct cell borders. A fusiform cellular shape may be encountered in spindle cell tumors, but the grouping of such cells into small clusters helps distinguish them from mesenchymal proliferations. The lymphoid elements in thymoma are a potential diagnostic pitfall, and nuclear activation may be seen with increases in the nuclear-to-cytoplasmic ratios. Convolution of the nuclear borders can also be present, as may mitotic figures. The overall image of activated intratumoral lymphocytes is quite similar to that of lymphoblastic lymphoma, and a misdiagnosis may ensue unless adjunctive studies are performed to detect the epithelial elements of thymoma.^451,464 Predictably, invasive thymomas cannot be distinguished from encapsulated tumors using the FNA technique.

Electron microscopy of thymomas shows elongated and interdigitating cytoplasmic processes emanating from constituent epithelial cells, and these are joined to one another by well-formed desmosomes into which broad tonofibrils insert. Plasmalemmal microvilli are absent, and intralesional lymphoid cells are usually intercalated between the epithelial elements.⁴⁶⁷

Cytogenetic analysis has shown no consistent karyotypic aberrations in thymomas. Several different abnormalities have been documented, including deletions of chromosome 6p; t(1;8) and t(15;22) chromosomal translocations; pseudodicentric (16;12)(q11;p11.2); and ring chromosome 6.^468-470 However, none of these findings is typically associated with other primary pleuropulmonary tumors.

Immunohistologic studies are paramount in confirming the cellular nature of ectopic thymomas. Keratin immunostains show a characteristically arborizing network of reactivity, reflecting the presence of interconnecting cytoplasmic processes (Fig. 20.119).⁴⁷¹ the keratin subtype 5/6 is also characteristic of thymic epithelium.⁴⁷² A member of the p53 protein family, p63 protein, is likewise consistently present in thymoma (Fig. 20.120), as it is in squamous neoplasms.⁴⁷³ Finally, the lymphoid cells in thymomas are true thymocytes. They express CD1a, nuclear terminal deoxynucléotidyl transferase (TdT), and CD99.⁴⁵¹ the latter phenotype is shared only by the tumor cells of lymphoblastic lymphomas, but these hematopoietic neoplasms are uniformly nonreactive for p63 and keratin. Thus There is a truly diagnostic immunoprofile for thymoma. Parenthetically, it should be noted that pseudomesotheliomatous pleural thymomas may be reactive for calretinin, keratin 5/6, and thrombomodulin, all of which are commonly associated with mésothélial cells.⁴⁵⁸ ttat combination of results may easily lead to misdiagnosis if studies for p63, CD1a, TdT, and CD99 are omitted.

Figure 20.119 Interconnecting cell processes in a thymoma are labeled for keratin, yielding a "lacy” immunostaining pattern. (Image courtesy Dr. Anja Roden, Mayo Clinic, Rochester, Minnesota.)

Figure 20.120 Nuclear immunoreactivity for p63 protein in the epithelial cells of a pleural thymoma. This finding is helpful in the differential diagnosis with mesothelioma, which is p63-negative.

Differential diagnostic considerations include lymphoma, metastatic somatic carcinoma, metastatic seminoma, mesothelioma, and pleural sarcomas (especially synovial sarcoma and hemangiopericytoma), depending on the microscopic nuances of the lesion. The immunophénotype of thymoma discussed earlier is unique among those possibilities.

Behaviorally, ectopic thymomas in the lung and pleura are typically indolent lesions that can be cured by complete surgical resection if they are solitary.⁴⁷⁴ However, several examples have been reported in which recurrence, distant metastasis, or both, was observed.^448-455 Moreover, lesions that simulate mesothelioma because of their encasement of the lungs or heart are associated with a greater risk of adverse behavior.^456-458 Because a minority of all pleuropulmonary thymomas are fatal, they are justifiably considered borderline.

Heterotopic Meningeal Proliferations

Meningiomas are typically considered neoplasms of the main neural axis, but they are perhaps the most widely distributed of any tumor in that group. Tumefactive proliferations with meningothelial differentiation have been reported in a wide variety of locations, including the mediastinum and lungs, in the absence of involvement of the coverings of the brain and spinal cord.⁴⁷⁵ Patients with such lesions seem to be somewhat younger on average than those with intracranial meningiomas, most of whom are middle-aged or older. Because these neoplasms are clearly not expected outside of their usual confines, their clinical presentation in heterotopic locations is typically undiagnosed at a clinical level.⁴⁷⁶ For example, those in the lung are usually believed to represent granulomas or adenocarcinomas radiographically (Fig. 20.121). Ectopic meningiomas generally pursue a relatively favorable clinical course; although local recurrence is a possibility, these lesions are uncommonly associated with distant metastasis.⁴⁷⁷

Grossly, meningioma of the lung is usually sharply marginated and easily dissected from the surrounding parenchyma (Fig. 20.122). It measures between 1 and 5 cm in diameter and has a globoid configuration and a uniformly white-gray cut surface. Those rare lesions that are malignant may show areas of necrosis and hemorrhage, as well as infiltration of the adjacent lung.^477,478

Histologically, heterotopic meningiomas show preferential expression of méningothélial, fibroblastic, or transitional growth patterns.^479-490 As such, meningiomas of the lung are composed of polygonal or fusiform cells with monomorphic oval nuclei and dispersed chromatin (Fig. 20.123). Whorled aggregates of tumor cells may be observed multifocally, with or without secondary psammomatous microcalcifications. In some cases, the latter structures are numerous.

Purely meningotheliomatous lesions—comprising a pure population of polygonal cells—may simulate the appearance of a carcinoma. At the other pole of the spectrum, fibroblastic or solely spindle cell meningiomas can imitate the configuration of SFT-hemangiopericytoma or other primary soft tissue neoplasms (Fig. 20.124).^475,478 Mitotic activity is limited, nuclear atypia is only modest, and necrosis is usually absent in benign pulmonary meningiomas, but the presence of those findings should raise concern about the rare possibility of malignancy.⁴⁹¹

The premise has been advanced by some authors that primary pulmonary meningioma may arise from meningothelial-like micronodules in the lung^479,481 (formerly and erroneously called minute pulmonary chemodectomas), which are related to parenchymal damage as a result of cardiac failure, chronic obstructive pulmonary disease, and throm- boemboli (Fig. 20.125).⁴⁹² the conclusion that they are the precursors of meningioma was derived from the fact that both lesions have been seen together in the same case; however, no molecular analyses have been done to further address that possibility. In our opinion, however, this is unlikely; pertinent data show that meningothelial-like micronodules are polyclonal and probably reactive.⁴⁹³ When multiple, the phenomenon has been called meningotheliomatosis,⁴⁹⁴ which may lead to radiologic confusion with interstitial lung disease or metastases (Fig. 20.126).

FNA biopsy specimens of pulmonary meningioma^479,483 show scanty material, represented by whorls of cells with a concentric internal configuration (Fig. 20.127), as well as isolated individual cells. Intranuclear inclusions may be apparent, and psammomatous calcifications can be observed in rare instances.

Figure 20.121 Computed tomograms of the thorax showing a slightly spiculated nodular mass in the mid-right lung field (A, arrow) and a small nodular peripheral lesion in the right lung (B), both of which proved to be primary pulmonary meningiomas.

Figure 20.122 This gross photograph of a primary intrapulmonary meningioma shows a globose mass that was shelled out by the surgeon from the surrounding parenchyma.

Figure 20.123 Intrapulmonary meningiomas with meningotheliomatous (A) and transitional (mixed) (B) features.

Figure 20.124 Blunt spindle cells are arranged around a vascular structure resembling "staghorns” in meningioma, potentially simulating the appearance of hemangiopericytoma-solitary fibrous tumor.

Electron microscopy is still an extremely useful tool for the resolution of differential diagnostic questions surrounding these tumors.⁴⁹⁵ Meningioma has a singular ultrastructural appearance that features numerous interdigitating cell processes attached by prominent desmosomes. Skeins of well-formed tonofibrils insert into those attachment complexes. To our knowledge, this particular constellation of findings is not recapitulated by any other tumor type.

Prototypically, meningiomas are reactive for vimentin, to the exclusion of other intermediate filament proteins; EMA is also present universally, as is immunoreactivity for desmoplakin, a desmosomal constitu- ent.^{475,478-480,495} Intracranial meningiomas are immunoreactive for progesterone receptor protein in the majority of cases.^496,497 However, that marker has not yet been assessed in primary pulmonary meningothelial tumors. Immunophenotypic characteristics of ectopic meningiomas also differ from those of their neuraxis analogs, in that the former lesions appear to express keratin more often. Admittedly, this attribute is probably influenced by the site of origin. Additional markers that are germane to the differential diagnosis, such as CD34 and S-100 protein, have also been reported sporadically in heterotopic meningiomas in some sites.

Figure 20.126 Occasionally, numerous meningothelial micronodules are seen radiographically throughout both lung fields, as in this computed tomogram, a condition termed meningotheliomatosis.

Figure 20.127 Fine-needle aspiration biopsy specimens of primary pulmonary meningioma show cohesive ovoid tumor cells with dispersed chromatin with typical whorling.

Other pertinent diagnostic considerations for primary pulmonary meningiomas include carcinomas with or without spindle cell features, SFTs, hemangiopericytomas, schwannomas, and amelanotic malignant melanomas.⁴⁷⁸ Electron microscopy is still very effective in resolving such uncertainties because of the distinctive profile of meningioma. Immunohistochemical analyses require the application of antibodies to Ber-EP4, MOC-31, carcinoembryonic antigen, CD56, CD57, CD99, melan-A/MART-1, and tyrosinase. Podoplanin (recognized by antibody D2-40), a relative newcomer to clinical immunohistochemistry, is not useful in this specific context. It may be seen in SFT, schwannoma, meningioma, and sarcomatoid melanoma.^498-500 However, another useful modality of investigation is fluorescent in situ hybridization, which demonstrates monosomy of chromosome 22 in a majority of menin- giomas,⁵⁰¹ a cytogenetic abnormality that is not shared by other differential diagnostic possibilities.

Figure 20.128 This computed tomogram of the chest in a young man shows a solid mass that occupies virtually the entire left hemithorax. It proved to be an immature teratoma, apparently arising in the lung.

None of these studies is effective in separating primary ectopic from metastatic neuraxis-based meningiomas.^488,502 However, it is an exceedingly rare situation for the latter neoplasms to present in distant sites with no previous knowledge of a primary tumor within the cranial vault or spine.⁵⁰²

Intrapulmonary Teratomas

Examples of primary intrapulmonary teratoma have been reported with extraordinary rarity (Fig. 20.128).^503-506 the overwhelming majority of teratoid tumors in the lungs and pleura represent altered metastases of gonadal germ cell tumors, in which malignant histologic components were formerly present but have been complete removed by chemo- therapy.⁵⁰⁷ Another small group of cases comprises primary malignant teratoid tumors of the lung that contain seminoma, embryonal carcinoma, yolk sac carcinoma, or choriocarcinoma.^508-510 Primary pulmonary teratomas without cytologically malignant components are extremely uncommon; they have principally been seen as variably cystic masses in young adults. One such lesion was associated with pyothorax, and others have presented with extrusion of hair (from the contents of the lesion) into a large airway.^503,511,512

Grossly, the most obvious constituents of such neoplasms are squamous epithelium with associated keratinous debris and cartilage (Fig. 20.129). Mucoid contents may sometimes be seen in cystic areas, and nondescript solid foci may also be present.

Microscopically, teratomas of the lung can be divided into mature and immature varieties, as is true of these tumors occurring elsewhere in the body. The first of those subtypes is self-explanatory, but the term immature in this context refers specifically to the presence of primitive neuroectodermal tissue that resembles the developing neural tube. Otherwise, virtually any tissue in the body can be reflected in the constituents of teratoid lesions, including such unexpected elements as retina (Fig. 20.130). To qualify as teratomatous, the tumor must demonstrate derivatives from at least two of the three germinal lines (ectoderm, endoderm, and mesoderm).

Special pathologic studies are generally unnecessary diagnostically. However, immunostains may sometimes be undertaken to search for possible production of such oncofetal proteins as a-fetoprotein by endodermally derived elements, including intestinal and hepatic tissue.

Too few cases of mature or immature primary intrapulmonary teratomas have been studied to determine their biologic potential with certainty. However, by extrapolation from other anatomic locations, immature teratomas are known to have a potential for recurrence or metastasis. Thus, as a group, we have tentatively classified these lesions as borderline neoplasms.

Cystic Fibrohistiocytic Tumor of the Lung

Joseph et al.⁵¹³ described two adult patients who were found to have variably cystic lung lesions, represented by multiple parenchymal abnormalities on chest radiographs. One patient had pneumothorax and shortness of breath, and lesions in the other case were asymptomatic. Open-lung biopsies showed a proliferation of relatively bland spindle cells and histiocyte-like elements, mantling cystic spaces that were lined by metaplastic bronchiolar epithelium, squamous cells, or type II pneumocytes (Fig. 20.131). Some of the cysts contained erythrocytes and hemosiderin deposits. Another case has been illustrated anecdotally by Han_.⁵¹⁴

Figure 20.129 This gross photograph of an intrapulmonary teratoma shows a largely solid white-gray mass in the parenchyma with some central cystification.

Although the lesions described by Joseph and coworkers⁵¹³ enlarged very slowly over time, the authors suggested that the ultimate biologic potential and recommended treatment of pulmonary cystic fibrohis-tiocytic tumors was unclear. Currently, in accord with the opinions of Colome-Grimmer and Evans⁵¹⁵ and the authors of the original report on this entity (T.V. Colby, personal communication), it is believed that cystic fibrohistiocytic tumors are actually not primary lesions of the lung. Instead, they likely represent metastases of extrapulmonary low-grade fibrohistiocytic tumors, including such tumors as cellular dermatofibroma of skin.

Figure 20.130 Retinal pigment epithelium is apparent in this mature teratoma.

Figure 20.131 (A and B) Cystic fibrohistiocytic tumor of the lung demonstrates groups of relatively bland spindle cells, histiocyte-like cells, and foamy histiocytes (A; upper right). These lesions are currently considered metastases of low-grade extrapulmonary neoplasms rather than primary tumors of the lung.

Other Lesions

Well-differentiated papillary mesothelioma of the pleura and intrapulmonary paraganglioma are other borderline lesions that are properly mentioned here. Because of its specialized nature and possible relationship to malignant mesotheliomas, well-differentiated papillary mesothelioma is discussed in Chapter 20. Intrapulmonary paraganglionic tumors are discussed in Chapter 13, dealing with neuroendocrine neoplasms. Because its biologic characteristics are more aggressive than those of most other borderline lesions, hemangioendothelioma is discussed in Chapter 14, on malignant mesenchymal tumors of the lung and pleura.

Self-assessment questions and e-cases related to this chapter can be found online at ExpertConsult.com.

References

1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97(12 suppl):3133-3275.

2. Lutz JM, Francisci S, Mugno E, et al. Cancer prevalence in Central Europe: the EUROPREVAL study. Ann Oncol. 2003;14:313-322.

3. Oei TK, Wouters EF, Visser R, VanEngelshoven JM, Greve LH. The value of conventional radiography and computed tomography (CT) in diagnosis of pulmonary hamartoma. Rontgenblatter. 1983;36:324-327.

4. Erasmus JJ, Connolly JE, McAdams HP, Roggli VL. Solitary pulmonaiy nodules: part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics. 2000;20:43-58.

5. Petticrew MP, Sowden AJ, Lister-Sharp D, Wright K. False-negative results in screening programs: systematic review of impact and implications. Health Technol Assess. 2000;4:1-120.

6. Cardillo G, Regal M, Sera F, et al. Videothoracoscopic management of the solitary pulmonary nodule: a single-institution study on 429 cases. Ann Thorac Surg. 2003;75:1607-1611.

7. Barzo P, Molnar L, Minik K. Bronchial papilloma of various origins. Chest 1987;92:132-136.

8. Spencer H, Dail DH, Arneaud J. Noninvasive bronchial epithelial papillary tumors. Cancer. 1980;45:1486-1497.

9. Zimmerman A, Lang HR, Muhlberger F, Bachman M. Papilloma of the bronchus. Respiration. 1980;39:286-290.

10. Maxwell RJ, Gibbons JR, O'Hara MD. Solitary squamous papilloma of the bronchus. Thorax. 1985;40:68-71.

11. Laubscher FA. Solitary squamous cell papilloma of bronchial origin. Am J Clin Pathol. 1969;52:599-603.

12. Greene JG, Tassin L, Saberi A. Endobronchial epithelial papilloma associated with a foreign body. Chest. 1990;97:229-230.

13. Miura H, Tsuchida T, Kawate N, et al. Asymptomatic solitary papilloma of the bronchus: review of occurrence in Japan. Eur Respir J. 1993;6:1070-1073.

14. Basheda S, Gephardt GN, Stoller JK. Columnar papilloma of the bronchus: case report and literature review. Am Rev Respir Dis. 1991;144:1400-1402.

15. Trillo A, Guha A. Solitary condylomatous papilloma of the bronchus. Arch Pathol Lab Med. 1988;112:731-733.

16. Desai AV, Scolyer RA, McCaughan B, Torzillo PJ. Middle lobe syndrome due to obstructing solitary bronchial papilloma. Aust N Z J Med. 1999;29:745-747.

17. Hurt R. Benign tumors of the bronchus and trachea, 1951-1981. Ann R Coil Surg Engl. 1984;66:22-26.

18. Roviaro GC, Varoli F, Pagnini CA. Is the solitary papilloma of the bronchus always a benign tumor? J Otorhinoiaryngol Relat Spec. 1981;43:301-308.

19. Katial RK, Ranlett R, Whitlock WL. Human papillomavirus associated with solitary squamous papilloma complicated by bronchiectasis and bronchial stenosis. Chest 1994;106:1887-1889.

20. Roglic M, Jukic S, Damjanov I. Cytology of the solitary papilloma of the bronchus. Acta Cytol. 1975;19:11-13.

21. Flieder DB, Koss MN, Nicholson A, et al. Solitary pulmonary papillomas in adults: a clinicopathologic and in-situ hybridization study of 14 cases combined with 27 cases in the literature. Am J Surg Pathol. 1998;22:1328-1342.

22. Lee YO, Kim DH, Kim CH, Park TI, Cho S. Rare tumor of the tracheobronchial tree: solitary squamous papilloma. Thorac Cardiovasc Surg. 2009;57:178-179.

23. Popper HH, El-Shabrawi Y, Wockel W, et al. Prognostic importance of human papillomavirus typing in squamous cell papilloma of the bronchus: comparison of in-situ hybridization and the polymerase chain reaction. Hum Pathol. 1994;25:1191-1197.

24. Popper HH, Wirnsberger G, Juttner-Smolle FM, Pongratz MG, Sommersgutter M. The predictive value of human papillomavirus (HPV) typing in the prognosis of bronchial squamous cell papillomas. Histopathology. 1992;21:323-330.

25. Clavel CE, Nawrocki B, Bosseaux B, et al. Detection of human papillomavirus DNA in bronchopulmonary carcinomas by hybrid capture. II. A study of 185 tumors. Cancer. 2000;88:1347-1352.

26. Smith E, Pignatari S, Gray S, Haugen T, Turak L. Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis, using the polymerase chain reaction. Arch Otolaryngol Head Neck Surg. 1993;119:554-557.

27. Rady PL, Schnadig VJ, Weiss RL, Hughes TK, Tyring SK. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope. 1998;108:735-740.

28. Syrjanen RJ. Epithelial lesions suggestive of a condylomatous origin found closely associated with invasive bronchial squamous cell carcinomas. Respiration. 1980;40:150-160.

29. DiMarco AF, Montenegro H, Payne CB Jr, Kwon KH. Papillomas of the tracheobronchial tree with malignant degeneration. Chest. 1978;74:464-465.

30. Bejui-Thivolet F, Chardonnet Y, Patricot LM. Human papillomavirus type 11 DNA in papillary squamous cell lung carcinoma. Virchows Arch. 1990;A 417:457-461.

31. Inoue Y, Oka M, Ishii H, et al. A solitary bronchial papilloma with malignant changes. Intern Med. 2001;40:56-60.

32. Kramer S, Wehunt W, Stocker J, Kashima H. Pulmonary manifestations of juvenile laryngotracheal papillomatosis. Am J Roentgenol. 1985;144:687-694.

33. Fechner RE, Fitz-Hugh G. Invasive tracheal papillomatosis. Am J Surg Pathol. 1980;4:79-86.

34. Peterson BL, Buchwald C, Gerstoft J, Bretlau P, Lindeberg H. An aggressive and invasive growth of juvenile papillomas involving the total respiratory tract. J Layngol Otol. 1998;112:1101-1104.

35. Franzmann MB, Buchwald C, Larsen P, Balle V. Tracheobronchial involvement of laryngeal papillomatosis at onset. J Laryngol Otol. 1994;108:164-165.

36. Shykhon M, Kuo M, Pearman R. Recurrent respiratory papillomatosis. Clin Otolaryngol. 2002;27:237-243.

37. Blackledge RA, Anandi VK. Tracheobronchial extension of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2000;109:812-818.

38. Harada H, Miura K, Tsutsui Y, et al. Solitary squamous cell papilloma of the lung in a 40 year old woman with recurrent laryngeal papillomatosis. Pathol Int 2000;50:431-439.

39. Weingarten J. Cytologic and histologic findings in a case of tracheobronchial papillomatosis. Acta Cytol. 1981;25:167-170.

40. Kashima H, Mounts P, Leventhal B, Hruban RH. Sites of predilection in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 1993;102:580-583.

41. Al-Saleem T, Peale AR, Norris CM. Multiple papillomatosis of the lower respiratory tract: clinical and pathologic study of eleven cases. Cancer. 1968;22:1173-1184.

42. Rahman A, Ziment I. Tracheobronchial papillomatosis with malignant transformation. Arch Intern Med. 1983;143:577-578.

43. Batsakis JG, Raymond AK, Rice DH. The pathology of head and neck tumors: papillomas of the upper aerodigestive tracts, Part 18. Head Neck Surg. 1983;5:332-344.

44. Zarod A, Rutherford J, Corbitt G. Malignant progression of laryngeal papilloma associated with human papillomavirus type 6 (HPV-6). J Clin Pathol. 1988;41:280-283.

45. Byrne J, Tsao MS, Fraser R, Howley P. Human papillomavirus-11 DNA in a patient with chronic laryngotracheobronchial papillomatosis and metastatic squamous cell carcinoma of the lung. N Engl J Med. 1987;317:873-878.

46. Wilde E, Duggan M, Field S. Bronchogenic squamous cell carcinoma complicating localized recurrent respiratory papillomatosis. Chest. 1994;105:1887-1888.

47. Lindsay F, Bloom D, Pransky S, Stabley R, Shick P. Histologic review of cidofovir-treated recurrent respiratory papillomatosis. Ann Otol Rhinol L 2008;117:113-117.

48. Yousem SA, Ohori NP, Sonmez-Alpan E. Occurrence of human papillomavirus DNA in primary lung neoplasms. Cancer. 1992;69:693-697.

49. Liebow AA. Tumors of the lower respiratory tract. Atlas of Tumor Pathology, Series 1, Fascicle 17. Washington: Armed Forces Institute of Pathology; 1952:22.

50. England DM, Hochholzer L. Truly benign "bronchial adenoma:" report of 10 cases of mucous gland adenoma with immunohistochemical and ultrastructural findings. Am J Surg Pathol. 1995;19:887-899.

51. Markel SF, Abell MR, Haight C, French AJ. Neoplasms of the bronchus commonly designated as adenomas. Cancer. 1964;17:590-608.

52. Payne WS, Fontana RS, Woolner LB. Bronchial tumors originating from mucous glands: current classification and unusual manifestations. Med Clin North Am Dis Respir. 1964;48:945-960.

53. Milenkovic B, Stojsic J, Mandaric D, Stevic R. Mucous gland adenoma simulating bronchial asthma: case report and literature review. J Asthma. 2007;44:789-793.

54. Spencer H. Bronchial mucous gland tumors. Virchows Arch Pathol Anat 1979;383:101-115.

55. Allen MS Jr, Marsh WL Jr, Greissinger WT. Mucous gland adenoma of the bronchus. J Thorac Cardiovasc Surg. 1974;67:966-968.

56. Emory WB, Mitchel WT Jr, Hatch HG Jr. Mucous gland adenoma of the bronchus. Am Rev Respir Dis. 1973;108:1407-1410.

57. Edwards CW, Matthews HR. Mucous gland adenoma of the bronchus. Thorax. 1981;36:147-148.

58. Kroe DJ, Pitcock JA. Benign mucous gland adenoma of the bronchus. Arch Pathol. 1967;84:539-540.

59. Heard BE, Corrin B, Dewar A. Pathology of seven mucous cell adenomas of the bronchial glands with particular reference to ultrastructure. Histopathology. 1985;9:687-701.

60. Akhtar M, Young I, Reyes F. Bronchial adenoma with polymorphous features. Cancer. 1974;33:1572-1576.

61. Rosenblum P, Klein RI. Adenomatous polyp of the right main bronchus producing atelectasis. Pediatrics. 1936;78:791-796.

62. Smith AG. Benign epithelial tumors of the bronchus. South Med J. 1965;58:1535-1541.

63. Courtin P, Janin A, Sault MC, et al. Pure bronchial adenoma. Anatomic, clinical, and ultrastructural study of a case. Ann Pathol. 1987;7:315-319.

64. Weinberger MA, Katz S, Davis EW. Peripheral bronchial adenoma of mucous gland type: clinical and pathological aspects. J Thorac Surg. 1955;29:626-635.

65. Key BM, Pritchett PS. Mucous gland adenoma of the bronchus. South Med J. 1979;72:83-85.

66. Arrigoni MG, Woolner LB, Bernatz PE, Miller WE, Fontana RS. Benign tumors of the lung: a ten-year experience. J Thorac Cardiovasc Surg. 1970;60:589-599.

67. Kwon JW, Goo JM, Seo JB, Seo JW, Im JG. Mucous gland adenoma of the bronchus: CT findings in two patients. J Comput Assist Tomogr. 1999;23:758-760.

68. Mejean-Lebreton F, Barnoud R, De la Roche E, Devouassoux-Shisheboran M. Benign salivary gland-type tumors of the bronchus: expression of high molecular-weight cytokeratins. Ann Pathol. 2006;26:30-34.

69. Delpiano C, Claren R, Sironi M, Cenacchi G, Spinelli M. Cytological appearance of papillary mucous gland adenoma of the left lobar bronchus with histological confirmation. Cytopathology. 2000;11:193-196.

70. Moran CA, Suster S, Askin FB, Koss MN. Benign and malignant salivary gland-type mixed tumors of the lung: clinicopathologic and immunohistochemical study of eight cases. Cancer. 1994;73:2481-2490.

71. Davis PW, Briggs JC, Leal RME, et al. Benign and malignant mixed tumors of the lung. Thorax. 1972;27:657-673.

72. Hayes MM, Van der Westhuizen NG, Forgie R. Malignant mixed tumors of the bronchus: a biphasic neoplasm of epithelial and myoepithelial cells. Mod Pathol. 1993;6:85-88.

73. Payne WS, Scier J, Woolner LB. Mixed tumors of the bronchus (salivary gland type). J Thorac Cardiovasc Surg. 1965;49:663-668.

74. Sakamoto H, Uda H, Tanaka T, et al. Pleomorphic adenoma in the periphery of the lung: report of a case and review of the literature. Arch Pathol Lab Med. 1991;115:393-396.

75. Baghai-Wadji M, Sianati M, Nikpour H, Koochekpour S. Pleomorphic adenoma of the trachea in an 8 year-old boy: a case report. J Pediatr Surg. 2006;41:e23-e26.

76. Kamiyoshihara M, Ibe T, Takeyoshi I. Pleomorphic adenoma of the main bronchus in an adult treated using a wedge bronchiectomy. Gen Thorac Cardiovasc Surg. 2009;57:43-45.

77. Fitchett J, Luckraz H, Gibbs A, O'Keefe P A rare case of primary pleomorphic adenoma in main bronchus. Ann Thorac Surg. 2008;86:1025-1026.

78. Jin HY, Park TS. Pulmonary pleomorphic adenoma: report of a rare case. Korean J Intern Med. 2007;22:122-124.

79. Kourda J, Ismail O, Smati BH, et al. Benign myoepithelioma of the lung—a case report and review of the literature. Cases J. 2010;13:25.

80. Angelov A, Dikranian K, Trosheva M. Immunomorphological characteristics of pleomorphic adenoma of salivary glands. Bull Group Int Rech Sci Stomatol Odontol. 1996;39:67-75.

81. Ang KL, Dhannapuneni VR, Morgan WE, Soomro IN. Primary pulmonary pleomorphic adenoma: an immunohistochemical study and review of the literature. Arch Pathol Lab Med. 2003;127:621-622.

82. Takeuchi E, Shimizu E, Sano N, et al. A case of pleomorphic adenoma of the lung with multiple distant metastases—observations on its oncogene and tumor suppressor gene expression. Anticancer Res. 1998;18:2015-2020.

83. Fechner RE, Bentnick BR. Ultrastructure of bronchial oncocytoma. Cancer. 1973;31:1451-1457.

84. Nielsen AL. Malignant bronchial oncocytoma: a case report and review of the literature. Hum Pathol. 1985;16:852-854.

85. Santos-Briz A, Jenron J, Sastre R, Romero L, Valle A. Oncocytoma of the lung. Cancer. 1977;40:1330-1336.

86. Burrah R, Kini U, Correa M, Srirangapatna S. Pulmonary oncocytoma: a rare case. Asian Cardiovasc Thorac Ann. 2006;14:e113-e114.

87. Laforga JB, Aranda FI. Multicentric oncocytoma of the lung diagnosed by fine-needle aspiration. Dlagn Cytopathol. 1999;21:51-54.

88. Tashiro Y, Iwata Y, Nabae T, Manage H. Pulmonary oncocytoma: report of a case in conjunction with an immunohistochemical and ultrastructural study. Pathol Int. 1995;45:448-451.

89. De Jesus MG, Poon TP, Chung KY. Pulmonary oncocytoma. N Y State J Med. 1989;89:477-480.

90. Tesluk H, Dajee A. Pulmonary oncocytoma. J Surg Oncol. 1985;29:173-175.

91. Fernandez MA, Nyssen J. Oncocytoma of the lung. Can J Surg. 1982;25:332-333.

92. Black WC III. Pulmonary oncocytoma. Cancer. 1969;23:1347-1357.

93. Ritter JH, Nappi O. Oxyphilic proliferations of the respiratory tract and paranasal sinuses. Semin Dlagn Pathol. 1999;16:105-116.

94. Arora R, Mathur SR, Aron M, et al. Oncocytic carcinoid tumor of the lung: a case report of diagnostic pitfall in filter membrane preparation of bronchial washings. Acta Cytol. 2007;51:907-910.

95. Zhou CX, Gao Y. Oncocytoma of the salivary glands: a clinicopathologic and immunohistochemical study. Oral Oncol. 2009;45:e232e238.

96. Mete O, Kilicasian I, Gulluoglu MG, Uysal V. Can renal oncocytoma be differentiated from its renal mimics? the utility of anti-mitochondrial, caveolin-1, CD63, and cytokeratin 14 antibodies in the differential diagnosis. Virchows Arch. 2005;447:938-946.

97. Bartley TD, Arean VM. Intrapulmonary neurogenic tumors. J Thorac Cardiovasc Surg. 1965;50:114-123.

98. Roviaro G, Montorsi M, Varoli F, Binda R, Cecchetto A. Primary pulmonary tumors of neurogenic origin. Thorax. 1983;38:942-945.

99. Silverman JF, Leffers BR, Kay S. Primary pulmonary neurilemmoma: report of a case with ultrastructural examination. Arch Pathol Lab Med. 1976;100:644-648.

100. Yamakawa H. Intrapulmonary schwannoma: a case report. J Jpn Assoc Chest Surg. 1993;7: 165-169.

101. Sugita M, Fujimura S, Hasumi T, Kondo T, Sagawa M. Sleeve superior segmentectomy of the right lower lobe for endobronchial neurinoma: report of a case. Respiration. 1996;63:191-194.

102. McCluggage WG, Bharucha H. Primary pulmonary tumors of nerve sheath origin. Histopathology. 1995;26:247-254.

103. Lin YC, Lin MC, Chen TC, Huang CC, Lee CH. Tracheal neurilemmoma mimicking bronchial asthma—a dilemma of difficult diagnosis: case report. Changgeng Yi Xue Za Zhi. 1999;22:525-529.

104. Tsukada H, Hsada H, Kojima K, Yamata N. Bronchial wall schwannoma removed by sleeve resection of the right mainstem bronchus without lung resection. J Cardiovasc Surg. 1998;39:511-513.

105. Ashkan K, Casey AT. Pulmonary apex schwannoma. J Neurol Neurosurg Psych. 1997;63:719.

106. Bosch X, Ramirez J, Font J, et al. Primary intrapulmonary benign schwannoma: a case with ultrastructural and immunohistochemical confirmation. Eur Respir J. 1990;3:234-237.

107. Muhrer KH, Fischer HP Primary pulmonary neurilemmoma. Thorac Cardiovasc Surg. 1983;31:313-316.

108. Imaizumi M, Takahashi T, Niimi T, et al. A case of primary intrapulmonary neurilemmoma and review of the literature. Jpn J Surg. 1989;19:740-746.

109. Feldhaus RJ, Anene C, Bogard P A rare endobronchial neurilemmoma (schwannoma). Chest. 1989;95:461-462.

110. Nesbitt JC, Vega DM, Burke T, Mackay B. Cellular schwannoma of the bronchus. Ultrastruct Pathol. 1996;20:349-354.

111. Noah MA, Gorecha M, Firmin RK. Primary benign bronchial schwannoma presenting as asthma. J Asthma. 2009;46:856-857.

112. Onal M, Ernam D, Atikcan S, Memis L. Endobronchial schwannoma with massive hemoptysis. Tuberk Toraks. 2009;57:89-92.

113. Unger PD, Geller SA, Anderson PJ. Pulmonary lesions in a patient with neurofibromatosis. Arch Pathol Lab Med. 1984;108:654-657.

114. Bacha EA, Wright CD, Grillo HC, et al. Surgical treatment of primary pulmonary sarcomas. Eur J Cardiothorac Surg. 1999;15:456-460.

115. Moran CA, Suster S, Koss MN. Primary malignant "triton" tumor of the lung. Histopathology. 1997;30:140-144.

116. Attanoos RL, Appleton MA, Gibbs AR. Primary sarcomas of the lung: a clinicopathological and immunohistochemical study of 14 cases. Histopathology. 1996;29:29-36.

117. Simansky DA, Aviel-Ronen S, Reder I, et al. Psammomatous melanotic schwannoma: presentation of a rare primary lung tumor. Ann Thorac Surg. 2000;70:671-672.

118. Abrikossoff A. Uber Myome ausgehend von der quergestreiften willkurlichen Muskulatur Virchows Arch Pathol Anat Physiol Kiln Med. 1926;260:215-233.

119. Lack EE, Worsham GF, Callihan MD, et al. Granular cell tumor: a clinicopathologic study of 110 patients. J Surg Oncol. 1980;13:301-316.

120. Alvarez-Fernandez E, Carretero-Albinana L. Bronchial granular cell tumor: presentation of three cases with tissue culture and ultrastructural study. Arch Pathol Lab Med. 1987;111:1065-1069.

121. DeClerq D, Van der Straten M, Roels H. Granular cell myoblastoma of the bronchus. Eur J Respir Dis. 1983;64:72-76.

122. Hurwitz SS, Conlan AA, Gritzman MC, Krut LH. Granular cell myoblastoma. Thorax. 1982;37:392-393.

123. Hosaka T, Suzuki S, Niikawa H, et al. A rare case of a pulmonary granular cell tumor presenting as a coin lesion. Jpn J Thorac Cardiovasc Surg. 2003;51:107-109.

124. Abdulhamid I, Rabah R. Granular cell tumor of the bronchus. Pediatr Pulmonol. 2000;30:425-428.

125. Husain M, Nguyen GK. Cytopathology of granular cell tumor of the lung. Diagn Cytopathol. 2000;23:294-295.

126. Al-Ghamdi AM, Flint JD, Muller NL, Stewart KC. Hilar pulmonary granular cell tumor: a case report and review of the literature. Ann Diagn Pathol. 2002;4:245-251.

127. Scala R, Naldi M, Fabianelli F, et al. Endobronchial granular cell tumor. Monaldi Arch Chest Dis. 1999;54:404-406.

128. Thomas de Montpreville V, Dulmet EM. Granular cell tumors of the lower respiratory tract. Histopathology. 1995;27:257-262.

129. Deavers M, Guinee D, Koss MN, Travis WD. Granular cell tumors of the lung: clinicopathologic study of 20 cases. Am J Surg Pathol. 1995;19:627-635.

130. Hernandez OG, Haponik EF, Summer WR. Granular cell tumor of the bronchus: bronchoscopic and clinical features. Thorax. 1986;41:927-931.

131. Mullen CV Jr, Hewan-Lowe K, Gilman MJ. Massive hemoptysis associated with granular cell tumor of the bronchus. South Med J. 1983;76:1452.

132. Lack EE, Harris GB, Eraklis AJ, Vawter GF Primary bronchial tumors in childhood: a clinicopathologic study of six cases. Cancer. 1983;51:492-497.

133. Guillou L, Gloor E, Anani PA, Kaelin R. Bronchial granular cell tumor: report of a case with preoperative cytologic diagnosis on bronchial brushings and immunohistochemical studies. Acta Cytol. 1991;35:375-380.

134. Majmudar B, Thomas J, Gorelkin L, Symbas PN. Respiratory obstruction caused by a multicentric granular cell tumor of the laryngotracheobronchial tree. Hum Pathol. 1981;12: 283-286.

135. Oparah SS, Subramanian VA. Granular cell myoblastoma of the bronchus: report of 2 cases and review of the literature. Ann Thorac Surg. 1976;22:199-202.

136. Robinson JM, Knoll R, Henry DA. Intrathoracic giant cell myoblastoma. South Med J. 1988;81:1453-1457.

137. Schulster PL, Khan FA, Azueta V Asymptomatic pulmonary granular cell tumor presenting as a coin lesion. Chest. 1975;68:256-258.

138. Chen KTK. Cytology of bronchial benign granular cell tumor. Acta Cytol. 1991;35:381-384.

139. Miyake M, Tateishi U, Maeda T, et al. Bronchial granular cell tumor: a case presenting secondary obstructive changes on CT Radiat Med. 2006;24:154-157.

140. Fang HY, Wu CY, Huang HJ, Lin YM. Granular cell tumor of the lung. Lungs. 2010;188(4):355-357.

141. Muhammed AA, Sikka P, Dhillon RS, Gibbons WJ, Ahmed A. Coexisting granular cell tumor and adenocarcinoma of the lung: a case report and review of the literature. Respir Care. 2001;46:702-704.

142. Cutlan RT, Eltorky M. Pulmonary granular cell tumor coexisting with bronchogenic carcinoma. Ann Diagn Pathol. 2001;5:74-79.

143. Althausen AM, Kowalski DP, Ludwig ME, Curry SL, Greene JF. Granular cell tumors: a new clinically important histologic finding. Gynecol Oncol. 2000;77:310-313.

144. Elmberger PG, Skold CM, Collins BT Fine needle aspiration biopsy of intrabronchial granular cell tumor. Acta Cytol. 2005;49:223-224.

145. Sobel HJ, Marquet E, Avrin E, Schwarz R. Granular cell myoblastoma: an electron microscopic and cytochemical study illustrating the genesis of granules and aging of myoblastoma cells. Am J Pathol. 1971;65:59-78.

146. Miettinen M, Lehtonen E, Lehtola H, et al. Histogenesis of granular cell tumor: an immunohistochemical and ultrastructural study. J Pathol. 1984;142:221-229.

147. Mazur M, Shultz JJ, Myers JL. Granular cell tumor: immunohistochemical analysis of 21 benign tumors and one malignant tumor. Arch Pathol Lab Med. 1990;114:692-696.

148. Liu Z, Mira JL, Vu H. Diagnosis of malignant granular cell tumor by fine needle aspiration cytology. Acta Cytol. 2001;45:1011-1021.

149. Ordonez NG, Mackay B. Granular cell tumor: a review of the pathology and histogenesis. Ultrastruct Pathol. 1999;23:207-222.

150. Fine SW, Li M. Expression of calretinin and the alpha-subunit of inhibin in granular cell tumors. Am J Clin Pathol. 2003;119:259-264.

151. Nappi O, Ferrara G, Wick MR. Neoplasms composed of eosinophilic polygonal cells: an overview with consideration of different cytomorphologic patterns. Semin Diagn Pathol. 1999;16:82-90.

152. Franzblau MJ, Manwaring M, Plumhof C, Listrom JB, Burgdorf WHC. Metastatic breast carcinoma mimicking granular cell tumor. J Cutan Pathol. 1989;16:218-221.

153. Reuter VE. Renal tumors exhibiting granular cytoplasm. Semin Diagn Pathol. 1999;16:135-145.

154. Ogino S, Al-Kaisi N, Abdul-Karim FW. Cytopathology of oncocytic carcinoid tumor of the lung mimicking granular cell tumor: a case report. Acta Cytol. 2000;44:247-250.

155. Yousem SA, Hochholzer L. Alveolar adenoma. Hum Pathol. 1986;17:1066-1071.

156. Sak SD, Koseoglu RD, Demirag F, Akbulut H, Gungor A. Alveolar adenoma of the lung: immunohistochemical and flow-cytometric characteristics of two new cases and a review of the literature. APMIS. 2007;115:1443-1449.

157. Fujimoto K, Muller NL, Sadohara J, et al. Alveolar adenoma of the lung: computed tomography and magnetic resonance imaging findings. J Thorac Imaging. 2002;17:163-166.

158. Hartman MS, Epstein DM, Geyer SJ, Keenan RJ. Alveolar adenoma. Ann Thorac Surg. 2004;78:1842-1843.

159. Cavazza A, Paci M, De Marco L, et al. Alveolar adenoma of the lung: a clinicopathologic, immunohistochemical, and molecular study of an unusual case. Int J Surg Pathol. 2004;12:155-159.

160. Semeraro D, Gibbs AR. Pulmonary adenoma: a variant of sclerosing hemangioma of lung? J Clin Pathol. 1989;42:1222-1223.

161. Oliveira P, Moura-Nunes JF, Clode AL, da Costa JD, Almeida MO. Alveolar adenoma of the lung: further characterization of this uncommon tumor. Virchows Arch. 1996;429:101-108.

162. Burke LM, Rush WI, Khoor A, et al. Alveolar adenoma: a histochemical, immunohistochemical, and ultrastructural analysis of 17 cases. Hum Pathol. 1999;30:158-167.

163. Al-Hilli F. Lymphangioma (of alveolar adenoma?) of the lung. Histopathology. 1987;11:979-986.

164. Wada A, Tateishi R, Terazawa T, Matsuda M, Hattori S. Lymphangioma of the lung. Arch Pathol. 1974;98:211-213.

165. Miller RR. Bronchioloalveolar cell adenomas. Am J Surg Pathol. 1990;14:904-912.

166. Glaab R, Turina M, Achermann E, et al. Alveolar adenoma—a rare pulmonary mass: case report and review of the literature. Zenbrabl Chir. 2009;134:478-480.

167. Nakamura H, Adachi Y, Arai T, et al. A small alveolar adenoma resected by thoracoscopic surgery. Ann Thorac Surg. 2009;87:956-957.

168. Hegg CA, Flint A, Singh G. Papillary adenoma of the lung. Am J Clin Pathol. 1992;97:393-397.

169. Fukuda T, Ohnishi Y, Kanai I, et al. Papillary adenoma of the lung: histological and ultrastructural findings in two cases. Acta Pathol Jpn. 1992;42:56-61.

170. Mori M, Chiba R, Tezuka F, et al. Papillary adenoma of type II pneumocytes might have malignant potential. Virchows Arch. 1996;428:195-200.

171. Yamamoto T, Horiguchi H, Shibagaki T, et al. Encapsulated type II pneumocyte adenoma: a case report & review of the literature. Respiration. 1993;60:373-377.

172. Noguchi M, Kodama T, Shimosato Y, et al. Papillary adenoma of type 2 pneumocytes. Am J Surg Pathol. 1986;10:134-139.

173. Fine G, Chang CH. Adenoma of type 2 pneumocytes with oncocytic features. Arch Pathol Lab Med. 1991;115:797-801.

174. Kurotaki H, Kamata Y, Kimura M, Nagai K. Multiple papillary adenomas of type II pneumocytes found in a 13 year old boy with von Recklinghausen's disease. Virchows Arch. 1993;423:319-322.

175. Sanchez-Jimenez J, Ballester-Martinez A, Lodo-Besse J, et al. Papillary adenoma of type II pneumocytes. Pediatr Puimonoi. 1994;17:396-400.

176. Gesierich W, Diwersy C, Leinsinger G, et al. Papillary adenoma of type II pneumocytes as a rare differential diagnosis of a solitary pulmonary nodule. Pneumologie. 2007;61:697-699.

177. Papla B. Papillary adenoma of the lung. Pol J Pathol. 2009;60:49-51.

178. Fantone JC, Geisinger KR, Appelman HD. Papillary adenoma of the lung with lamellar and electron-dense granules: an ultrastructural study. Cancer. 1982;50:2839-2844.

179. Dessy E, Braidotti P, Del Curto B, et al. Peripheral papillary tumor of type II pneumocytes: a rare neoplasm of undetermined malignant potential. Virchows Arch. 2000;436:289-295.

180. Tomashefski JF. Benign endobronchial mesenchymal tumors: their relationship to parenchymal pulmonary hamartomas. Am J Surg Pathol. 1982;6:531-540.

181. Yellin A, Roserman Y, Lieberman Y Review of smooth muscle tumors of the lower respiratory tract. Br J Dis Chest. 1984;78:337-351.

182. White SH, Ibrahim NBN, Forrester-Wood CP, Jeyasingham R. Leiomyomas of the lower respiratory tract. Thorax. 1985;40:306-311.

183. Orlowski TM, Stasiak K, Kolodziej J. Leiomyoma of the lung. J Thorac Cardiovasc Surg. 1978;76:257-261.

184. Van den Bosch JM, Wagenaar SS, Corrin B, et al. Mesenchymoma of the lung (so-called hamartoma): a review of 154 parenchymal and endobronchial cases. Thorax. 1987;42:790-793.

185. Gal AA, Brooks JJ, Pietra GG. Leiomyomatous lung neoplasms: a clinical, histologic, and immunohistochemical study. Mod Pathol. 1989;2:209-216.

186. Van Way CW, McCracken RL, Carlisle BB. Leiomyoma of the lower respiratory tract. Ann Thorac Surg. 1968;6:273-276.

187. Taylor TL, Miller DR. Leiomyoma of the bronchus. J Thorac Cardiovasc Surg. 1969;57:245-248.

188. Yamada H, Katoh O, Yamaguchi T, Natsuaki M, Itoh T Intrabronchial leiomyoma treated by localized resection vis bronchotomy and bronchoplasty. Chest. 1987;91:283-284.

189. Shahian DM, McEnahy MR. Complete endobronchial resection of leiomyoma of the bronchus. J Thorac Cardiovasc Surg. 1979;77:87-91.

190. Kim KH, Suh JS, Han WS. Leiomyoma of the bronchus treated by endoscopic resection. Ann Thorac Surg. 1993;56:1164-1166.

191. Mouveroux FA, Bourcereau J, Fressinaud C, Bourras P. Bronchial leiomyoma: report of a case successfully treated by Nd-YAG laser. Thorac Cardiovasc Surg. 1988;95:536-537.

192. Cardenas-Garcia J, Lee-Chang A, Chung V, et al. Bronchial leiomyoma, a case report and review of literature. Respir Med Case Rep. 2014;12:59-62

193. Silverman JF, Kay S. Multiple pulmonary leiomyomatous hamartomas: report of case with ultrastructural examination. Cancer. 1976;38:1199-1204.

194. Hull MT, Gonzalez-Crussi F, Grosfeld JL. Multiple pulmonary fibroleiomyomatous hamartomata in childhood. J Pediatr Surg. 1979;14:428-431.

195. Itoh H, Yanagi M, Setoyama T, et al. Solitary fibroleiomyomatous hamartoma of the lung in a patient without a preexisting smooth muscle tumor. Pathol Int 2001;51:661-665.

196. Shmookler BM, Lauer DH. Retroperitoneal leiomyosarcoma: a clinicopathologic analysis of 36 cases. Am J Surg Pathol. 1983;7:269-280.

197. Mackay B, Legha SS. Coin lesion of the lung in a 19 year old male. Ultrastruct Pathol. 1981;2:289-294.

198. Alt B, Huffer WE, Belchis DA. A vascular lesion with smooth muscle differentiation presenting as a coin lesion in the lung: glomus tumor versus hemangiopericytoma. Am J Clin Pathol. 1983;80:765-771.

199. Fabich DR, Hafez GR. Glomangioma of the trachea. Cancer. 1980;45:2337-2341.

200. Tang C, Toker CK, Foris NP, Trump BF. Glomangioma of the lung. Am J Surg Pathol. 1978;2:103-109.

201. Gaertner EM, Steinberg DM, Huber M, et al. Pulmonary and mediastinal glomus tumors: report of five cases including a pulmonary glomangiosarcoma. A clinicopathologic study with literature review. Am J Surg Pathol. 2000;24:1105-1114.

202. Yilmaz A, Bayramgurler B, Aksoy F, et al. Pulmonary glomus tumor: a case initially diagnosed as carcinoid tumor. Respirology. 2002;7:369-371.

203. Shugart RR, Soule EH, Johnson EW. Glomus tumors. Surg Gynecol Obstet. 1963;117:334-340.

204. Miettinen M, Paal E, Lasota J, Sobin LH. Gastrointestinal glomus tumors: a clinicopatho- logic, immunohistochemical, and molecular genetic study of 32 cases. Am J Surg Pathol. 2002;26:301-311.

205. Littlefield JB, Drash EC. Myxoma of the lung. J Thorac Surg. 1959;37:745-749.

206. Pollak ER, Naunheim KS, Little AG. Fibromyxoma of the trachea. Arch Pathol Lab Med. 1985;109:926-929.

207. Butler C, Kleinerman J. Pulmonary hamartoma. Arch Pathol. 1969;88:584-592.

208. Gjevre JA, Myers JL, Prakash UBS. Pulmonary hamartomas. Mayo Clin Proc. 1996;71:14-20.

209. Hamper UM, Khouri NF, Stitik FP, et al. Pulmonary hamartoma: diagnosis by transthoracic needle-aspiration biopsy. Radiology. 1985;155:15-18.

210. Wiatrowska BA, Yazdi HM, Matzinger FR, MacDonald LL. Fine needle aspiration biopsy of pulmonary hamartomas: radiologic, cytologic, and immunocytochemical study of 15 cases. Acta Cytol. 1995;39:1167-1174.

211. Carney JA. The triad of gastric epithelioid leiomyosarcoma, functioning extra-adrenal paraganglioma, and pulmonary chondroma. Cancer. 1979;43:374-382.

212. Wick MR, Ruebner BH, Carney JA. Gastric tumors in patients with pulmonary chondroma or extra-adrenal paraganglioma: an ultrastructural study. Arch Pathol Lab Med. 1981;105: 527-531.

213. Rodriguez FJ, Aubry MC, Tazelaar HD, Slezak J, Carney JA. Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma. Am J Surg Pathol. 2007;31:1844-1853.

214. Abrahams NA, Colby TV, Pearl RH, et al. Pulmonary hemangiomas of infancy and childhood: report of two cases and review of the literature. Pediatr Dev Pathol. 2002;5:283-292.

215. Fugo K, Matsuno Y, Okamoto K, et al. Solitary capillary hemangioma of the lung: report of 2 resected cases detected by high-resolution CT. Am J Surg Pathol. 2006;30:750-753.

216. Ritter JH, Mills SE, Nappi O, Wick MR. Angiosarcoma-like neoplasms of epithelial organs: true endothelial tumors or variants of carcinoma? Semin Diagn Pathol. 1995;12:270-282.

217. Almagro P, Julia J, Sanjaume M, et al. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore). 2002;81:417-424.

218. Havlik DM, Massie LW, Williams WL, Crooks LA. Pulmonary capillary hemangiomatosis-like foci: an autopsy study of 8 cases. Am J Clin Pathol. 2000;113:655-662.

219. Eastridge CF, Young JM, Steplock AL. Endobronchial lipoma. South Med J. 1984;77:759-761.

220. Politis J, Funahashi A, Gehlsen JA, et al. Intrathoracic lipomas: report of three cases and review of the literature with emphasis on endobronchial lipoma. J Thorac Cardiovasc Surg. 1979;77:550-556.

221. Kamiyoshihara M, Sakata K, Ohtani Y, et al. Endobronchial lipoma accompanied with primary lung cancer: report of a case. Surg Today. 2002;32:402-405.

222. Moran CA, Suster S, Koss MN. Endobronchial lipomas: a clinicopathologic study of four cases. Mod Pathol. 1994;7:212-214.

223. Muraoka M, Oka T, Akamine S, et al. Endobronchial lipoma: review of 64 cases reported in Japan. Chest. 2003;123:293-296.

224. Gaerte SC, Meyer CA, Winer-Muram HT, Tarver RD, Conces DJ Jr. Fat-containing lesions of the chest. Radiographics. 2002;22(suppl):S61-S78.

225. Solli P Rossi G, Carbagnani P et al. Pulmonary abnormalities in Cowden's disease. J Cardiovasc Surg. 1998;40:753-755.

226. Irani F, Kumar B, Reddy P et al. An endobronchial lipoma mimicking asthma and malignancy. Prim Care Respir J. 2010;19(3):281-283.

227. Sekine I, Kodama T, Yokose T, et al. Rare pulmonary tumors—a review of 32 cases. Oncology. 1998;55:431-434.

228. Matsuba K, Saito T, Ando K, Shirakusa T. Atypical lipoma of the lung. Thorax. 1991;46:685.

229. Bridge JA, Roberts CA, Degenhardt J, et al. Low-level chromosome 12 amplification in a primary lipoma of the lung: evidence for a pathogenetic relationship with common adipose tissue tumors. Arch Pathol Lab Med. 1998;122:187-190.

230. Hirata J, Reshad K, Itoi K, Muro K, Akiyama J. Lipomas of the peripheral lung—a case report and review of the literature. Thorac Cardiovasc Surg. 1989;37:385-387.

231. Erkilic S, Kocer NE, Tuncozgur B. Peripheral intrapulmonary lipoma: a case report. Acta Chir Belg. 2007;107:700-702.

232. Shimoyama T, Kimura B. Peripheral intrapulmonary lipoma: report of a case. Jpn J Thorac Surg. 2009;62:1186-1189.

233. Coffin CM. Lipoblastoma: an embryonal tumor of soft tissue related to organogenesis. Semin Diagn Pathol. 1994;11:98-103.

234. Kanu A, Oermann CM, Malicki D, Wagner M, Langston C. Pulmonary lipoblastoma in an 18-month-old child: a unique tumor in children. Pediatr Puimonol. 2002;34:150-154.

235. Mathew J, Sen S, Chandi SM, et al. Pulmonary lipoblastoma: a case report. Pediatr Surg Int. 2001;17:543-544.

236. Achir A, Ouadnouni Y, Smahi M, et al. Primary pulmonary liposarcoma—a case report. Thorac CardiovascSurg. 2009;57:119-120.

237. Loddenkempter C, Perez-Canto A, Leschber G, Stein H. Primary dedifferentiated liposarcoma of the lung. Histopathology. 2005;46:710-712.

238. Kitizawa R, Kitazawa S, Nishimura Y, Kondo T, Obayashi C. Lung carcinosarcoma with liposarcoma element: autopsy case. Pathol Int. 2006;56:449-452.

239. Hicks J, Dilley A, Patel D, et al. Lipoblastoma and lipoblastomatosis in infancy and childhood: histopathologic, ultrastructural, and cytogenetic features. Utrastruct Pathol. 2001;25:321-333.

240. Nicolas M, Moran CA, Suster S. Pulmonary metastasis from liposarcoma: a clinicopathologic and immunohistochemical study of 24 cases. Am J Clin Pathol. 2005;123:265-275.

241. Meis-Kindblom JM, Sjogren H, Kindblom LG, et al. Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Arch. 2001;439:141-151.

242. Tallini G, Vanni R, Manfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest. 2000;80:359-369.

243. Johansson M, Dietrich C, Mandahl N, et al. Recombinations of chromosomal bands 6p21 and 14q24 characterize pulmonary hamartomas. Br J Cancer. 1993;67:1236-1241.

244. Pea M, Bonetti F, Zamboni G, et al. Clear cell tumor and angiomyolipoma. Am J Surg Pathol. 1991;15:199-202.

245. Bacchi CE, Bonetti F, Pea M, Martignoni G, Gown AM. HMB-45: a review. Appl Immunohistochem Mol Morphol. 1996;4:73-85.

246. Bonetti F, Pea M, Martignoni G, et al. Clear cell ("sugar") tumor of the lung is a lesion strictly related to angiomyolipoma— The concept of a family of lesions characterized by the presence of the perivascular epithelioid cell (PEC). Pathology. 1994;26:230-236.

247. Hornick JL, Fletcher CDM. PEComa: what do we know so far? Histopathology. 2006;48: 75-82.

248. Folpe AL, McKenney JK, Li Z, Smith SJ, Weiss SW. Clear cell myomelanocytic tumor of the thigh: report of a unique case. Am J Surg Pathol. 2002;26:809-812.

249. Garcia TR, Mestre-de-Juan MJ. Angiomyolipoma of the liver and lung: a case explained by the presence of perivascular epithelioid cells. Pathol Res Pract. 2002;198:363-367.

250. Wu K, Tazelaar HD. Pulmonary angiomyolipoma and multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis. Hum Pathol. 1999;30:1266-1268.

251. Papla B, Malinowski E. Angiomyolipoma of the lung. Pol J Pathol. 1999;50:47-50.

252. Ito M, Sugamura Y, Ikari H, Sekine I. Angiomyolipoma of the lung. Arch Pathol Lab Med. 1998;122:1023-1025.

253. Guinee DG Jr, Thornberry DS, Azumi N, et al. Unique pulmonary presentation of an angio- myolipoma: analysis of clinical, radiographic, and histopathologic features. Am J Surg Pathol. 1995;19:476-480.

254. Marcheix B, Brouchet L, Lamarche Y, et al. Pulmonary angiomyolipoma. Ann Thorac Surg. 2006;82:1504-1506.

255. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangi- oleiomyomatosis. Chest. 1999;115:1041-1052.

256. Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151:527-533.

257. Matsumoto S, Nishioka T, Akiyama T. Renal angiomyolipoma associated with micronodular pneumocyte hyperplasia of the lung with tuberous sclerosis. Int J Urol. 2001;8:242-244.

258. Takahashi N, Kitihara R, Hishimoto Y, et al. Malignant transformation of renal angiomyolipoma. Int J Urol. 2003;10:271-273.

259. Adachi Y, Horie Y, Kitamura Y, et al. CD1a expression in PEComas. Pathol Int. 2008;58:169-173.

260. Gee WF, Chikos PM, Greaves JP Ikemoto N, Tremann JA. Adrenal myelolipoma. Urology. 1975;5:562-566.

261. Singla AK, Kechejian G, Lopez MJ. Giant presacral myelolipoma. Am Surg. 2003;69:334-338.

262. Hunter SB, Schemankewitz EH, Patterson C, Varma VA. Extraadrenal myelolipoma: a report of two cases. Am J Clin Pathol. 1992;97:402-404.

263. Sabate CJ, Shahian DM. Pulmonary myelolipoma. Ann Thorac Surg. 2002;74:573-575.

264. Piccinini L, Barbolini G. A case of lung myelolipomatosis in a patient with bronchial carcinoid. Panminerva Med. 1999;41:175-178.

265. Ziolkowski P, Muszczynska-Bernhard B, Dziegiel P. Myelolipoma: the report of two cases in a pulmonary location. Pol J Pathol. 1996;47:141-142.

266. Sato K, Ueda Y, Katsuda S, Tsuchihara K. Myelolipoma of the lung: a case report and brief review. J Clin Pathol. 2007;60:728-730.

267. Quigley JC, Hart WR. Adenomatoid tumors of the uterus. Am J Clin Pathol. 1981;76:627-635.

268. Srigley JR, Hartwick RW. Tumors and cysts of the paratesticular region. Pathol Annu. 1990;25:51-108.

269. Kaplan MA, Tazelaar HD, Hayashi T, Schroer KR, Travis WD. Adenomatoid tumors of the pleura. Am J Surg Pathol. 1996;20:1219-1223.

270. Handra-Luca A, Couvelard A, Abd-Alsamad I, et al. Adenomatoid tumor of the pleura: case report. Ann Pathol. 2000;20:369-372.

271. Umezu H, Kuwata K, Ebe Y, et al. Microcystic variant of localized malignant mesothelioma accompanying an adenomatoid tumor-like lesion. Pathol Int. 2002;52:416-422.

272. Minato H, Nojima T, Kurose N, Kinoshita E. Adenomatoid tumor of the pleura. Pathol Int. 2009;59:567-571.

273. Pinkard NB, Wilson RW, Lawless N, et al. Calcifying fibrous pseudotumor of the pleura: a report of three cases of a newly described entity involving the pleura. Am J Clin Pathol. 1996;105:189-194.

274. Murray JG, Pinkard NB. Calcifying fibrous pseudotumor of the pleura: radiologic features in three cases. J Comput Assist Tomogr. 1996;20:763-765.

275. Hainaut P Lesage V, Weynand B, Coche E, Noirhomme P Calcifying fibrous pseudotumor (CFPT): a patient presenting with multiple pleural lesions. Acta Clin Belg. 1999;54:162-164.

276. Cavazza A, Gelli MC, Agostini L, et al. Calcified pseudotumor of the pleura: description of a case. Pathologica. 2002;94:201-205.

277. Rosenthal NS, Abdul-Karim FW. Childhood fibrous tumor with psammoma bodies: clinicopathologic features in two cases. Arch Pathol Lab Med. 1988;112:798-800.

278. Suh JH, Shin OR, Kim YH. Multiple calcifying fibrous pseudotumor of the pleura. J Thorac Oncol. 2008;3:1356-1358.

279. Shibata K, Yuki D, Sakata K. Multiple calcifying fibrous pseudotumors disseminated in the pleura. Ann Thorac Surg. 2008;85:e3-e5.

280. Soyer T, Ciftci AO, Gucer S, Orhan D, Senocak ME. Calcifying fibrous pseudotumor of lung: a previously-unreported entity. J Pediatr Surg. 2004;39:1729-1730.

281. Maeda T, Hirose T, Furuya K, Kameoka K. Calcifying fibrous pseudotumor: an ultrastructural study. Ultrastruct Pathol. 1999;23:189-192.

282. Hill KA, Gonzalez-Crussi F, Chou PM. Calcifying fibrous pseudotumor versus inflammatory myofibroblastic tumor: a histological and immunohistochemical comparison. Mod Pathol. 2001;14:784-790.

283. Nascimento AF, Ruiz R, Hornick JL, Fletcher CDM. Calcifying fibrous "pseudotumor": clinico- pathologic study of 15 cases and analysis of its relationship to inflammatory myofibroblastic tumor. Int J Surg Pathol. 2002;10:189-196.

284. Gibbs AR. Smooth muscle tumors of the pleura. Histopathology. 1995;27:295-296.

285. Mochizuki H, Okada T, Yoshizawa H, Suzuki E, Gejyo F. A case of primary pleural leiomyoma. J Jpn Resp Soc. 2004;42:625-628.

286. Brunn H. Two interesting benign lung tumors of contradictory histopathology. J Thorac Cardiovasc Surg. 1939;9:119-131.

287. Umiker WO, Iverson L. Postinflammatory "tumors" of the lung: report of four cases simulating xanthoma, fibroma, or plasma cell tumor. J Thorac Cardiovasc Surg. 1954;28:55-63.

288. Bahadori M, Liebow AA. Plasma cell granulomas of the lung. Cancer. 1973;31:191-208.

289. Spencer H. The pulmonary plasma cell/histiocytoma complex. Histopathology. 1984;8:903-916.

290. Berardi RS, Lee SS, Chen HP, et al. Inflammatory pseudotumors of the lung. Surg Gynecol Obstet. 1983;156:89-96.

291. Souid AK, Ziemba MC, Dubansky AS, et al. Inflammatory myofibroblastic tumor in children. Cancer. 1993;72:2042-2048.

292. Wick MR, Ritter JH, Nappi O. Inflammatory sarcomatoid carcinoma of the lung: report of three cases with comparison with inflammatory pseudotumors in adult patients. Hum Pathol. 1995;26:1014-1021.

293. Su LD, Atayde-Perez A, Sheldon S, Fletcher JA, Weiss SW. Inflammatory myofibroblastic tumor: cytogenetic evidence supporting a clonal origin. Mod Pathol. 1998;11:364-368.

294. Snyder CS, Dell'Aquila M, Haghighi P, et al. Clonal changes in inflammatory pseudotumor of the lung: a case report. Cancer. 1995;76:1545-1549.

295. Yamamoto H, Oda Y, Saito T, et al. p53 mutation and MDM2 amplification in inflammatory myofibroblastic tumors. Histopathology. 2003;42:431-439.

296. Pettinato G, Manivel JC, DeRosa N, et al. Inflammatory myofibroblastic tumor (plasma cell granuloma): a clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations. Am J Clin Pathol. 1990;94:538-546.

297. Meis JM, Enzinger FM. Inflammatory fibrosarcoma of the mesentery and retroperitoneum: a tumor closely simulating inflammatory pseudotumor. Am J Surg Pathol. 1991;15:1146-1156.

298. Coffin CM, Dehner LP, Meis-Kindblom JM. Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations. Semin Diagn Pathol. 1998;15:102-110.

299. Lioulias A, Misthos P, Neofotistos E, Legaki S. Primary myofibrosarcoma of the lung: a rare case with challenging diagnosis. J BUON. 2009;14:143-145.

300. Takeda S, Onishi Y, Kawamura T, Maeda H. Clinical spectrum of pulmonary inflammatory myofibroblastic tumor. Interact Cardiovasc Thorac Surg. 2008;7:629-633.

301. Matsubara O, Tan-Liu NS, Kenney RM, et al. Inflammatory pseudotumors of the lung: progression from organizing pneumonia to fibrous histiocytoma or to plasma cell granuloma in 32 cases. Hum Pathol. 1988;19:807-814.

302. Cessna MH, Zhou H, Sanger WG, et al. Expression of ALK1and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol. 2002;15:931-938.

303. Coffin CM, Hornick JL, Fletcher CDM. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007;31:509-520.

304. Yamamoto H, Yamaguchi H, Aishima S, et al. Inflammatory myofibroblastic tumor versus IgG4- related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study. Am J Surg Pathol. 2009;33:1330-1340.

305. Antic T, Kapur U, Vigneswaran WT, Oshima K. Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance. Arch Pathol Lab Med. 2005;129:1334-1337.

306. Hussong JW, Brown M, Perkins SL, Dehner LP, Coffin CM. Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors. Mod Pathol. 1999;12:279-286.

307. Messineo A, Mognato G, D'Amore ES, et al. Inflammatory pseudotumors of the lung in children: conservative or aggressive approach? Med Pediatr Oncol. 1998;31:100-104.

308. Liebow AA, Hubbell DS. Sclerosing hemangioma (histiocytoma, xanthoma) of the lung. Cancer. 1956;9:53-75.

309. Gross RE, Wolbach SB. Sclerosing hemangiomas: their relationship to dermatofibroma, histiocytoma, xanthoma, and to certain pigmented lesions of the skin. Am J Pathol. 1943;19:533-546.

310. Katzenstein AL, Weise D, Fuilling K, Battifora H. So-called sclerosing hemangioma of the lung: evidence for mesothelial origin. Am J Surg Pathol. 1983;7:3-14.

311. Kennedy A. "Sclerosing hemangioma" of the lung: an alternative view of its development. J Clin Pathol. 1973;26:792-799.

312. Hill GS, Eggleston JC. Electron microscopic study of so-called pulmonary "sclerosing hemangioma": report of a case suggesting an epithelial origin. Cancer. 1972;30:1092-1106.

313. Kay S, Still WJ, Borochovitz D. Sclerosing hemangioma of the lung: an endothelial or epithelial neoplasm? Hum Pathol. 1977;8:468-474.

314. Spencer H, Nambu S. Sclerosing hemangiomas of the lung. Histopathology. 1986;10:477-487.

315. Keylock JB, Galvin JR, Franks TJ. Sclerosing hemangioma of the lung. Arch Pathol Lab Med. 2009;133:820-825.

316. Kalhor N, Staerkel GA, Moran CA. So-called sclerosing hemangioma of lung: current concepts. Ann Diagn Pathol. 2010;14:60-67.

317. Shimosato Y Lung tumors of uncertain histogenesis. Semin Diagn Pathol. 1995;12:185-192.

318. Batinica S, Gunek G, Raos M, Jelasic D, Bogovic M. Sclerosing hemangioma of the lung in a 4-year-old child. Eur J Pediatr Surg. 2002;12:192-194.

319. Devouassoux-Shisheboran M, Hayashi T, Linnoila R, Koss MN, Travis WD. A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium. Am J Surg Pathol. 2000;24:906-916.

320. Kuo KT, Hsu WH, Wu YC, Huang MH, Li WY Sclerosing hemangioma of the lung: an analysis of 44 cases. J Chin Med Assoc. 2003;66:33-38.

321. Miyagawa-Hayashino A, Tazelaar HD, Langel DJ, Colby TV. Pulmonary sclerosing hemangioma with lymph node metastases: report of 4 cases. Arch Pathol Lab Med. 2003;127:321-325.

322. Hayashi A, Takamori S, Mitsuoka M, et al. Unilateral progressive multiple sclerosing hemangioma in a young female successfully treated by pneumonectomy: report of a case. Int Surg. 2002;87:69-72.

323. Iyoda A, Baba M, Saitoh H, et al. Imprint cytologic features of pulmonary sclerosing hemangioma: comparison with well-differentiated papillary adenocarcinoma. Cancer. 2002;96:146-149.

324. Nam JE, Ryu YH, Cho SH, et al. Air-trapping zone surrounding sclerosing hemangioma of the lung. J Comput Assist Tomogr. 2002;26:358-361.

325. Yano M, Yamakawa Y, Kiriyama M, Hara M, Murase T. Sclerosing hemangioma with metastases to multiple nodal stations. Ann Thorac Surg. 2002;73:981-983.

326. Gal AA, Nassar VH, Miller JI. Cytopathologic diagnosis of pulmonary sclerosing hemangioma. Diagn Cytopathol. 2002;26:163-166.

327. Ng WK, Fu KH, Wang E, Tang V. Sclerosing hemangioma of lung: a close cytologic mimicker of pulmonary adenocarcinoma. Diagn Cytopathol. 2001;25:316-320.

328. Illei PB, Rosai J, Klimstra DS. Expression of thyroid transcription factor-1 and other markers in sclerosing hemangioma of the lung. Arch Pathol Lab Med. 2001;125:1335-1339.

329. Chan AC, Chan JKC. Pulmonary sclerosing hemangioma consistently expresses thyroid transcription factor-1 (TTF-1): a new clue to its histogenesis. Am J Surg Pathol. 2000;24:1531-1536.

330. Wani Y, Notohara K, Tsukayama C, Okumura N. Sclerosing hemangioma with florid endobronchial and endobronchiolar growth. Virchows Arch. 2007;450:221-223.

331. Guibaud L, Pracros JP, Rode V, et al. Sclerosing hemangioma of the lung: radiological findings and pathological diagnosis. Pediatr Radiol. 1995;25(suppl 1):S207-S208.

332. Komatsu T, Fukuse T, Wada H, Sakurai T. Pulmonary sclerosing hemangioma with pulmonary metastasis. Thorac Cardiovasc Surg. 2006;54:348-349.

333. Katzenstein AL, Gmelich J, Carrington C. Sclerosing hemangioma of the lung: a clinicopathologic study of 51 cases. Am J Surg Pathol. 1980;4:343-356.

334. Moran CA, Zeren H, Koss MN. Sclerosing hemangioma of the lung: granulomatous variant. Arch Pathol Lab Med. 1994;118:1028-1030.

335. Wojcik E, Sneige N, Lawrence D, Ordonez NG. Fine needle aspiration cytology of sclerosing hemangioma of the lung: case report with immunohistochemical study. Diagn Cytopathol. 1993;9:304-309.

336. Gottschalk-Sabag S, Hadas-Halpern I, Glick T. Sclerosing hemangioma of lung mimicking carcinoma, diagnosed by fine needle aspiration (FNA) cytology. Cytopathology. 1995;6:115-120.

337. Krishnamurthy SC, Naresh KN, Soni M, Bhasin SD. Sclerosing hemangioma of the lung: a potential source of error in fine needle aspiration cytology. Acta Cytol. 1995;38:111-112.

338. Islam S, Roustan-Delatour NL, Salahdeen SR, et al. Cytologic features of benign solitary pulmonary nodules with radiologic correlation and diagnostic pitfalls: a report of six cases. Acta Cytol. 2009;53:201-210.

339. Yousem SA, Wick MR, Singh G, et al. So-called sclerosing hemangiomas of lung: an immunohistochemical study supporting a respiratory epithelial origin. Am J Surg Pathol. 1988;12:582-590.

340. Satoh Y, Tsuchiya E, Weng SY, et al. Pulmonary sclerosing hemangioma of the lung: type II pneumocytoma by immunohistochemistry and immunoelectron microscopic studies. Cancer. 1989;64:1310-1317.

341. Alvarez-Fernandez B, Carretero-Albinana L, Menarquez-Palanca J. Sclerosing hemangioma of the lung: an immunohistochemical study of intermediate filaments and endothelial markers. Arch Pathol Lab Med. 1989;113:121-124.

342. Fukayama M, Mikoike M. So-called sclerosing hemangioma of the lung: an immunohistochemical, histochemical, and ultrastructural study. Acta Pathol Jpn. 1988;38:627-642.

343. Leong ASY, Chan KW, Seneviratne HS. A morphological and immunohistochemical study of 25 cases of so-called sclerosing hemangioma of the lung. Histopathology. 1995;27:121-128.

344. Nagata N, Dairaku M, Sueishi K, Tanaka K. Sclerosing hemangioma of the lung: an epithelial tumor composed of immunohistochemically heterogeneous cells. Am J Clin Pathol. 1987;88: 552-559.

345. Xu HM, Li WH, Hou N, et al. Neuroendocrine differentiation in 32 cases of so-called sclerosing hemangioma of the lung, identified by immunohistochemistry and ultrastructural study. Am J Surg Pathol. 1997;21:1013-1022.

346. Wu CT, Chang YL, Lee YC. Expression of the estrogen receptor beta in 37 surgically treated pulmonary sclerosing hemangiomas in comparison with non-small-cell lung carcinomas. Hum Pathol. 2005;36:1108-1112.

347. Wei S, Tian J, Song X, Chen Y. Recurrence of pulmonary sclerosing hemangioma. Thorac Cardiovasc Surg. 2008;56:120-122.

348. Tanaka I, Inoue M, Matsui Y, et al. A case of pneumocytoma (so-called sclerosing hemangioma) with lymph node metastasis. Jpn J Clin Oncol. 1986;16:77-86.

349. Vaideeswar P. Sclerosing hemangioma with lymph node metastases. Indian J Pathol Microbiol. 2009;52:392-394.

350. Chien NC, Lin CW, Tzeng JE. Sclerosing hemangioma with lymph node metasatasis. Respirology. 2009;14:614-616.

351. Guillou L, DeLuze P, Zysset F, Costa J. Papillary variant of low-grade mucoepidermoid carcinoma— an unusual bronchial neoplasm: a light microscopic, ultrastructural, and immunohistochemical study. Am J Clin Pathol. 1994;101:269-274.

352. Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139-152.

353. Izumo A, Yamaguchi K, Eguchi T, et al. Mucinous cystic tumor of the pancreas. Oncol Rep. 2003;10:515-525.

354. Sambrook-Gowar FJ. An unusual mucous cyst of the lung. Thorax. 1978;33:796-799.

355. Butnor KJ, Sporn TA, Dodd LG. Fine needle aspiration cytology of mucinous cystadenocarci- noma of the lung: report of a case with radiographic and histologic correlation. Acta Cytol. 2001;45:779-783.

356. Monaghan H, Salter DM, Ferguson T. Pulmonary mucinous cystic tumor of borderline malignancy: a rare variant of adenocarcinoma. J Clin Pathol. 2002;55:156.

357. Divisi D, Battaglia C, Giusti L, et al. Mucinous cystadenoma of the lung. Acta Biomed Ateneo Parmense. 1997;68:115-118.

358. Papla B, Malinowski E, Harazda M. Pulmonary mucinous cystadenoma of borderline malignancy: a report of two cases. Pol J Pathol. 1996;47:87-90.

359. Roux FJ, Lantuejoul S, Brambilla E, Brambilla C. Mucinous cystadenoma of the lung. Cancer. 1995;76:1540-1544.

360. Pelletier B, Dubigeon P, Despins P, Dehajartre AY. Cystic mucinous pulmonary tumor of borderline malignancy: report of a case. Ann Pathol. 1993;13:405-408.

361. Davison AM, Lowe JW, DaCosta P. Adenocarcinoma arising in a mucinous cystadenoma of the lung. Thorax. 1992;47:129-130.

362. Traub B. Mucinous cystadenoma of the lung. Arch Pathol Lab Med. 1991;115:740-741.

363. Kragel PJ, Devaney KO, Meth BM, et al. Mucinous cystadenoma of the lung: a report of two cases with immunohistochemical and ultrastructural analysis. Arch Pathol Lab Med. 1990;114:1053-1056.

364. Matsuo T, Yusuke-Kimura N, Takamori S, Shirouzu K. Recurrent pulmonary mucinous cystadenoma. Eur J Cardiothorac Surg. 2005;28:176-177.

365. Gao ZH, Urbanski SJ. The spectrum of pulmonary mucinous cystic neoplasia: a clinicopathologic & immunohistochemical study of ten cases and review of literature. Am J Clin Pathol. 2005;124:62-70.

366. Klein J, Zhuang Z, Lubensky I, et al. Multifocal microcysts and papillary cystadenoma of the lung in von Hippel-Lindau disease. Am J Surg Pathol. 2007;31:1292-1296.

367. Kleinert R, Popper H. Giant fibroma of the lung: a morphologic study. Virchows Arch A. 1987;410:363-367.

368. Sauk JJ, Pliego M, Anderson WR. Primary pulmonary fibroma. Minn Med. 1972;55:220-223.

369. Klemperer P, Rabin CB. Primary neoplasms of the pleura. Arch Pathol. 1931;11:385-412.

370. Briselli MF, Mark EJ. Solitary fibrous tumors of the pleura and benign extrapleural tumors of mesothelial origin. In: Antman K, Aisner J, eds. Asbestos-Related Malignancy. Philadelphia: Grune & Stratton; 1986:165-178.

371. Dalton W, Zollike A, McCaughey WT, Jacques J, Kannerstein M. Localized primary tumors of the pleura. Cancer. 1979;44:1465-1475.

372. Vallat-Decouvelaere AV, Dry SM, Fletcher CDM. Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intrathoracic tumors. Am J Surg Pathol. 1998;22:1501-1511.

373. Magdeleinat P, Alifano M, Petino A, et al. Solitary fibrous tumors of the pleura: clinical characteristics, surgical treatment, and outcome. Eur JCardiothoracSurg. 2002;21:1087-1093.

374. Cardillo G, Facciolo F, Cavazzana AO, et al. Localized (solitary) fibrous tumors of the pleura: an analysis of 55 patients. Ann Thorac Surg. 2000;70:1808-1812.

375. Duster P Mayer E, Kramm T, et al. Solitary fibrous pleural tumors—rare tumors with unpredictable clinical behavior. Pneumologie. 2000;54:16-19.

376. Meyer M, Krause U. Solitary fibrous tumors of the pleura. Chirurgie. 1999;70:949-952.

377. Khan JH, Rahman SB, Clary-Macy C, et al. Giant solitary fibrous tumor of the pleura. Ann Thorac Surg. 1998;65:1461-1464.

378. Briselli MF, Mark EJ, Dickersin GR. Solitary fibrous tumors of the pleura: eight new cases and review of 360 cases in the literature. Cancer. 1981;47:2678-2689.

379. Hanau CA, Miettinen M. Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol. 1995;26:440-449.

380. Moran CA, Suster S, Koss MN. The spectrum of histologic growth patterns in benign and malignant fibrous tumors of the pleura. Semin Diagn Pathol. 1992;9:169-180.

381. England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. Am J Surg Pathol. 1989;13:640-658.

382. Patsios D, Hwang DM, Chung TB. Intraparenchymal solitary fibrous tumor of the lung: an uncommon cause of a pulmonary nodule. J Thorac Imaging. 2006;21:50-53.

383. Sakurai H, Tanaka W, Kaji M, Yamazaki K, Suemasu K. Intrapulmonary localized fibrous tumor of the lung: a very unusual presentation. Ann Thorac Surg. 2008;86:1360-1362.

384. Cardinale L, Ardissone F, Cataldi A, et al. Solitary fibrous tumor of the lung: three rare cases of intraparenchymal nodules. Acta Radiol. 2009;50:379-382.

385. Fujiu K, Miyamoto H, Sakuma H, Mori M. Solitary fibrous tumors of the pleura presenting satellite tumors. Gen Thorac Cardiovasc Surg. 2009;57:382-384.

386. Ali SZ, Hoon V, Hoda S, Heelan R, Zakowski MF. Solitary fibrous tumor: a cytologic-histologic study with clinical, radiologic, and immunohistochemical correlations. Cancer. 1997;81:116-121.

387. Harrison-Phipps KM, Nichols FC, Schleck CD, et al. Solitary fibrous tumors of the pleura: results of surgical treatment and long-term prognosis. J Thorac Cardiovasc Surg. 2009;138:19-25.

388. Weynand B, Collard P, Galant C. Cytopathological features of solitary fibrous tumor of the pleura: a study of 5 cases. Diagn Cytopathol. 1998;18:118-124.

389. Caruso RA, LaSpada F, Gaeta M, Minutoli I, Inferrera C. Report of an intrapulmonary solitary fibrous tumor: fine needle aspiration cytologic findings, clinicopathological, and immunohistochemical features. Diagn Cytopathol. 1996;14:64-67.

390. Khalifa MA, Montgomery EA, Azumi N, et al. Solitary fibrous tumors: a series of lesions, some in unusual sites. South Med J. 1997;90:793-799.

391. Van de Rijn M, Lombard CM, Rouse RV Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung. Am J Surg Pathol. 1994;18:814-820.

392. Suster S, Fisher C, Moran CA. Expression of bcl-2oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol. 1998;22:863-872.

393. Flint A, Weiss SW. CD34 and keratin expression distinguishes solitary fibrous tumor (fibrous mesothelioma) of pleura from desmoplastic mesothelioma. Hum Pathol. 1995;26:428-431.

394. Ledet SC, Brown RW, Cagle PT p53 immunostaining in the differentiation of inflammatory pseudotumor from sarcoma involving the lung. Mod Pathol. 1995;8:282-286.

395. Krismann M, Adams H, Jaworska M, Muller KM, Johnen G. Patterns of chromosomal imbalances in benign solitary fibrous tumors of the pleura. Virchows Arch A. 2000;70:1808-1812.

396. Dal Cin P Pauwels P Van den Berghe H. Solitary fibrous tumor of the pleura with t(4;15) (q13;q26). Histopathology. 1999;35:94-95.

397. Carbone M, Rizzo P Powers A, et al. Molecular analyses, morphology, and immunohistochemisty together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications. Anticancer Res. 2002;22:3443-3448.

398. Knosel T, Hertsch S, Alendorf-Hofmann A, et al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer. 2010;46:1170-1176.

399. Sumathi VP, McCluggage WG. CD10 is useful in demonstrating endometrial stroma at ectopic sites and in confirming a diagnosis of endometriosis. J Clin Pathol. 2002;55:391-392.

400. Takagi M, Kuwano K, Watanabe K, Akiba T A case of recurrence and rapid growth of pleural solitary fibrous tumor 8 years after initial surgery. Ann Thorac Cardiovasc Surg. 2009;15:178-181.

401. Miyoshi N, Takami K, Okami J, et al. Extrapleural pneumonectomy for relapsed solitary fibrous tumors of the pleura with pleural dissemination. Jpn J Thorac Surg. 2007;60:800-805.

402. Liu CC, Wang HW, Li FY, et al. Solitary fibrous tumors of the pleura: clinicopathological characteristics, immunohistochemical profiles, and surgical outcomes with long-term followup. Thorac Cadiovasc Surg. 2008;56:291-297.

403. Anthony T, Rodriguez-Bigas MA, Weber TK, Petrelli NJ. Desmoid tumors. J Am Coll Surg. 1996;182:369-377.

404. Dashiell TG, Payne WS, Hepper NG, Soule EH. Desmoid tumors of the chest wall. Chest. 1978;74:157-162.

405. Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, Petrelli NJ. Desmoid tumors in patients with familial adenomatous polyposis. Cancer. 1994;74:1270-1274.

406. Andino L, Cagle PT, Maurer B, et al. Pleuropulmonary desmoid tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of beta-catenin and cyclin-D1 expression. Arch Pathol Lab Med. 2006;130:1503-1509.

407. Varghese TK Jr, Gupta R, Yeldandi AV, Sundaresan SR. Desmoid tumor of the chest wall with pleural involvement. Ann Thorac Surg. 2003;76:937-939.

408. Peled N, Babyn PS, Manson D, de Nanassy J. Aggressive fibromatosis simulating congenital lung malformation. Can Assoc Radiol J. 1993;44:221-223.

409. Takeshima Y, Nakayori F, Nakano T, et al. Extra-abdominal desmoid tumor presenting as an intrathoracic tumor: case report and literature review. Pathol Int 2001;51:824-828.

410. Wilson RW, Gallateau-Salle F, Moran CA. Desmoid tumors of the pleura: a clinicopathologic mimic of localized fibrous tumor. Mod Pathol. 1999;12:9-14.

411. Montgomery EA, Meis JM. Nodular fasciitis: its morphologic spectrum and immunohistochemical profile. Am J Surg Pathol. 1991;15:942-948.

412. Owens CL, Sharma R, Ali SZ. Deep fibromatosis (desmoid tumor): cytopathologic characteristics, clinicoradiologic features, and immunohistochemical findings on fine-needle aspiration. Cancer. 2007;111:166-172.

413. Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;29:653-659.

414. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18:68-74.

415. Carlson JW, Fletcher CDM. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle-cell lesions: analysis of a series and review of the literature. Histopathology. 2007;51:509-514.

416. De Bree E, Keus R, Melissas J, Tsiftsis D, van Coevorden F. Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther. 2009;9:525-535.

417. Abbas AE, Deschamps C, Cassivi SD, et al. Chest-wall desmoid tumors: results of surgical intervention. Ann Thorac Surg. 2004;78:1219-1223.

418. Liebow AA, Castleman B. Benign "clear cell tumors" of the lung. Am J Pathol. 1963;43:13-14.

419. Liebow AA, Castleman B. Benign clear cell ("sugar") tumors of the lung. Yale J Biol Med. 1971;43:213-222.

420. Hoch WS, Patchefsky AS, Takeda M, Gordon G. Benign clear-cell tumor of the lung: an ultrastructural study. Cancer. 1974;33:1328-1336.

421. Ozdemir IA, Zaman NU, Rullis I, Webb WR. Benign clear cell tumor of lung. J Thorac Cardiovasc Surg. 1974;68:131-133.

422. Kung M, Landa JF, Lubin J. Benign clear cell tumor ("sugar tumor") of the trachea. Cancer. 1984;54:517-519.

423. Hashimoto T, Oka K, Hakozaki H, et al. Benign clear cell tumor of the lung. Ultrastruct Pathol. 2001;25:479-483.

424. Slodkowska J, Suilkowska-Rowinska A, Dorosz P, Radomski P, Wasiutynski A. Benign clear cell tumor of the lung ("sugar tumor"): morphologic, immunohistochemical, and ultrastructural evaluation. Pneumonol Alergol Pol. 2000;68:60-64.

425. Gaffey MJ, Mills SE, Ritter JH. Clear cell tumors of the lower respiratory tract. Semin Diagn Pathol. 1997;14:222-232.

426. Jeanfaivre T, Savary L, Richard C. Benign clear cell tumor ("sugar tumor"): an unusual cause of intrapulmonary coin lesion. Rev Mal Respir. 1997;14:223-224.

427. Andrion A, Mazzucco G, Gugliotta P, Monga G. Benign clear-cell ("sugar") tumor of the lung: a light microscopic, histochemical, and ultrastructural study with a review of the literature. Cancer. 1985;56:2657-2663.

428. Sale GE, Kulander BG. Benign clear-cell tumor of lung with necrosis. Cancer 1976;37: 2355-2358.

429. Lantuejoul S, Isaac S, Pinel N, et al. Clear cell tumor of the lung: an immunohistochemical and ultrastructural study supporting a pericytic differentiation. Mod Pathol. 1997;10:1001-1008.

430. Flieder DB, Travis WD. Clear cell "sugar" tumor of the lung associated with lymphangioleio- myomatosis and multifocal micronodular pneumocyte hyperplasia in a patient with tuberous sclerosis. Am J Surg Pathol. 1997;21:1242-1247.

431. Gal AA, Koss MN, Hochholzer L, Chejfec G. An immunohistochemical study of benign clear-cell ("sugar") tumor of the lung. Arch Pathol Lab Med. 1991;115:1034-1038.

432. Gaffey MJ, Mills SE, Askin FB, et al. Clear cell tumor of the lung: a clinicopathologic, immunohistochemical, and ultrastructural study of eight cases. Am J Surg Pathol. 1991;15:199-202.

433. Stolz AJ, Schutzner J, Lischke R, et al. Benign clear cell tumors of the lung—sugar tumors. Rozhl Chir. 2003;82:149-151.

434. Sale GE, Kulander BG. Benign clear-cell tumor (sugar tumor) of the lung with hepatic metastases ten years after resection of pulmonary primary tumor. Arch Pathol Lab Med. 1988;112:1177-1178.

435. Cavazza A, Sgarbi G, Ferrari G, Putrino I, Gardini G. Clear cell tumor of the lung: description of a case 1 mm in diameter ("micro-sugar tumor. Pathologica. 2001;93:556-560.

436. Justrabo E, Mergey E, Piard F, Michiels R, Viard H. Benign clear cell tumour of the lung. Sem Hop. 1982;58:673-677.

437. Urban T. Clinical and molecular epidemiology of lymphangioleiomyomatosis and pulmonary pathology in tuberous sclerosis. Rev Mal Respir. 2000;17:597-603.

438. Knowles MA, Hornigold N, Pitt E. Tuberous sclerosis complex (TSC) gene involvement in sporadic tumors. Biochem Soc Trans. 2003;31:597-602.

439. Panizo-Santos A, Sola I, DeAlava E, et al. Angiomyolipoma and PEComa are immunoreactive for Myo-D1 in a cell cytoplasmic staining pattern. Appl Immunohistochem Mol Morphol. 2003;11:156-160.

440. Nappi O, Mills SE, Swanson PE, Wick MR. Clear-cell tumors of unknown nature and origin: a systematic approach to diagnosis. Semin Diagn Pathol. 1997;14:164-174.

441. Rosai J, Limas C, Husband EM. Ectopic hamartomatous thymoma. A distinctive benign lesion of lower neck. Am J Surg Pathol. 1984;8:501-513.

442. Cohen JB, Troxell M, Kong CS, McDougall JR. Ectopic intrathyroidal thymoma: a case report and review. Thyroid. 2003;13:305-308.

443. Ben-Hami B, Caulet-Maugendre S, Valla J, et al. Primary pericardial thymoma: an unusual etiology of neoplastic pericarditis. Ann Pathol. 1996;16:445-448.

444. Marchevsky AM. Lung tumors derived from ectopic tissues. Semin Diagn Pathol. 1995;12:172-184.

445. Gong L, Li YH, He XL, et al. Primary intrapulmonary thymomas: case report and review of the literature. J Int Med Res. 2009;37:1252-1257.

446. Sajwani RA, Gowani SA, Khowaja AA, Khan A, Fatimi SH. Extensive primary malignant thymoma involving pericardium, pleura, diaphragm, and lungs—a case report. J Pak Med Assoc. 2008;58:287-288.

447. Velojic D, Marsenic B, Nikolic D, Bosnic M, Djordjevic A. Ectopic thymoma with myasthenic and cardiac symptomatology. Plucne Bolesti Tuberk. 1972;24:199-204.

448. Veynovich B, Masetti P Kaplan PD, et al. Primary pulmonary thymoma. Ann Thorac Surg. 1997;64:1471-1473.

449. Moran CA, Suster S, Fishback NF, Koss MN. Primary intrapulmonary thymoma: a clinicopathologic and immunohistochemical study of eight cases. Am J Surg Pathol. 1995;19:304-312.

450. James CL, Iyer PV, Leong ASY. Intrapulmonary thymoma. Histopathology. 1992;21:175-177.

451. Fukayama M, Maeda Y, Funata N, et al. Pulmonary and pleural thymoma: diagnostic application of lymphocyte markers to the thymoma of unusual site. Am J Clin Pathol. 1988;89:617-621.

452. Green WR, Pressoir R, Gumbs RV, et al. Intrapulmonary thymoma. Arch Pathol Lab Med. 1987;111:1074-1076.

453. Kung IT, Loke SL, So SY, et al. Intrapulmonary thymoma: report of two cases. Thorax. 1985;40:471-474.

454. Yeoh CB, Ford JM, Lattes R, Wylie RH. Intrapulmonary thymoma. J Thorac Cardiovasc Surg. 1966;51:131-136.

455. Shih DF, Wang JS, Tseng HH, Tiao WM. Primary pleural thymoma. Arch Pathol Lab Med. 1997;121:79-82.

456. Honma K, Shimada K. Metastasizing ectopic thymoma arising in the right thoracic cavity and mimicking diffuse pleural mesothelioma—an autopsy study of a case with review of literature. Wien KUn Wochenschr. 1986;98:14-20.

457. Fushimi H, Tanio Y, Kotoh K. Ectopic thymoma mimicking diffuse pleural mesothelioma: a case report. Hum Pathol. 1998;29:409-410.

458. Attanoos RL, Galateau-Salle F, Gibbs AR, et al. Primary thymic epithelial tumors of the pleura mimicking malignant mesothelioma. Histopathology. 2002;41:42-49.

459. Bernatz PE, Harrison EG, Clagett OT Thymoma: a clinicopathologic study. J Thorac Cardiovasc Surg. 1961;42:424-444.

460. Muller-Hermelink HK, Marino M, Palestro G. Pathology of thymic epithelial tumors. Cur Top Pathol 1986;75:207-268.

461. Dadmanesh F, Sekihara T, Rosai J. Histologic typing of thymoma according to the new World Health Organization classification. Chest Surg Clin N Am. 2001;11:407-420.

462. Suster S, Moran CA. Thymoma, atypical thymoma, and thymic carcinoma: a novel conceptual approach to the classification of thymic epithelial neoplasms. Am J Cln Pathol. 1999;111:826-833.

463. Kirchner T, Schalke B, Buchwald J, et al. Well-differentiated thymic carcinoma: an organotypical low- grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol. 1992;16:1153-1169.

464. Wakely PE Jr. Cytopathology-histopathology of the mediastinum: epithelial, lymphoproliferative, and germ cell neoplasms. Ann Diagn Pathol. 2002;6:30-43.

465. Chhieng DC, Rose D, Ludwig ME, Zukowski MF Cytology of thymomas: emphasis on morphology and correlation with histologic subtypes. Cancer. 2000;90:24-32.

466. Shabb NS, Fahl M, Shabb B, Haswani P Zaatari G. Fine needle aspiration of the mediastinum: a clinical, radiologic, cytologic, and histologic study of 42 cases. Diagn Cytopathol. 1998;19:428-436.

467. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 1978;9:495-515.

468. Mirza I, Kazimi SN, Ligi R, Burns J, Braza F Cytogenetic profile of a thymoma: a case report and review of the literature. Arch Pathol Lab Med. 2000;124:1714-1716.

469. Goh SG, Lau LC, Sivaswaren C, et al. Pseudodicentric (16;12)(q11;p11.2) in a type AB (mixed) thymoma. Cancer Genet Cytogenet. 2001;131:42-47.

470. Van den Berghe I, Debiec-Rychter M, Proot L, Hagemeijer A, Michielssen P Ring chromosome 6 may represent a cytogenetic subgroup in benign thymoma. Cancer Genet Cytogenet. 2002;137:75-77.

471. Kuo TT. Cytokeratin profiles of the thymus and thymomas: histogenetic correlations and proposal for a histological classification of thymomas. Histopathology. 2000;36:403-414.

472. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol. 2002;15:6-10.

473. DiComo CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8:494-501.

474. Myers PO, Kritikos N, Bongiovanni M, et al. Primary intrapulmonary thymoma: a systematic review. Eur J Surg Oncol. 2007;33:1137-1141.

475. Wick MR, Nappi O. Ectopic neural and neuroendocrine neoplasms. Semin Diagn Pathol. 2003;20:305-323.

476. Cesario A, Galetta D, Margaritora S, Granone P Unsuspected primary pulmonary meningioma. Eur J Cardiothorac Surg. 2002;21:553-555.

477. Prayson RA, Farver CF Primary pulmonary malignant meningioma. Am J Surg Pathol. 1999;23:722-726.

478. Moran CA, Hochholzer L, Rush W, Koss MN. Primary intrapulmonary meningiomas: a clinico- pathologic and immunohistochemical study of ten cases. Cancer 1996;78:2328-2333.

479. Gomez-Aracil V, Mayayo E, Alvira R, Arraiza A, Ramon y Cajal S. Fine needle aspiration cytology of primary pulmonary meningioma associated with minute meningothelial-like nodules. Report of a case with histologic, immunohistochemical, and ultrastructural studies. Acta Cytol. 2002;46:899-903.

480. Falleni M, Roz E, Dessy E, et al. Primary intrathoracic meningioma: histopathological, immunohistochemical, and ultrastructural study of two cases. Virchows Arch. 2001;A 439:196-200.

481. Spinelli M, Claren R, Colombi R, Sironi M. Primary pulmonary meningioma may arise from meningothelial-like nodules. Adv Clin Path. 2000;4:35-39.

482. DePerrot M, Kurt AM, Robert J, Spiliopoulos A. Primary pulmonary meningioma presenting as lung metastasis. Scand Cardiovasc J. 1999;33:121-123.

483. Ueno M, Fujiyama J, Yamazaki I, et al. Cytology of primary pulmonary meningioma: report of the first multiple case. Acta Cytol. 1998;42:1424-1430.

484. Kaleem Z, Fitzpatrick MM, Ritter JH. Primary pulmonary meningioma: report of a case and review of the literature. Arch Pathol Lab Med. 1997;121:631-636.

485. Lockett L, Chiang V, Scully N. Primary pulmonary meningioma: report of a case and review of the literature. Am J Surg Pathol. 1997;21:453-460.

486. Maiorana A, Ficarra G, Fano RA, Spagna G. Primary solitary meningioma of the lung. Pathologica. 1996;88:457-462.

487. Flynn SD, Yousem SA. Pulmonary meningiomas: report of two cases. Hum Pathol. 1991;22:469-474.

488. Kodama K, Doi O, Higashiyama M, et al. Primary and metastatic pulmonary meningioma. Cancer 1991;67:1412-1417.

489. Strimlan CV, Golembiewski RS, Celko DA, Fino GJ. Primary pulmonary meningioma. Surg Neurol. 1988;29:410-413.

490. Rowsell C, Sirbovan J, Rosenblum MK, Perez-Ordonez B. Primary chordoid meningioma of lung. Virchows Arch. 2005;446:333-337.

491. Incarbone M, Ceresoli GL, Di Tommaso L, et al. Primary pulmonary meningioma: report of a case and review of the literature. Lung Cancer. 2008;62:401-407.

492. Churg AM, Warnock ML. So-called "minute pulmonary chemodectoma:" a tumor not related to paragangliomas. Cancer. 1976;37:1759-1769.

493. Ionescu DN, Sasatomi E, Aldeeb D, et al. Pulmonary meningothelial-like nodules: a genotypic comparison with meningiomas. Am J Surg Pathol. 2004;28:207-214.

494. Suster S, Moran CA. Diffuse pulmonary meningotheliomatosis. Am J Surg Pathol. 2007;31:624-631.

495. Drlicek M, Grisold W, Lorber J, et al. Pulmonary meningioma: immunohistochemical and ultrastructural features. Am J Surg Pathol. 1991;15:455-459.

496. Omulecka A, Papierz W, Nawrocka-Kunecka A, Lewy-Trenda I. Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol. 2006;44:111-115.

497. Leaes CG, Meurer RT, Coutinho LB, et al. Immunohistochemical expression of aromatase and estrogen, androgen, & progesterone receptors in normal and neoplastic human meningeal cells. Neuropathology. 2010;30:44-49.

498. Shintaku M, Honda T, Sakai T Expression of podoplanin and calretinin in meningiomas: an immunohistochemical study. Brain Tumor Pathol. 2010;27:23-27.

499. Hu Y, Yang Q, McMahon LA, Wang HL, Xu H. Value of D2-40 in the differential diagnosis of pleural neoplasms, with emphasis on its positivity in solitary fibrous tumor Appl Immunohistochem Mol Morphol. 2010;18(5):411-413.

500. Jokinen CH, Dadras SS, Goldblum JR, et al. Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. Am J Clin Pathol. 2008;129:886-893.

501. Ishino S, Hashimoto N, Fushiki S, et al. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in-situ hybridization. Cancer. 1998;83:360-366.

502. Adlakha A, Rao K, Adlakha H, et al. Meningioma metastatic to the lung. Mayo Clin Proc. 1999;74:1129-1133.

503. Tandon S, Kant S, Singh AK, et al. Primary intrapulmonary teratoma presenting as pyothorax. Indian J Chest Dis Allied Sci. 1999;41:51-55.

504. Kayser K, Gabius HJ, Hagemeyer O. Malignant teratoma of the lung with lymph node metastasis of the ectodermal compartment: a case report. Ann Cell Pathol. 1993;5:31-37.

505. Eggerath A, Ammon J, Karstens JH, Rubben H, Morales MR. Extragonadal germ cell tumors— diagnostic and therapeutic aspects. Strahlentheraple. 1984;160:1-7.

506. Hartman GE, Shochat SJ. Primary pulmonary neoplasms of childhood: a review. Ann Thorac Surg. 1983;36:108-119.

507. Moran CA, Travis WD, Carter D, Koss MN. Metastatic mature teratoma in lung following testicular embryonal carcinoma and teratocarcinoma. Arch Pathol Lab Med. 1993;117:641-644.

508. Kakkar N, Vashishta RK, Banerjee AK, et al. Primary pulmonary malignant teratoma with yolk sac elements associated with hematologic neoplasia. Respiration. 1996;63:52-54.

509. Stair JM, Stevenson DR, Schaefer RF, Fullenwider JP, Campbell GS. Primary teratocarcinoma of the lung. J Surg Oncol. 1986;33:262-267.

510. Berghout A, Mallens WM, TeVelde J, Haak HL. Teratoma of the lung in a hemophilic patient. Acta Hematol. 1983;70:330-334.

511. Turna A, Ozgul A, Kahraman S, et al. Primary pulmonary teratoma: report of a case and the proposition of "bronchotrichosis" as a new term. Ann ThoracCardiovascSurg. 2009;15:247-249.

512. Saini ML, Krishnamurthy S, Kumar RV Intrapulmonary mature teratoma. Diagn Pathol. 2006;1:38.

513. Joseph MB, Colby TV, Swensen SJ, Mikus JP, Gaensler EA. Multiple cystic fibrohistiocytic tumors of the lung: report of two cases. Mayo Clin Proc. 1990;65:192-197.

514. Han JH. Uncommon tumors of the lung (Internet presentation). http://www.pathology.orkr/ studygroup/cardiopulmonary/lecture/lenote/hjh.htm.

515. Colome-Grimmer MI, Evans HL. Metastasizing cellular dermatofibroma: a report of two cases. Am J Surg Pathol. 1996;20:1361-1367.

Multiple Choice Questions

1. Which one of the following statements concerning the general attributes of benign pulmonary neoplasms is true?

A. They are two times more common than lung cancers.

B. They are exclusively endobronchial in location.

C. Brush cytology sampling is diagnostic in 90% of cases.

D. More of them are excised today than 30 years ago.

E. None of the above

ANSWER: D

2. Solitary tracheobronchial papillomas:

A. May coexist with squamous papillary lesions of the larynx

B. Are particularly similar histologically to condyloma acuminatum

C. Often show clumped keratohyaline granules in the cytoplasm

D. Rarely give rise to squamous carcinomas

E. All of the above

ANSWER: E

3. Multifocal tracheobronchial papillomatosis:

A. Is not known to coexist with upper airway papillomas

B. Is principally caused by human papillomavirus type 18

C. May demonstrate inverting growth into the bronchial submucosa

D. Can be ablated clinically by using oral antiviral medications

E. Has no potential for malignant change, unlike solitary papillomas

ANSWER: C

4. Mucous gland adenoma of the lungs:

A. Is synonymous semantically to bronchial adenoma of Liebow

B. Is the third most common type of intrapulmonary neoplasm

C. Occurs twice as often in men than in women

D. Is variably cystic and micropapillary histologically

E. Shows a paradoxically high mitotic index

ANSWER: D

5. Which one of the following lesions is most likely to be confused with pulmonary mucous gland adenoma microscopically?

A. Solitary tracheobronchial papilloma

B. Mucinous-type bronchioloalveolar carcinoma

C. Pleomorphic adenoma with mucinous metaplasia

D. Mucoepidermoid carcinoma

E. Epithelial-myoepithelial carcinoma

ANSWER: D

6. Pleomorphic adenomas of the lung:

A. Are more common in children than in adults

B. Are polyploid when located in central airways

C. Show more well-developed cartilage-like stroma than salivary gland pleomorphic adenomas

D. Demonstrate malignant transformation in 30% of cases

E. Can be immunoreactive for glial fibrillary acidic protein

ANSWER: E

7. Pulmonary oncocytomas:

A. Are more common than salivary gland tumors of the same type

B. Contain numerous phagolysosomes by electron microscopy

C. Have a neural-mesenchymal lineage

D. May be confused diagnostically with neuroendocrine neoplasms

E. Are usually aggressive with malignant behavior in 75% of cases

ANSWER: D

8. Benign schwannian tumors of the lung:

A. May have a biphasic histologic appearance

B. Can contain nuclei that line up in register with one another

C. Often contain intralesional mast cells

D. Are commonly partially or completely encapsulated

E. All of the above

ANSWER: E

9. All of the following are recognized subtypes of intrapulmonary neurilemmoma/schwannoma except:

A. Cellular

B. Plexiform

C. Glandular

D. Anaplastic

E. Pigmented

ANSWER: D

10. Intrapulmonary granular cell tumors:

A. Are seen exclusively in the peripheral lung parenchyma

B. May appear to be infiltrative and aggressive radiologically

C. Show smooth-muscle differentiation

D. Contain crystalline rhomboid cytoplasmic inclusions ultrastructurally

E. Paradoxically appear as spindle-cell lesions in fine-needle aspiration biopsies

ANSWER: B

11. Alveolar adenoma of the lung:

A. Shows progression to adenocarcinoma in 10% of cases

B. Is typically multifocal

C. Causes hemoptysis in 25% of cases

D. Is microcystic

E. All of the above

ANSWER: D

12. Papillary adenoma of the lung:

A. Has not been reported in children to date

B. Shows a surprising degree of mitotic activity

C. Is immunoreactive for chromogranin-A

D. Manifests cytoplasmic lamellar bodies ultrastructurally

E. Is devoid of intralesional inflammation

ANSWER: D

13. The histologic differential diagnosis of primary intrapulmonary leiomyoma includes:

A. Hamartoma of the lung

B. Sarcomatoid carcinoma

C. Neurofibroma

D. Neurilemmoma

E. All of the above

ANSWER: E

14. Which one of the following statements regarding intrapulmonary glomus tumors is true?

A. They are predominantly seen in adolescents.

B. They are consistently asymptomatic and incidental peripheral lesions.

C. ’Hiey are often confused histologically with granular cell tumors.

D. Immunoreactivity is expected in these lesions for actins.

E. No examples with malignant change have been documented.

ANSWER: D

15. Carney chondromas of the lung:

A. Are exclusively seen in women younger than 50 years of age

B. Do not contain entrapped epithelial tissue

C. May be associated with gastric or endocrine tumors

D. All of the above

E. None of the above

ANSWER: D

16. Lipomatous tumors of the lung:

A. Are restricted in localization to the large central airways

B. Include liposarcoma, lipoblastoma, and lipoma, in order of frequency

C. Are better detected with plain film radiographs than with computed tomography scans

D. May show cytogenetic abnormalities in chromosomes 1, 5, or 10

E. Are potentially immunoreactive for high-mobility-group proteins

ANSWER: E

17. Angiomyolipomas of the lung:

A. Are also known as lipoblastomas of adults

B. Show diffuse immunoreactivity for CD117

C. May be seen in patients with von Hippel-Lindau disease

D. May coexist with micronodular pneumocytic hyperplasia

E. Demonstrate malignant transformation in 5% of cases

ANSWER: D

18. Adenomatoid tumors of the pleura:

A. Show immunoreactivity for calretinin

B. Are multifocal lesions that measure 3-5 cm in diameter

C. Present themselves clinically by causing pleural effusions

D. Typically have distinct fibrous capsules

E. Can be distinguished ultrastructurally from mesothelioma

ANSWER: A

19. “Sclerosing hemangioma” of the lung:

A. Predominates in men in a ratio of 3 : 1

B. May have a satellitotic macroscopic appearance

C. Are immunoreactive for CD31

D. Have a diagnostic appearance in fine-needle aspiration biopsies

E. Involves regional lymph nodes in 10% of cases ANSWER: B

20. Which one of the following statements concerning solitary fibrous tumors of the pleura is false?

A. They can cause paraneoplastic hypoglycemia (Doege-Potter syndrome).

B. They can be effectively subclassified as benign, atypical, and malignant.

C. Immunoreactivity is common for bcl-2 protein.

D. Approximately 10% of histologically banal lesions recur.

E. They may show nuclear palisading of tumor cells histologically.

ANSWER: B

Case 1

eSlide 20.1

A 44-year-old man complained of progressively worsening dyspnea and audible wheezing, especially with exertion. Computed tomography of the thorax showed a 3-cm endobronchial mass in the left mainstem bronchus. It was removed by sleeve resection, and the patient is well 10 years later.

Discussion

Sections show a proliferation of bland glandular epithelial cells, some of which contain cytoplasmic mucin. The tumor cells form interconnecting cords and luminal spaces, essentially filling the bronchial lumen. No squamous elements are present, and nuclear atypicality is absent. These features support the diagnosis of mucous gland adenoma.

(See the section on “Mucous Gland Adenoma” in Chapter 20.)

Case 2

eSlide 20.2

A 50-year-old man underwent preoperative screening prior to undergoing orthopedic surgery. Chest radiographs showed an asymptomatic 4 cm mass in the lower lobe of the left lung. After fine-needle aspiration established a diagnosis of neoplasia, the lesion was removed by wedge resection. The patient is well 10 years There after.

Discussion

Microscopic evaluation shows a well-demarcated tumor comprising monotonous epithelioid cells arranged in nests and sheets. Many of the cells contain clear cytoplasm; nuclear atypia and mitotic activity are minimal. Immunostains showed no reactivity for pankeratin, epithelial membrane antigen, p63, thyroid transcription factor-1, S-100 protein, or napsin-A. However, diffuse labeling was seen for HMB-45, melan-A, and muscle-specific actin in the lesional cells. These results support the diagnosis of myomelanocytoma of the lung, also known as clear-cell “sugar” tumor.

(See the section on “Clear-Cell Tumor” in Chapter 20.)

Case 3

eSlide 20.3

This 61-year-old woman presented with shortness of breath and was found to have a large pleural-based mass in the right hemithorax. Fine-needle aspiration biopsy of the lesion showed a neoplastic spindlecell proliferation, and the tumor was excised by open thoracotomy. Despite the fact that the surgical margins were uninvolved, a local intrathoracic recurrence was observed 4 years afterward. It was again excised, and the patient is currently well.

Discussion

Histologic assessment shows a neoplasm comprising bluntly fusiform cells, with only modest nuclear atypia and limited mitotic activity, set in a fibrous stroma that focally has keloid-like features. The differential diagnosis was thought to center on solitary fibrous tumor versus synovial sarcoma of the pleura. The lesion was immunoreactive for CD34 and bcl-2 protein (STAT6 was not available in 1998 or 2002). Other stains for pankeratin, epithelial membrane antigen, and CD99 were negative. Those results supported the diagnosis of pleural solitary fibrous tumor. (See the section on “Solitary Fibrous Tumor” in Chapter 20.)

Case 4

eSlide 20.4

A 48-year-old man complained of vague right-sided chest pain, which had been present for 5 months. Chest radiographs showed an internally calcified, well-circumscribed mass based in the right pleura. It was excised by open thoracotomy, and the patient is currently well 10 years later.

Discussion

Sections show a hypocellular, collagenized mass, with multiple foci of dystrophic calcification throughout it. Intralesional cells are bland, and There is no necrosis. The histologic image just described is prototypical for the lesion known as calcifying fibrous tumor.

(See the section on “Calcifying Fibrous Tumor” in Chapter 20.)

Case 5

eSlide 20.5

This 20-year-old man underwent a preathletic health assessment. Chest films showed an asymptomatic 3 cm mass in the lower lobe of the right lung. Fine-needle aspiration biopsy established the diagnosis of an epithelioid neoplasm, which was removed by wedge excision. The patient is well 10 years later.

Discussion

Microscopic examination shows a distinctive proliferation of cytologically monotonous epithelioid cells with compact nuclei and markedly granular cytoplasm. Some cells contain “targetoid” inclusions as well. There is no nuclear atypia or mitotic activity, and necrosis is absent. The lesional cells were immunoreactive for S-100 protein, calretinin, and inhibin. No labeling was seen for pankeratin, epithelial membrane antigen, HMB45, muscle-specific actin, or thyroid transcription factor-1. Those results supported the diagnosis of granular cell tumor.

(See the section on “Granular Cell Tumor” in Chapter 20).